News & Insights

The Latest Headlines

Featured Posts

Great Point Partners Exits Vālenz® Health After 6-Year Partnership

Introduction

GREENWICH, CT – (June 22, 2023) Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, today announced that it has exited its investment in Vālenz® Health (“Valenz”) to Kelso & Company (“Kelso”), a New York-based private equity firm, after growing revenue close to 30% per year during a six-year partnership.

Since partnering with Great Point Partners in 2017, Valenz grew its enterprise value by over 700% and completed eight tuck-in acquisitions primarily sourced by GPP, including Zebu Compliance Solutions and Kozani Health. GPP also supported the Company’s establishment of an experienced Board of Directors in the payment integrity space.

“We selected Great Point Partners as our partner because of the firm’s expertise in the payment integrity field, track record of investment success with founder owned businesses and deep commitment to both advancing and improving the health care industry,” said Josh Carder, Founder and Chairman of Valenz.

“GPP leveraged its broad network of advisors fostered through its experience with prior investments in the payment integrity field to transform our business through strategic M&A, ultimately growing Valenz’s revenue by over 500%,” added Rob Gelb, Chief Executive Officer of Valenz. “We’re grateful for their help in scaling our business and our partnership with GPP.”

“Rob was a visionary leader also capable of handling the chess board of operational complexities associated with explosive growth,” added Dr. Jeffrey Jay, Founder of Great Point Partners.

Over a six-year period, GPP, in partnership with Rob Gelb, CEO, and the Valenz Management Team, expanded Valenz’s distribution channel and increased its existing market penetration to support the Company in addressing many key market challenges of the self-insured industry, including the lack of transparency within medical costs and wide variances in reimbursement rates.

“We are proud of the accomplishments the collective GPP and Valenz team has made in expanding Valenz’s footprint, strengthening its network, and fostering growth opportunities for the future,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP. “We appreciate the importance of the payment integrity sector in simplifying and improving access to health care, and we look forward to seeing Valenz continue to grow in its next chapter,” added Eddie Hjerpe, Senior Vice President.

Since 2007, GPP has partnered with two providers of payment integrity solutions to the healthcare industry, Equian and Valenz. GPP exited Equian in 2015, after sourcing and completing eleven add-on acquisitions, arranging multiple debt financings for acquisitions as well as a dividend recapitalization, and increasing EBITDA more than ten-fold.

This transaction was advised by TripleTree.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages over $1.9B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Valenz

Vālenz® Health is a leading medical cost containment firm and industry disruptor with 300+ employees dedicated to simplifying complexities of self-insurance for employers through a steadfast commitment to data transparency and decision enablement powered by its Healthcare Ecosystem Optimization Platform. Offering a strong foundation with deep roots in clinical and member advocacy, alongside decades of expertise in the validation, integrity and accuracy of claims, and a suite of risk affinity solutions, Valenz optimizes healthcare for the provider, payer, plan, and member. By leveraging data transparency and delivering an omnichannel approach across the healthcare journey, Valenz improves cost, quality and outcomes for employers and their members – engaging early and often for smarter, better, faster healthcare. More information is available at valenzhealth.com.

Great Point Partners Exits Portfolio Company Bionova Scientific

INTRODUCTION

GREENWICH, CT, and FREMONT, CA June 1, 2022 – Great Point Partners, a Greenwich, CT-based health care investment firm, announced today that it had sold its portfolio company Bionova Scientific, a biologics contract development and manufacturing organization (“CDMO”) specializing in the development and manufacturing of recombinant protein therapeutics, to a U.S. subsidiary of Asahi Kasei Corp. of Tokyo. Under Great Point’s ownership, the Company grew revenues over 100% per year and opened a 57,000 sq. ft. GMP biologics manufacturing facility to provide clinical and commercial production for clients, scaling Bionova’s capacity and capabilities.

Bionova CEO Darren Head said, “This is my third time as CEO of a Great Point Partners portfolio company and each time we have created exceeded the goals we set for ourselves.”  Head continued, “I am proud of the work we did to respond to market demand by significantly expanding Bionova’s ability to work with customers throughout the drug development process.”

Bionova co-founders, Chief Scientific Officer Amy Kong and Chief Technology Officer Chung Chun added, “We are amazed at how far Bionova Scientific has come since our modest  beginnings and grateful for  the partnership with Great Point Partners that enabled us to reach this point.  This acquisition is an endorsement of Bionova’s science-first, client-focused model and is a testament to the great work of our amazing team.”

Noah Rhodes, Managing Director at Great Point Partners commented, “We first reached out to Amy and Chung about a partnership when the Company had great potential but was capital constrained., We were  impressed with their scientific expertise and vision for the future.. With Darren leading the business over the last two years and Amy and Chung continuing to foster the company’s science-first culture, we were able to build a world-class CDMO. We were impressed with Asahi Kasei’s similar commitment to culture and quality and are excited to watch the Company continue to grow under their stewardship.”

 

ABOUT GREAT POINT PARTNERS

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Great Point manages $1.7B of capital (including GPP IV which has been closed but not been activated and co-investments on behalf of LPs) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

 

ABOUT BIONOVA SCIENTIFIC

Founded in 2014, Bionova offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with a staff that brings decades of experience in late stage and commercial launch projects. We firmly believe that a robust, well-understood process and well-characterized molecule are critical cornerstones of your molecule’s success. Our upstream PD group, with more than 60 benchtop bioreactors, offers a breadth and depth of capability typically found at only the largest CDMO’s. Bionova takes an expansive view at solving client process problems. In 2021, Bionova opened a 57,000 sq. ft. GMP biologics manufacturing facility to provide clinical and commercial production for clients. The fully single-use facility is located within Bionova’s headquarters, adjacent to existing process development and analytical laboratories, and is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.

Great Point Partners Closes Fourth Health Care Growth Buy-Out Fund at $507 Million

Introduction

GREENWICH, CT – Great Point Partners, a global health care investment firm today announced the closing of its fourth lower middle market growth buyout fund, Great Point Partners IV (GPP IV), focused on rapidly growing health care companies in the United States, Canada and Western Europe.  GPP IV, which closed  at $507 million was significantly oversubscribed in four months of fundraising and closed at its hard cap.

“Great Point is unique in that we have a both a private and public fund strategy, enabling us to have a team of approximately 30 people dedicated to generating and sharing investment ideas across the full spectrum of the health care field, regardless of whether it is a private or publicly traded health care company.  This concentration of talent working cooperatively gives us unique advantages.  Since we were founded in 2003, our private funds have generated over a 4x gross multiple on realized and partially realized investments as of March 31, 2022,” said Jeffrey Jay, MD Founding Managing Director.

“Since GPP I, we have focused on lower middle-market health care investments in pharmaceutical services and products, health care information technology enabled services, medical contract manufacturing and health care services.  We seek to create long-term value for our investors by maintaining a best-in-class proprietary sourcing program, partnering with the best entrepreneurs and investing in sectors with sustainable tailwinds of growth,” added Noah Rhodes Managing Director.

“GPP IV will target majority and at times minority investments in profitable companies generally with $1 to 10 million of EBITDA.  We are pursuing the same strategy we pioneered two decades ago,” said Rohan Saikia, Managing Director.  “We have had particular success helping US or European only companies become global companies with operations in multiple countries.”

“Obviously we are grateful for our investor support, especially in a hectic and crowded fundraising environment,” added Emily St. Thomas, Head of Investor Relations and Marketing for our private funds and our public life sciences fund, the BioMedical Value Fund.  “We continued to diversify our investor base, particularly in Europe.  We manage capital for some of the most sophisticated clients in the world.  It is also gratifying from an Environmental, Social and Governance perspective that our firm is dedicated to improving the health and well-being of people across the globe.”

 

ABOUT GREAT POINT PARTNERS

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV, which has $507 million of committed capital. Great Point manages [$1.5B of] capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Past performance is not necessarily indicative of future results and there can be no assurance that any fund will achieve comparable results or avoid substantial losses.  Etc.

Latest News

Explore current and past announcements and news regarding Great Point Partners and our Portfolio Companies.

Ephicacy Bolsters Leadership Team with Four New Hires

ISELIN, N.J.–(BUSINESS WIRE)–Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) and global provider of statistical programming, biostatistics, data management and real-world evidence analytics services, today announced four senior leadership appointments that further position the company for continued growth.

Ludi, Inc. Appoints Chief Commercial Officer and VP of Provider Compensation

NASHVILLE, Tenn.–(BUSINESS WIRE)–Nashville-based Ludi, Inc., the leader in provider compensation management, today announces the appointment of Tom Arena as Chief Commercial Officer and Eric Leafgreen as Vice President of Provider Compensation.

Cellipont Bioservices Announces Grand Opening of Cell Therapy Manufacturing Facility

THE WOODLANDS, Texas — Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the grand opening of its purpose-built 76,000 sq. ft. manufacturing facility in The Woodlands, TX. This facility includes 7 clean rooms, QC labs, temperature-controlled storage, segregated shipping bays, warehouse, and administrative offices, marking a significant milestone in Cellipont’s mission to advance cell therapy development and manufacturing, while serving patients worldwide.

“Equipped with the latest technology and designed to meet the highest quality standards, this facility represents our dedication to advancing cell therapy manufacturing and, most importantly, to serving the patients in need,” remarked Darren Head, Executive Chairman of the Board for Cellipont. “We’re thrilled to see this investment come to fruition and contribute to the advancement of life-saving therapies worldwide.”

Michael O’Mara, Chief Operating Officer of Cellipont, emphasized the company’s forward-thinking approach during the facility’s design phase: “As Cellipont commenced the design phase for The Woodlands facility in early 2022, we made a strategic decision: to not only meet current regulatory standards but also anticipate future ones. In the continually evolving landscape of cell therapy, we, as a leading CDMO, aimed to stay ahead of the curve.”

“Cellipont’s commitment to advancing cell therapy manufacturing is truly commendable,” commented Ann Tanabe, CEO of BioHouston. “Their new facility sets a remarkable standard for quality and efficiency in the industry, and we’re excited to have this resource in the Houston region.”

About Cellipont

Cellipont Bioservices is a premier Contract Development and Manufacturing Organization (CDMO) specializing in the advancement of cell therapy. With a team of industry-leading experts, Cellipont is at the forefront of cell therapy development and manufacturing, offering comprehensive solutions from process development, analytical services, to large-scale commercial manufacturing. Our purpose-built facility, combined with our cutting-edge technology and commitment to quality enable us to support our clients in delivering life-changing cell therapies to patients worldwide. Cellipont Bioservices is dedicated to excellence in all aspects of our operations, ensuring that we not only meet but exceed the expectations of our clients and the communities we serve. To learn more, visit www.cellipont.com.

Great Point Partners Announces Growth Investment of Ludi, Inc.

GREENWICH, Conn. and NASHVILLE, Tenn., December 13, 2023Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, today announced the growth recapitalization of Ludi, Inc. (“Ludi”), the leader in physician payment automation, based in Nashville, TN.

Founded in 2012 by industry veteran Gail Peace and trusted by hundreds of hospitals nationwide, Ludi’s DocTime Suite helps hospitals track, manage and audit any type of payment to physicians. The proprietary technology enhances the financial performance of health care systems by optimizing their entire physician payment processes, increasing physician satisfaction and reducing compliance risk and administrative burden on hospital teams.

The growth recapitalization of Ludi will enable the company to expand its market-leading DocTime Suite of products and enhance the value proposition it offers to hospital systems and physicians. As part of the transaction, Ludi will implement a series of changes to its management team:

  • Gail Peace has guided Ludi from inception through a period of significant growth and expansion. In the next phase of Ludi’s development, she will maintain her role on the company’s board of directors, where she will continue to actively support Ludi’s business objectives and provide strategic guidance. Gail will remain an integral part of Ludi’s continued evolution.
  • Danielle O’Rourke will become Chief Executive Officer, having previously served as Chief Operating Officer since joining Ludi in 2019. Based in Indianapolis, IN, Danielle has played a pivotal role in accelerating Ludi’s growth over the last four years, streamlining operational processes, building an in-house analytics department, spearheading sales strategies, developing strategic channel partner relationships and contributing to product development. With extensive experience across many areas of the health care industry, including as former principal at Martin Ventures and former board member of Ovia Health and Clockwise.MD by Lightshed Healthcare, Danielle will harness her strong operational and financial capabilities and historical knowledge of the company as she succeeds Gail Peace, Founder of Ludi and outgoing Chief Executive Officer.
  • Steven Lefar, Former Chief Strategy Officer at Strata Decision Technology, a leading health care financial performance platform employed by over 2,000 hospitals, will join Ludi’s board of directors. Steven brings over 30 years of experience in the health care sector, holding board member roles for Casechek, Thirdeye Health and Wildflower Health, and previously serving as CEO of Applied Pathways, Sg2 and MediRegs, which respectively exited to AIM Healthcare by Anthem, MedAssets and WoltersKluwer.

“Partnering with Ludi underscores our commitment to the advancement of better, faster and more efficient health care solutions that address crucial pain points in the industry,” said Alex Gulotta, Senior Vice President at GPP. “We look forward to supporting the talented team and further strengthening the innovative solutions it brings to hospitals and health systems nationwide.”

“I am incredibly proud of all that Ludi has accomplished since I founded the company more than a decade ago, and I believe the company is well positioned for continued growth and innovation long into the future in partnership with GPP,” said Gail Peace, Founder and outgoing Chief Executive Officer of Ludi. “As the hospital industry continues to face complex financial and workforce challenges, there is no better time for our DocTime solution to help strengthen the relationships that hospitals have with one of their most critical partners: physicians. In Danielle, Ludi will have a smart and talented leader who will build on the company’s track record of success and take Ludi to new heights.”

“Witnessing firsthand the incredible growth that Ludi has fostered under Gail’s leadership, I am thrilled to take the reins in partnership with GPP,” said Danielle O’Rourke, incoming Chief Executive Officer. “The physician compensation space is at another inflection point, with the rise of value-based care, the increase in employed physicians at hospitals and recently updated compliance guidance from the OIG around physician arrangements. I feel lucky to have such an innovative team of colleagues at Ludi and an amazing technology to meet this moment.  Although we have many exciting developments in store for DocTime, Ludi will always remain focused on our core commitments of helping hospitals optimize their physician payment processes, enhance physician satisfaction and achieve substantial cost savings. Since initial discussions with GPP, we were impressed with the firm’s expertise in physician compensation and contract management, and we share GPP’s vision for the future of Ludi.”

Ziegler served as financial advisor to Ludi.

About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Ludi, Inc.
Ludi, Inc. is a Nashville-based health care technology company that makes it easier for hospitals to pay physicians. Ludi’s DocTime Suite automates the payment process for any type of physician arrangement from a signed contract to payment. A robust financial and compliance management system, DocTime helps hospitals manage all the complex tasks, rules and data associated with their physician agreements – all in one easy-to-use system. On average, DocTime customers experience an 80 percent reduction in administrative time and costs alone, generating a 5-6x ROI.

Great Point Partners Named to Inc.’s 2023 List of Founder-Friendly Investors

GREENWICH, CT – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today that it was included on Inc.’s Founder-Friendly Investors list, which honors the private equity, venture capital, and debt firms with track records of successfully partnering with entrepreneurs.

The list recognizes firms that remain actively involved with the businesses in which they invest and that have earned the trust of the entrepreneurs they support to help drive growth.

Since GPP’s inception in 2003, the firm has been dedicated to helping health care companies achieve their full potential. Over the last two decades, GPP has supported entrepreneurs by providing capital, facilitating acquisitions, and offering unparalleled resources and strategic long-term guidance – all without taking over daily operational control. The firm is led by a team of Managing Directors who have invested together for close to two decades and is advised by a CEO Board of leading health care industry executives, as well as a Medical Advisory Board of physicians and scientists.

“As a firm that is committed to supporting the health care industry’s most innovative entrepreneurs, we are honored to be recognized for our approach to partnership,” said Dr. Jeffrey Jay, Founder and Managing Partner of GPP. “I am proud of our exceptional team, and we look forward to continuing to elevate businesses that are improving and advancing health care in the United States and around the world.”

Introduced in 2019, the Founder-Friendly Investors has become a go-to guide for entrepreneurs who want to grow their companies while retaining an ownership stake. To compile the list, Inc. went straight to the source: entrepreneurs who have sold to private equity and venture capital firms. Founders filled out a questionnaire about their experiences partnering with investment firms and shared data on how their portfolio companies have grown during these partnerships.

“Now more than ever, founder-led companies need financing partners that offer guidance, expertise, and understanding—not just capital. These are the private equity, venture capital, and debt firms that have founders’ backs when it comes to accelerating growth,” said Scott Omelianuk, editor-in-chief of Inc. Business Media.

The November 2023 issue of Inc. magazine is available online now at https://www.inc.com/magazine and will be on newsstands beginning October 31. To see the complete list, go to: https://www.inc.com/founder-friendly-investors/2023.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Inc.

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community they need to build great companies. Its award-winning multiplatform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc.5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced by Inc. For more information, visit www.inc.com.

Great Point Partners Portfolio Company JPA Health Completes Acquisition of True North Solutions, Inc.

GREENWICH, CT – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce its portfolio company, JPA Health, has completed the acquisition of True North Solutions, Inc. (True North) of Cambridge, Mass. True North specializes in commercial, clinical, and medical affairs, with expertise in digital acceleration and customized predictive analytics, as well as solutions powered by AI and natural language processing.

JPA Health, a global full-service, integrated agency that serves biopharmaceutical, medical device, non-profit, and public health clients, has over 90 employees today with offices in Washington D.C., Boston, New York and London. JPA Health’s strategic offerings include providing end-to-end integrated medical affairs, clinical development, commercial strategy, creative marketing, public relations, and patient advocacy solutions to clients.

“Here at JPA Health, we utilize cutting-edge data and analytics technology to uncover valuable insights that fuel our success,” said Carrie Jones, CEO of JPA Health. “The addition of True North Solutions, with its expertise in creating custom solutions rooted in data sciences, will help keep our clients ahead of their competition in connecting with target audiences and driving results.”

“The addition of True North’s capabilities is not only applicable to JPA’s current service offerings, but also additional ones we plan to expand into,” said Bret Tenenhaus, Principal at Great Point Partners. “We’re excited to continue down the path of investing both organically and via acquisitions to further enhance JPA’s offerings.”

True North Solutions, led by founder Colin Baughman, was established in 2016. The company has led projects spanning dozens of therapeutic areas, including CNS, oncology, infectious diseases and rare diseases for many of the largest pharmaceutical companies globally. True North focuses on eight key areas: brand strategy, healthcare professional & patient experience, launch excellence, medical strategy, performance management, KPIs & evaluation, predictive analytics and visualization, and segmentation and persona modeling.

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.7B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.8B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About JPA Health

JPA Health is an award-winning independent, full-service agency established in 2007. With four offices in the U.S. and UK (Washington, D.C., New York, Boston, London), the company provides omnichannel marketing, public relations, and advocacy services. JPA Health recently was awarded PR Daily’s Agency of the Year, 2023 and included in MM+M’s Agency 100. The firm is a leader in the health sector recognized for its work designing health campaigns that drive change and deliver measurable results. The JPA Health team is passionate about helping people live healthier lives. To learn more, visit www.jpa.com

 

What Makes A PE Firm-Home Care Provider Relationship Successful

Insights from Jeff Wiberg, CEO of GPP portfolio company Family Resource Home Care, on what makes a PE firm and home care provider partnership successful.

Life sciences, pharma services to dominate health care M&A

Founder and Managing Partner Jeffrey Jay’s observations on the current health care M&A environment, highlighted in Axios.

Great Point Partners Portfolio Company Family Resource Home Care Completes Acquisition of Companion Care, Inc.

GREENWICH, CT – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce its portfolio company, Family Resource Home Care (Family Resource), has completed the acquisition of Companion Care, Inc. (Companion Care) of Woodinville, Washington. The strategic acquisition accelerates Family Resource Home Care’s plan to expand access to high-quality home care across the Pacific Northwest. With the acquisition of Companion Care, Family Resource has grown to seven locations in the greater Puget Sound region and 29 locations across Idaho, Oregon and Washington, employing over 1,700 home care professionals.

Family Resource is the largest independent home care agency in the Northwest and one of the largest in the United States. It provides home care services to the elderly and disabled, such as personal care, medication management, meal preparation, housekeeping, companionship, dementia support and end-of-life, transitional and respite care. The company has scaled from eight locations in 2019 to 29 to expand access to home care to more of the country’s aging population.

“Family Resource has established itself as one of the premier independent home care agencies in the country,” said Alex Gulotta, Senior Vice President at GPP. “The addition of Companion Care extends Family Resource’s ability to deliver exceptional care and support to families and caregivers in communities across the Puget Sound region. Family Resource’s management team has excelled at achieving sustainable growth while maintaining their reputation as the agency of choice in their markets. We’re excited to continue to partner with Jeff Wiberg and the Family Resource team as they continue to gain market share through organic and inorganic growth.”

Companion Care is a non-medical in-home care agency in Woodinville Washington, offering compassionate care and support to elderly and disabled individuals in need within the King and Snohomish County communities. Founded in 2004, Companion Care is a female-owned and operated business employing 100 people, all of whom have been offered roles with Family Resource.

“We are thrilled to announce our acquisition of Companion Care, Inc., a successful home care agency in the Puget Sound region,” said Jeff Wiberg, CEO of Family Resource Home Care. “Their exceptional track record and dedication to providing outstanding care aligns perfectly with our values. We look forward to warmly welcoming Companion Care, Inc. into our family and together, we will continue to deliver industry best services to even more individuals and families in need within the community.”

GPP completed a growth recapitalization of Family Resource in 2020, representing the firm’s eighth partnership with a health care services organization since its formation in 2003. In 2021, Family Resource acquired Adeo In Home Care and Helping Hands Home Care, two of the largest, independently owned agencies in Oregon.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages approximately $1.8B of capital (including committed and uncalled capital) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Family Resource Home Care

Family Resource Home Care is the largest provider of home care services based in the Pacific Northwest and one of the largest in the United States. The company provides home care services that include but are not limited to personal care such as bathing, dressing and help with medications, meal planning and preparation, light housekeeping, and companion care. The company also provides care for clients facing dementia and Alzheimer’s Disease as well as end-of-life, transitional and respite care. More information is available at www.familyresourcehomecare.com.

 

Great Point Partners Exits Vālenz® Health After 6-Year Partnership

Introduction

GREENWICH, CT – (June 22, 2023) Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, today announced that it has exited its investment in Vālenz® Health (“Valenz”) to Kelso & Company (“Kelso”), a New York-based private equity firm, after growing revenue close to 30% per year during a six-year partnership.

Since partnering with Great Point Partners in 2017, Valenz grew its enterprise value by over 700% and completed eight tuck-in acquisitions primarily sourced by GPP, including Zebu Compliance Solutions and Kozani Health. GPP also supported the Company’s establishment of an experienced Board of Directors in the payment integrity space.

“We selected Great Point Partners as our partner because of the firm’s expertise in the payment integrity field, track record of investment success with founder owned businesses and deep commitment to both advancing and improving the health care industry,” said Josh Carder, Founder and Chairman of Valenz.

“GPP leveraged its broad network of advisors fostered through its experience with prior investments in the payment integrity field to transform our business through strategic M&A, ultimately growing Valenz’s revenue by over 500%,” added Rob Gelb, Chief Executive Officer of Valenz. “We’re grateful for their help in scaling our business and our partnership with GPP.”

“Rob was a visionary leader also capable of handling the chess board of operational complexities associated with explosive growth,” added Dr. Jeffrey Jay, Founder of Great Point Partners.

Over a six-year period, GPP, in partnership with Rob Gelb, CEO, and the Valenz Management Team, expanded Valenz’s distribution channel and increased its existing market penetration to support the Company in addressing many key market challenges of the self-insured industry, including the lack of transparency within medical costs and wide variances in reimbursement rates.

“We are proud of the accomplishments the collective GPP and Valenz team has made in expanding Valenz’s footprint, strengthening its network, and fostering growth opportunities for the future,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP. “We appreciate the importance of the payment integrity sector in simplifying and improving access to health care, and we look forward to seeing Valenz continue to grow in its next chapter,” added Eddie Hjerpe, Senior Vice President.

Since 2007, GPP has partnered with two providers of payment integrity solutions to the healthcare industry, Equian and Valenz. GPP exited Equian in 2015, after sourcing and completing eleven add-on acquisitions, arranging multiple debt financings for acquisitions as well as a dividend recapitalization, and increasing EBITDA more than ten-fold.

This transaction was advised by TripleTree.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages over $1.9B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About Valenz

Vālenz® Health is a leading medical cost containment firm and industry disruptor with 300+ employees dedicated to simplifying complexities of self-insurance for employers through a steadfast commitment to data transparency and decision enablement powered by its Healthcare Ecosystem Optimization Platform. Offering a strong foundation with deep roots in clinical and member advocacy, alongside decades of expertise in the validation, integrity and accuracy of claims, and a suite of risk affinity solutions, Valenz optimizes healthcare for the provider, payer, plan, and member. By leveraging data transparency and delivering an omnichannel approach across the healthcare journey, Valenz improves cost, quality and outcomes for employers and their members – engaging early and often for smarter, better, faster healthcare. More information is available at valenzhealth.com.

Rise of self insurance fueled growth at Valenz before sale to Kelso

PE Hub’s coverage of Great Point Partners’ exit in Valenz Health after growing revenue close to 30% per year during a six-year partnership.

Manufacturing M&A Success Among Gene and Cell Therapy Innovators

Managing Director and Head of Private Equity Noah Rhodes’ observations on investment opportunities within cell and gene therapies, featured in Middle Market Growth.

Great Point Partners eyes European healthcare deals

Private Equity News’ coverage of Great Point Partners’ London office opening, created to expand the firm’s ability to help growing health care companies reach transatlantic scale.

Great Point Partners Expands Transatlantic Value Creation Through London Office Opening

GREENWICH, CT and LONDON, UK – Great Point Partners (“GPP”), a Greenwich-based private investment firm, has opened an office in London, expanding the firm’s ability to help growing health care companies reach transatlantic scale.

The expansion is part of Great Point Partners’ strategy to integrate both its North American and European networks to support existing and prospective portfolio companies with global growth. GPP aims to leverage its deep health care industry expertise and network of entrepreneurs, operating partners and industry experts across Europe to remove barriers to entry for middle market health care companies seeking European expansion.

“Our London office will enable us to strengthen our partnerships with entrepreneurs to build global health care businesses,” said Jeffrey Jay, M.D., Founder and Managing Partner of GPP. “This expansion is a testament to our success in helping United States-based companies expand into European markets and vice versa.”

Noah Rhodes, Managing Director and Head of Private Equity, will lead the development of the new office both from the U.S. and on-the-ground in London. Working in close coordination with GPP’s U.S.-based team, the London office enables greater access to the firm’s operational knowledge base for navigating markets across the UK and EU.

“We believe that having an on-the-ground presence in Europe will benefit both our existing and prospective partners in accelerating their growth and expanding internationally, and also conveys our commitment to the European market,” said Rhodes.

To build out its European team, GPP has hired two London-based executives, including David Slattery, Senior Vice President, and Isaac Kang, Associate. Both join the firm with extensive global private equity investment experience.

GPP will continue to manage its European investing activities through an integrated team based out of both Greenwich and London. Examples of health care companies GPP has helped reach transatlantic scale include:

    • MaSTherCell: A Belgium-based cell and gene therapy contract development and manufacturing organization that opened its first US facility in partnership with GPP.
    • Softbox: A UK-based provider of passive temperature-controlled packaging solutions for the pharmaceutical, life science and cold chain logistics industries that GPP helped expand into the U.S. via a large facility built in South Carolina.
    • CorEvitas: A U.S.-based provider of evidence solutions and data that completed an accretive acquisition in London in partnership with GPP and grew into related areas of UK electronic medical records, claims data, and patient experience studies.
    • MLM Medical Labs: A Germany-based specialty central lab dedicated exclusively to clinical trials that completed two U.S. tuck-in transactions with GPP.
    • SteriPack: An Ireland-based contract manufacturing and value-added services provider that completed two U.S. acquisitions sourced and led by GPP.
    • Clinical Supplies Management: A U.S.-based pharmaceutical and services company that completed two transformational European acquisitions (in Belgium and Germany) with GPP.

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages over $1.9B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Cellipont bags investment from OrbiMed to complete Texas plant

BioProcessInternational’s coverage of Cellipont’s strategic debt facility investment from OrbiMed to finance its state-of-the-art commercial facility for cell therapies and gene-modified cell therapies.

Cellipont Receives Strategic Debt Investment from OrbiMed to Complete State-of-the-Art Commercial Manufacturing Facility

POWAY, CA – Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed, a healthcare investment firm. The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, Texas.

“We are energized by this partnership with OrbiMed, which helps us to bring this world-class facility to completion in 2023,” said Deborah Wild, President and CEO of Cellipont. “Once completed, Cellipont will be uniquely positioned to offer technically-superior, highly-responsive outsourced contract development and GMP manufacturing services to innovative cell therapy companies. OrbiMed understands our vision, has a unique portfolio of life science companies, and was the ideal partner for Cellipont in this journey.”

The 76,000-square-foot facility will feature significant capabilities including process and analytical development (PD/AD) and manufacturing services for CAR-T, IPSC, MSC and other types of cell therapies. OrbiMed’s support will enable clients to take advantage of cutting-edge cleanrooms, promising technological innovations, and a team with deep scientific expertise in a best-in-class facility.

Matthew Rizzo, General Partner of OrbiMed, commented “OrbiMed is excited to partner with Cellipont for their continued growth. Cellipont’s scientific expertise, state-of-the-art facilities, and unique capabilities were apparent to us throughout our debt process and we believe the Company is well prepared to capitalize on future demand as the cell and gene therapy CDMO market continues to grow and evolve.”

The new complex, which broke ground in November 2022, is specially designed to meet Cellipont’s agile manufacturing style that marries technical excellence and personal service to help clients get to target endpoints faster.

“This expansion underscores our unwavering commitment to going above and beyond for our clients and patients,” said Darren Head, Chairman of Cellipont. “We look forward to accelerating cell therapy innovation by offering our partners state-of-the-art facilities with the power to unlock life-changing medicines.”

Cellipont first announced plans to develop the new facility in August 2022, with construction set to be completed in several phases. The firm recently added two experienced executives to its commercial leadership team, hiring Brian Walsh as Senior Vice President of Business Development and Aaron Solis as Senior Director of Business Development. Cellipont also recently hired Tim Heher as CFO, who possesses extensive experience operating private equity backed CDMO investments. OrbiMed now teams up with existing financial sponsor, Great Point Partners, who first partnered with Cellipont in 2021.

William Blair acted as the exclusive financial advisor to Cellipont for this financing.

About Cellipont Bioservices

Cellipont Bioservices is a privately-held cell therapy CDMO operating in San Diego, CA and The Woodlands, TX with more than 15 years of experience in the development and manufacturing of cell therapies, ranging from small to large-scale batches. Cellipont has deep technical expertise and has been recognized by customers and partners for its ability to productively grow challenging cell types. Cellipont’s culture is customer-centric with a focus on partnering, flexibility and responsiveness. For more information, please visit www.cellipont.com.

About OrbiMed

OrbiMed is a healthcare investment firm, with approximately $18 billion in assets under management. OrbiMed invests globally across the healthcare industry through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed provides commercial-stage healthcare companies with non-dilutive structured debt capital. Additionally, OrbiMed can monetize royalty streams, providing valuable financing solutions to owners of intellectual property. OrbiMed’s team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya and other key global markets.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages over $1.5B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Great Point Partners Exits Portfolio Company Bionova Scientific

INTRODUCTION

GREENWICH, CT, and FREMONT, CA June 1, 2022 – Great Point Partners, a Greenwich, CT-based health care investment firm, announced today that it had sold its portfolio company Bionova Scientific, a biologics contract development and manufacturing organization (“CDMO”) specializing in the development and manufacturing of recombinant protein therapeutics, to a U.S. subsidiary of Asahi Kasei Corp. of Tokyo. Under Great Point’s ownership, the Company grew revenues over 100% per year and opened a 57,000 sq. ft. GMP biologics manufacturing facility to provide clinical and commercial production for clients, scaling Bionova’s capacity and capabilities.

Bionova CEO Darren Head said, “This is my third time as CEO of a Great Point Partners portfolio company and each time we have created exceeded the goals we set for ourselves.”  Head continued, “I am proud of the work we did to respond to market demand by significantly expanding Bionova’s ability to work with customers throughout the drug development process.”

Bionova co-founders, Chief Scientific Officer Amy Kong and Chief Technology Officer Chung Chun added, “We are amazed at how far Bionova Scientific has come since our modest  beginnings and grateful for  the partnership with Great Point Partners that enabled us to reach this point.  This acquisition is an endorsement of Bionova’s science-first, client-focused model and is a testament to the great work of our amazing team.”

Noah Rhodes, Managing Director at Great Point Partners commented, “We first reached out to Amy and Chung about a partnership when the Company had great potential but was capital constrained., We were  impressed with their scientific expertise and vision for the future.. With Darren leading the business over the last two years and Amy and Chung continuing to foster the company’s science-first culture, we were able to build a world-class CDMO. We were impressed with Asahi Kasei’s similar commitment to culture and quality and are excited to watch the Company continue to grow under their stewardship.”

 

ABOUT GREAT POINT PARTNERS

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Great Point manages $1.7B of capital (including GPP IV which has been closed but not been activated and co-investments on behalf of LPs) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device contract manufacturing and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

 

ABOUT BIONOVA SCIENTIFIC

Founded in 2014, Bionova offers world-class biologics CDMO services built on a foundation of strong process development and analytical science with a staff that brings decades of experience in late stage and commercial launch projects. We firmly believe that a robust, well-understood process and well-characterized molecule are critical cornerstones of your molecule’s success. Our upstream PD group, with more than 60 benchtop bioreactors, offers a breadth and depth of capability typically found at only the largest CDMO’s. Bionova takes an expansive view at solving client process problems. In 2021, Bionova opened a 57,000 sq. ft. GMP biologics manufacturing facility to provide clinical and commercial production for clients. The fully single-use facility is located within Bionova’s headquarters, adjacent to existing process development and analytical laboratories, and is optimized for multi-product manufacturing of monoclonal antibodies and other recombinant proteins.

Great Point Partners Closes Fourth Health Care Growth Buy-Out Fund at $507 Million

Introduction

GREENWICH, CT – Great Point Partners, a global health care investment firm today announced the closing of its fourth lower middle market growth buyout fund, Great Point Partners IV (GPP IV), focused on rapidly growing health care companies in the United States, Canada and Western Europe.  GPP IV, which closed  at $507 million was significantly oversubscribed in four months of fundraising and closed at its hard cap.

“Great Point is unique in that we have a both a private and public fund strategy, enabling us to have a team of approximately 30 people dedicated to generating and sharing investment ideas across the full spectrum of the health care field, regardless of whether it is a private or publicly traded health care company.  This concentration of talent working cooperatively gives us unique advantages.  Since we were founded in 2003, our private funds have generated over a 4x gross multiple on realized and partially realized investments as of March 31, 2022,” said Jeffrey Jay, MD Founding Managing Director.

“Since GPP I, we have focused on lower middle-market health care investments in pharmaceutical services and products, health care information technology enabled services, medical contract manufacturing and health care services.  We seek to create long-term value for our investors by maintaining a best-in-class proprietary sourcing program, partnering with the best entrepreneurs and investing in sectors with sustainable tailwinds of growth,” added Noah Rhodes Managing Director.

“GPP IV will target majority and at times minority investments in profitable companies generally with $1 to 10 million of EBITDA.  We are pursuing the same strategy we pioneered two decades ago,” said Rohan Saikia, Managing Director.  “We have had particular success helping US or European only companies become global companies with operations in multiple countries.”

“Obviously we are grateful for our investor support, especially in a hectic and crowded fundraising environment,” added Emily St. Thomas, Head of Investor Relations and Marketing for our private funds and our public life sciences fund, the BioMedical Value Fund.  “We continued to diversify our investor base, particularly in Europe.  We manage capital for some of the most sophisticated clients in the world.  It is also gratifying from an Environmental, Social and Governance perspective that our firm is dedicated to improving the health and well-being of people across the globe.”

 

ABOUT GREAT POINT PARTNERS

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP IV, which has $507 million of committed capital. Great Point manages [$1.5B of] capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Past performance is not necessarily indicative of future results and there can be no assurance that any fund will achieve comparable results or avoid substantial losses.  Etc.

Great Point Partners Sells Softbox Systems to CSafe Global

Introduction

GREENWICH, CT and DAYTON, OH – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today that it has sold Softbox Systems (“Softbox” or the “Company”), to CSafe Global, a portfolio company of Frazier Healthcare Partners and Thomas H. Lee Partners.  Softbox, based in Long Crendon, U.K., is a leading global innovator and provider of passive temperature-controlled packaging solutions for the pharmaceutical, life science, cold chain and third-party logistics industries. The critical importance of temperature-controlled packaging was highlighted over the last two years due to the temperature-controlled packaging requirements of mRNA COVID-19 vaccines. Softbox was and continues to be Pfizer’s primary supplier for COVID-19 vaccine temperature-controlled shipping needs.

Adam Dolder, Managing Director at GPP commented, “This successful investment was the result of our thematic approach, our proprietary sourcing, our global investment approach, our value enhancement resources and the recognition of the growing importance of temperature-controlled solutions for the pharmaceutical industry.  We were fortunate to work with great entrepreneurs and to recruit Kevin Valentine (CEO) to drive the business forward, capitalize on the growth dynamics in the industry and position Softbox to play a critical role in saving the global economy and aiding global health during the pandemic.”

“When I joined Softbox, I was excited to partner with Great Point because of their health care expertise and track record of success in pharmaceutical services. I am immensely proud of what we have accomplished together and of our prospects in the future,” Kevin Valentine, Chief Executive Officer at Softbox, stated.

“Our equity investment and expertise in proprietarily sourcing add-on acquisitions enabled Softbox to make several strategic acquisitions, expanding the Company’s product range, end markets and geographic reach, all of which helped drive significant value for all stakeholders. We are proud of what Softbox has accomplished not only for the pharmaceutical industry, but also for humanity with the development of its temperature-controlled solutions for COVID-19 vaccines. Great Point’s capital, experience and dedicated resources helped Softbox accelerate its growth and build a company of enduring value,” added Noah Rhodes, Managing Director at GPP.

Baird served as exclusive financial advisor to Softbox, and McDermott Will & Emery LLP served as the Company’s legal counsel.

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and public life sciences equity fund (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

 

About Softbox Systems

Softbox is an award-winning temperature control packaging innovator that has been designing and producing high-performance passive temperature control packaging systems for over 25 years. We offer consistent quality to our clients from our strategically located global manufacturing sites throughout EMEA, North America, Latin America, India and Asia Pacific. We have formed long-standing partnerships with the world’s leading biotech, pharmaceutical, clinical research and logistics companies, and apply innovative thinking to overcome the challenges that our clients face in managing the Cold Chain when shipping temperature-sensitive commercial and clinical trial products. Our range of engineered packaging systems has been designed and rigorously tested to ensure the cold chain can be maintained with confidence. Our personal approach, innovation, consistent quality and passion have made us the trusted partner to the life sciences and logistics industries.

Spine & Sport Physical Therapy Acquires Advanced Physical Therapy & Sports Medicine.

Introduction

San Diego, CA and Thousand Oaks, CA

Spine & Sport Physical Therapy (“Spine and Sport”), a leading provider of physical therapy in California acquires Advanced Physical Therapy & Sports Medicine (“Advanced”). Advanced adds an additional location to Ventura County, expanding Spine & Sports footprint to four in the area.

“We are excited to expand Spine & Sport into Thousand Oaks, California with the acquisition of Advanced Physical Therapy.  Eric Honbo, PT, DPT, OCS and Cody Jones, PT, DPT, OCS, Cert. DN have built a successful business with their strong clinical focus, sports medicine care and tremendous team. The Advanced Physical Therapy team will assist in our continued growth in Ventura County,” said Brett Raasch, PT, ATC and CEO of Spine & Sport PT.

“Advanced Physical Therapy & Sports Medicine was founded with the goal of providing best in class specialized care to patients.  We not only have found a partner who shares our goals, but one with integrity and strong vision.  Together we look forward to expanding in the greater Southern California region.” Eric S. Honbo, PT, DPT, OCS, Cert DN and Cody Jones, PT, DPT, OCS Advanced Physical Therapy & Sports Medicine Founders.

About Spine & Sport Physical Therapy:

Spine & Sport Physical Therapy (“Spine & Sport”), headquartered in San Diego, CA is a leading provider of physical therapy and rehabilitation services in Southern California. The Company operates 36 employee-owned outpatient physical therapy clinics. Spine & Sport is dedicated to personalized, measurable, active based, patient-centered care for orthopaedic, sports and work-related injuries. The Company’s outpatient clinics provide active based treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.  Reach Spine & Sport at 800-976-7544 or www.spineandsport.com/

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and public equity fund (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at 203-971-3300 or www.gppfunds.com

 

 

Great Point Partners Completes Growth Recapitalization of Velentium

Introduction

GREENWICH, CT and HOUSTON, TX – Great Point Partners (“GPP”) today announced a growth recapitalization of Houston, Texas-based Velentium, a professional engineering firm that specializes in the design and manufacturing of therapeutic and diagnostic medical devices for companies ranging from startups to Fortune 100s. This is GPP’s second investment in the medical device contract manufacturing industry. GPP’s investment will allow Velentium to pursue additional avenues of growth.

“When Great Point reached out to us earlier this year, we were immediately impressed with their deep knowledge of contract medical device manufacturing and track record building businesses,” said Dan Purvis, CEO of Velentium. “We continue to build an organization that improves the lives of people and families by helping to bring transformative medical devices to market. Today, with this capital for expansion we are able to take an important step in realizing our dream of having 1,000 families as part of Velentium.”

Tim Carroll, Velentium’s President and COO, added, “It was important to Dan and me to find a partner that recognized the non-negotiable need to preserve the quality of the work that we do and the culture we’ve built while we continue to grow. Great Point understands and shares our values, and we’re excited about what we can achieve together.”

“Velentium has played a pivotal role in the development of groundbreaking neuromodulation devices that have led to important medical technology advancements. We look forward to partnering with Dan, Tim and the entire team and helping them to achieve their goals for the Company” said GPP Managing Director Adam Dolder. “Not only is Velentium an exciting investment for GPP but with this investment GPP III is now approximately 70% invested.”

Eddie Hjerpe, Senior Vice President at GPP commented, “Velentium has grown at an impressive CAGR of over 40% since inception, and GPP looks forward to helping accelerate their growth even further with tuck-in acquisitions and adding additional engineering and manufacturing services.”

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and public equity fund (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at 203-971-3300 or www.gppfunds.com

About Velentium

Headquartered in Houston, Texas with operations globally, Velentium is a professional engineering firm that specializes in the design and manufacturing of therapeutic and diagnostic active medical devices for Fortune 100 companies and startups. The company offers world-class expertise in software, usability, cybersecurity, electrical and mechanical development for medical equipment. Velentium transforms IP into safe and secure products that will support healthcare professionals, patients and communities, and ultimately, change lives for a better world. For more information, visit www.velentium.com.

 

 

Spine & Sport Physical Therapy Acquires Envision Sport Physical Therapy & Pilates

Introduction

San Diego, CA and Irvine, CA – Spine & Sport Physical Therapy, a leading provider of physical therapy in California acquires Envision Sport Physical Therapy & Pilates (“Envision Sport”). Envision Sport, with two locations, creates a foothold for Spine & Sport in the Irvine market.

“We are excited to expand our Spine & Sport Physical Therapy team into the Orange County, California communities with Envision Sport.  Melissa Walls, PT, DPT and Darrin Yee have fostered a successful business since 2013, with their strong clinical care, values, culture and tremendous team.  Together we look forward to our continued growth in Orange County and throughout California,” said Brett Raasch, PT, ATC and CEO of Spine & Sport PT.

“Envision Sport is excited to announce our partnership with Spine & Sport. We were approached by many potential partners in the California physical therapy market; however, Spine & Sport was clearly the preferred partner for our culture, our growth plans and our clinical excellence. This partnership will allow Envision Sport to continue to deliver a high level of patient care and help our communities in Orange County achieve their rehabilitation goals, through individualized care and the power of Pilates. We look forward to expanding into more locations in Orange County.” Melissa Walls, PT, DPT and Darrin Yee, Co-Owners.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at 203-971-3300 or www.gppfunds.com

About Spine & Sport Physical Therapy:

Spine & Sport Physical Therapy (“Spine & Sport”), headquartered in San Diego, CA is a leading provider of physical therapy and rehabilitation services in Southern California. The Company operates 32 employee-owned outpatient physical therapy clinics. Spine & Sport is dedicated to personalized, measurable, active based, patient-centered care for orthopaedic, sports and work-related injuries. The Company’s outpatient clinics provide active based treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.  Reach Spine & Sport at 800-976-7544 or www.spineandsport.com/

 

 

Great Point Partners Portfolio Company Family Resource Home Care Announces Two Acquisitions

Introduction

GREENWICH, CT and LIBERTY LAKE, WA – Great Point Partners’ (“GPP”) portfolio company, Family Resource Home Care (“FRHC”), the leading provider of in-home caregiving services in the Pacific Northwest, announced today the acquisitions of Adeo In Home Care and Helping Hands Home Care – two of the largest, independently owned agencies in Oregon. The purchases signal a strategic move in the state by FRHC, with the Company now covering 79% of the population. The acquisitions are part of FRHC’s plan to continue expanding its share of the Pacific Northwest private duty home care market. The addition of Adeo and Helping Hands bring the Company’s total locations to 24 in three adjoining states.

“With Adeo and Helping Hands, we have advanced our goal of serving all major metropolitan markets in the Pacific Northwest,” said Jeff Wiberg, FRHC CEO. “The depth and breadth of our coverage positions us well to partner with large hospitals, health systems and post-acute providers.”

“After 15 years of serving thousands of seniors in Oregon, I was ready to join forces with a likeminded company,” said Kevin Call, Founder of Adeo In Home Care. “In FRHC, we found the ideal partner that can provide the resources for growth and alignment with Adeo’s core values and culture.”

“I believe FRHC and Helping Hands share best practices and the mission of enhancing the lives of Oregonians by providing compassionate, world-class care,” said Toby Forsberg, owner of Helping Hands. “I believe together we can achieve bigger and broader goals that benefit all stakeholders involved.”

About Family Resource Home Care

FRHC is the largest independent home care agency in the Northwest and one of the largest in the United States. It provides services primarily to the elderly such as personal care, medication management, meal preparation, housekeeping, companionship, dementia support and end-of-life, transitional and respite care. Family Resource is headquartered in Liberty Lake, WA, and has field offices in Arlington, Bellevue, Kennewick, Seattle, Spokane and Tacoma in Washington State, and Boise and Moscow, Idaho. More information about Family Resource and its services can be viewed online at www.familyresourcehomecare.com.

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and its health care public equity fund (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at 203-971-3300 or https://www.gppfunds.com/

 

 

 

 

Great Point Partners Backed Spine & Sport Physical Therapy Expands Presence to Sacramento, CA with Acquisition of Results Physical Therapy and Training Center

Introduction

GREENWICH, CT and SAN DIEGO, CA – Great Point Partners’ (“GPP”) portfolio company, Spine & Sport Physical Therapy (“Spine & Sport”), a leading provider of outpatient physical therapy and rehabilitation services in California, has acquired Results Physical Therapy and Training Center (“Results PT”).  Results PT operates four locations in Sacramento, CA.

“It has been a critical part of our strategic roadmap to enter Sacramento and we are excited to partner with Kyle Yamashiro and his team as we continue our growth,” said Brett Raasch PT, ATC, CEO of Spine & Sport. “Results PT has a strong brand and reputation in the community and with Kyle’s leadership, we will continue provide the highest quality of care to the Sacramento market.”

“Leading Spine & Sport’s expansion in Northern California with the same dedication to quality of care made this an exciting decision for me. I look forward to working with the team as we continue to expand our presence in Sacramento and Northern California,” said Kyle Yamashiro, DPT, founder of Results Physical Therapy and Training Center.

The addition is the fifth acquisition Spine & Sport has made since Great Point’s investment in December 2018.

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $307 million) and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com

 

 About Spine & Sport  

Spine & Sport Physical Therapy (“Spine & Sport”), headquartered in San Diego, CA is a leading provider of physical therapy and rehabilitation services in Southern California. The Company operates 29 owned outpatient physical therapy clinics as well as managing additional locations in Northern California.  The Company’s outpatient clinics provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.  Spine & Sport’s rehabilitation programs and services help patients minimize physical and cognitive impairments and maximize functional ability so that they can return to competition, the workplace and / or their normal lifestyle. Reach Spine & Sport at 800-976-7544 or www.spineandsport.com/

 

 

 

Vālenz® Announces Acquisition of Kozani Health

Introduction

PHOENIX, AZ And GREENWICH, CT

Vālenz®, a Great Point Partners II portfolio company, announced today it has acquired Kozani Health, integrating a new and innovative means for self-funded employers and the self-insured community to control costs across the life of a claim.

Kozani Health, which provides customized solutions to meet the challenges of paying medical claims appropriately, joins the ever-expanding Valenz portfolio of data and solutions as Valenz ProteKHt™. The new solution offers detailed line-by-line bill reviews performed by nurses, certified coders and practicing specialists to uncover inappropriate billing and care.

“We are excited to welcome Kozani Health as part of our data-driven Valenz ecosystem,” said Rob Gelb, Chief Executive Officer. “By bringing our teams together, we are providing self-funded employers and the self-insured community improved cost savings at each step in the life cycle of a claim.”

“We are energized to begin our company’s next chapter as Valenz ProteKHt,” said Michael Scott, Chief Executive Officer and Co-Founder of Kozani Health. “Integrating our claim management solutions into Valenz will accelerate the growth and evolution of our services and bring additional value to our customers.”

“Valenz and Kozani’s service offerings are highly complementary and the unified business provides self-insured groups with an enhanced value proposition”, said Noah Rhodes, Managing Director at Great Point Partners.  “We look forward to working with the Kozani team to provide our combined customer base with exceptional service.”

“Kozani is our third acquisition since GPP partnered with Valenz back in 2017. Each acquisition has added a unique product to Valenz’s ecosystem, and we look forward to adding additional products and services in the coming years,” said Eddie Hjerpe, Vice President at Great Point Partners.

 

About Valenz

Vālenz® enables self-insured employers to make better decisions that control costs across the life of a claim while empowering their members to lead strong, vigorous and healthy lives.  Valenz connects cost and quality data from comprehensive care management services (Valenz Care), high-value provider networks (Valenz Access), claim flow management (Valenz Claim), complete bill review (Valenz ProteKHt), and solutions for payment integrity, revenue cycle management and eligibility compliance (Valenz Assurance) for smarter, better, faster healthcare. More information is available at valenzhealth.com. Valenz is backed by Great Point Partners.

About Kozani Health

Kozani Health, headquartered in Mesa, Ariz., provides customized bill review sign-off and bill audit solutions to analyze pricing, coding and care provided to ensure appropriate payment. Since its inception in 2015, Kozani Health has forged long-term customer relationships and continuously improved solutions to solve customer challenges.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.3 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com

Great Point Partners-Backed Little Spurs Pediatric Urgent Care Appoints John Mizerany as Chief Executive Officer

Introduction

GREENWICH, CT and SAN ANTONIO, TX — Great Point Partners portfolio company, Little Spurs Pediatric Urgent Care, a provider of pediatric urgent care services with 13 locations across Texas, announced the appointment of John Mizerany as Chief Executive Officer. Mr. Mizerany brings nearly 20 years of relevant health care services experience to this new role having previously held positions at CareNow DFW (CEO), Alliance Spine & Pain Centers (COO), and Fresenius Medical Care North America (Group Vice President).  While CEO of CareNow DFW, Mr. Mizerany had full responsibility for its urgent care locations in North Texas as well as the management of a 50+ physician family practice group. Under his leadership, CareNow DFW experienced 33% revenue growth and 41% EBITDA growth.

“We welcome John’s experience and leadership to Little Spurs,” said Rohan Saikia, Managing Director at Great Point Partners. “John’s background, focus on high quality care, and vision make him well-equipped to continue the Company’s history of clinical excellence and growth. We are excited to have someone with his ability and record of accomplishments join and lead the Company.”

“I am excited to join Little Spurs as CEO where we will continue to focus on high quality pediatric patient care and increasing access for additional communities.,” said Mr. Mizerany. “Given my prior experience, I personally know the value proposition and potential of pediatric urgent care services, and I look forward to delivering an enhanced experience to the existing and future communities we serve.”

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.9 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.4 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Little Spurs  

We created Little Spurs Pediatric Urgent Care because we realize that most patients waiting in the Emergency Room for treatment are not there for life threatening emergencies, yet still need care that is not available in most pediatric offices. We have assembled a skilled staff of pediatric emergency room experienced, board certified pediatricians, and experienced advanced practice practitioners who are highly qualified to take care of your child’s minor emergencies. Our Vision: To become the premier pediatric urgent care provider in Texas; offering care for all children in our communities. Our Mission: To provide excellent medical care to all pediatric patients; strive for high quality customer service, and become a destination workplace for medical professionals. Our Values: Compassion, Respect, Teamwork, Dedication, Communication and Quality Care.

 

MLM Medical Labs continues international growth with acquisition of MD Biosciences, Inc. in Minnesota

Introduction

GREENWICH, CT and Moenchengladbach, GERMANY — MLM Medical Labs (“MLM”), a Great Point Partners portfolio company, today announced the acquisition of MD Biosciences, Inc., based in Oakdale, Minnesota.  MD Biosciences is a global, industry-leading provider of preclinical, translational and clinical-phase contract research services for the development of pharmaceutical and diagnostic assets.  With AAALAC-accredited, GLP-compliant and CLIA-certified facilities, MD Biosciences offers a wide range of validated and customizable models including inflammatory, autoimmunity, oncology, and metabolic diseases.  MD Biosciences operates a full-service histopathology lab including digital image analysis.  MD Biosciences Bioproducts and MD Biosciences Israel, which focuses on preclinical and translational research in neurology, are not part of this transaction.

MD Biosciences has a strong reputation for partnering closely with clients to help solve difficult scientific challenges.  This scientific expertise and high-touch emphasis fit perfectly with MLM’s core principles of strong scientific leadership with white glove customer service.  The addition of MD Biosciences follows the acquisition of CirQuest Labs in Memphis, Tennessee in July 2020 initiating MLM’s geographic expansion into the United States and adding key offerings to the expanded customer base now serving over 400 companies.

“We are extremely excited to welcome MD Biosciences to MLM.  MD Biosciences’ immunohistochemistry expertise and pre-clinical research are important additions to our core offerings.  Our customers are looking to MLM to meet their needs globally and this further strengthens our presence in the US.  With 150 employees between Europe and the US, MLM has the scale and capacity to support all stages of product development,” states Stephan Voswinkel, Managing Director, MLM.

“Joining MLM is the next step in the evolution of MD Biosciences, Inc., providing an expanded geographic reach in testing services.  This opens the opportunity to serve MD Biosciences’ growing roster of customers with their needs in Europe, the US and with the combined strength of MLM and CirQuest,” commented Eddie Moradian, CEO of MD Biosciences.

Bret Tenenhaus, Senior Vice President at Great Point Partners added, “Enhancing our capabilities for our existing customers and broadening our geographic reach globally are at the core of our strategic plan for MLM. The acquisition of MD Biosciences, Inc., with its presence in the U.S. and services spanning pre-clinical, clinical, and immunohistochemistry, is thus a significant milestone for MLM.”

The integration of the three operations will occur in the coming few months to align the operations and quality systems offering customers consistent access to MLM services in both the US and EU.  The addition of MD Biosciences further demonstrates MLM’s commitment to grow operations to meet the demand from its customers.

 

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.9 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.4 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About MLM Medical Labs

MLM Medical Labs founded 1993 is a Central and Specialty Laboratory dedicated exclusively to clinical trials. MLM offers a full range of laboratory services, including specialized biomarker testing, standard safety profiles, clinical chemistry, and analyses of drug compounds, metabolites and molecular diagnostic parameters. Internationally active in over 40 countries, including the U.S. and Eastern Europe, MLM is headquartered in Moenchengladbach, Germany (near Duesseldorf International Airport). MLM works 365 days a year in order to ensure valid, high-quality, results with a quick turnaround time. In December 2019 MLM became a Great Point Partners portfolio company. For more information, please visit www.mlm-labs.com

 

Great Point Partners Completes Growth Recapitalization of Family Resource Home Care

Introduction

GREENWICH, CT and SPOKANE, WA – Great Point Partners (“GPP”) today announced a growth recapitalization of Liberty Lake, Washington-based Family Resource Home Care (“FRHC”), a leading provider of home care services, operating nine field offices throughout Washington and Idaho. The Company’s locations provide a wide array of private duty home care services to thousands of clients each year. Family Resource Home Care drives quality and clinical standardization across its locations through its client-centric and data-driven operations. The Company’s focus on clinical excellence allow for best-in-class caregiver retention, quick turnaround times, and a high-touch experience for clients and families that have trusted FRHC since its inception in 1966.

“We first met Great Point in 2018 and we were immediately impressed with their deep knowledge of our market and health care expertise. Great Point’s unique insights into the home care market along with their expertise executing acquisitive growth strategies in health care services helped differentiate GPP from its peers,” said Jeff Wiberg, CEO of Family Resource Home Care. “Through this partnership we can achieve our goal of expanding our services to more client populations, while maintaining the highest level of care.”

“We are thrilled to partner with Jeff and the FRHC team to help the Company accelerate its growth and continue to establish itself as one of the Country’s largest independent providers of non-medical home care,” said Rohan Saikia, Managing Director at Great Point Partners.

“Given the fragmented landscape and industry tailwinds, Great Point identified the private-pay home care industry as a significant growth opportunity. FRHC has a successful track record as a consolidator in the sector and we are excited to help the Company continue its expansion strategy,” added Alex Gulotta, Vice President at Great Point Partners.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $2.0 billion of equity capital currently under management and 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.5 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, medical device, information technology enabled businesses and alternate site care. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About Family Resource Home Care

 Family Resource Home Care is the largest independent provider of home care services based in the Pacific Northwest and one of the largest in the United States. The Company provides home care services that include but are not limited to personal care such as bathing, dressing and help with medications, meal planning and preparation, light housekeeping, and companion care. The Company also provides care for clients facing dementia and Alzheimer’s Disease as well as end-of-life, transitional and respite care. Family Resource Home Care is focused on empowering clients to continue living at home by providing them with home care services that address their unique challenges. The Company is headquartered in Liberty Lake, WA, and has field offices in Arlington, Bellevue, Kennewick, Liberty Lake, Seattle, Spokane and Tacoma in Washington State, and Boise and Moscow, Idaho. More information on the Company and its services can be viewed online at www.familyresourcehomecare.com

MLM Medical Labs Begins Global Expansion Through Acquisition of CirQuest Labs in Memphis, Tennessee, USA

Introduction

GREENWICH, CT and Moenchengladbach, GERMANY — MLM Medical Labs (“MLM”), a Great Point Partners (“GPP”) portfolio company, a specialty central lab based in Germany, today announced it has acquired Memphis, Tennessee based CirQuest Labs (“CirQuest”) as part of its global expansion strategy. With the acquisition of CirQuest, MLM has expanded to the United States and will be able to better serve the needs of its global clients. CirQuest is an industry leader in specialized laboratory services for the drug development industry. CirQuest provides specialized assay development, biomarker testing, and central lab services to its global client base of leading pharmaceutical and life sciences companies.

“CirQuest has an excellent reputation in the centralized lab industry with a core focus on scientific excellence and customized service. A combination with MLM will allow us to better serve our combined customer base through a globally integrated platform,” said Dr. Stephan Wnendt, MLM CEO.

“CirQuest provides key services to many of the world’s leading drug developers. MLM’s acquisition of CirQuest will create a global and nimble central lab platform serving the global clinical trial market,” said Rohan Saikia, Managing Director at GPP.

Dr. Lisa Jennings, Founder and CEO of CirQuest, added “MLM is known globally as a leader in central lab and specialty testing solutions and together we have an extraordinary synergy in terms of our collective focus on scientific excellence and customized services. We are looking forward to joining forces and establishing a fully integrated central lab under one harmonized global brand.”

Finally, MLM is very proud to announce that Thomas Wollman, SVP Finance at Syneos Health, has joined MLM’s Board of Directors as of July 7, 2020. With his more than 25 years of experience in the central laboratory and CRO market, including responsibility for Quintiles’ central lab operations, he will help the team to further develop MLM as one of the leading international central labs for clinical trials.

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $2.2 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has $307 million of committed capital. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.6 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, medical device, information technology enabled businesses and alternate site care. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About MLM Medical Labs

MLM Medical Labs founded 1993 is a Central Laboratory dedicated exclusively to clinical trials. MLM offers a full range of laboratory services, including specialized biomarker testing, clinical chemistry, standard safety profiles, and analyses of drug compounds, metabolites and molecular diagnostic parameters. Internationally active in over 40 countries, including the U.S. and Eastern Europe, MLM is headquartered in Moenchengladbach, Germany (near Duesseldorf International Airport). MLM works 365 days a year in order to ensure valid, high-quality, results with a quick turnaround time. For more information, please visit https://www.mlm-labs.com/

 

Great Point Partners II Sells Citra Health Solutions to Cedar Gate Technologies

Introduction

GREENWICH, CT and RALEIGH, NC – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today that it has signed a definitive agreement to sell GPP II portfolio company, Citra Health Solutions (“Citra” or the “Company”),  to Cedar Gate Technologies, a portfolio company of GTCR Private Equity.  Citra, based in Raleigh, NC is a tech‐enabled software platform that automates and manages complex capitated arrangements for payers and providers. The Company provides a robust technology platform (EZ-SUITE) to support providers and payers managing at‐risk, value‐based arrangements. EZ-SUITE offers eligibility management, utilization management, care management, and administration of complex contractual arrangements including capitation and automated claims.

Adam Dolder, Managing Director at GPP commented, “This successful investment was grounded in our thematic approach in 2014 to capitalize on the changes in the health care system driven by increasing value-based care trends.  We were fortunate to recruit Scott Sanner (CEO) and an entirely new team to drive Citra and together, we made the key decision to focus the Company on its software solution and are thrilled with the outcome.”

“When I joined Citra two years ago, I was excited to partner with Great Point because of their health care expertise and track record of success in health care information technology,” Scott Sanner, Chief Executive Officer at Citra, stated.

“Our expertise in proprietarily sourcing add-on acquisitions enabled Citra to make a key acquisition of a highly strategic and complementary technology company, which helped drive significant value,” added Bret Tenenhaus, Senior Vice President at GPP.

“Over the last five years, the Company grew revenue at a 18% rate per year and EBITDA at a 43% rate per year,” said Eddie Hjerpe, Vice President at GPP.

 

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $2.0 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $307 million in committed capital) and public (BioMedical Value Fund family, approximately $1.5 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical and medical device services and supplies, alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About Citra Health Solutions

Citra provides a one-contract, connected solution for clinical, financial and administrative requirements. Solving for the needs of providers, payers, health systems and employers in the transition to value-based care, Citra empowers clients with proven technology, population health, analytics, care management, and administrative services to lower the cost of care and improve quality. Citra currently serves 6 of the top 7 Health Plans, 7 Fortune 500 Companies, 50+ IPAs and MSOs managing commercial, Medicare and Medicaid populations, and 100+ Provider Groups, Hospitals, Universities and Integrated Delivery Networks throughout the United States and in Puerto Rico.

 

Great Point Partners II Sells MaSTherCell Global to Catalent

Introduction

 GREENWICH, CT and GOSSELIES, BELGIUM – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce that it has signed a definitive agreement to sell GPP II portfolio company, MaSTherCell Global (“MaSTherCell”), a subsidiary of Orgenesis (NASDAQ: ORGS),  to Catalent Pharma Solutions, Inc. after significantly growing the business. MaSTherCell, based in Belgium and Houston, Texas, is a leading technology-focused cell and gene therapy contract development and manufacturing (“CDMO”) partner for leading biotechnology and pharmaceutical companies.  GPP made a growth equity investment in MaSTherCell in June 2018 alongside Orgenesis, a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry, and SFPI-FPIM, a Belgian sovereign wealth fund. In eighteen months, MaSTherCell has expanded from a single clinical facility in Belgium to three total facilities in the U.S. and EU, including a commercial manufacturing facility under construction.

Noah Rhodes, Managing Director at GPP commented, “We are very proud of what we accomplished with CEO Darren Head, President Denis Bedoret, our partners Orgenesis and SFPI-FPIM, and the entire MaSTherCell team in just over 18 months. During our ownership, we significantly expanded MaSTherCell’s manufacturing capacity, including establishing a U.S. facility in Houston, Texas, thereby creating a company that can serve biotechnology and pharmaceutical clients globally. We look forward to watching the company continue to grow under Catalent’s stewardship.”

“This is the second time I have had the opportunity to partner with GPP in building a contract development and manufacturing business serving life sciences companies. GPP’s expertise in growing global pharmaceutical services companies and their extensive network in the industry were integral to our success both times,” commented Darren Head, CEO of MaSTherCell.

Vered Caplan, CEO of Orgenesis, said, “When GPP reached out about an investment in our contract development manufacture organization, MaSTherCell, it was clear that they recognized the unique value of the company and the best way to position it for future growth.  GPP’s experience bringing European pharma services businesses into the U.S. market was invaluable as we executed our growth plan for MaSTherCell.”

“Our theme-based investment approach helped us identify cell and gene therapy manufacturing as a significant growth area and led us to pursue MaSTherCell as a platform company in this area,” added Eddie Hjerpe, Vice President at GPP.

Founded in 2011, MaSTherCell has a 25,000 square-foot facility in Gosselies, Belgium providing clinical services, and construction is in progress on a dedicated 60,000 square-foot commercial-scale production and fill-finish facility nearby, which is scheduled to open in the fall of 2021 and ultimately add over 250 new jobs to the current team of over 240. Its 32,000 square-foot U.S. facility in Houston, Texas, upon completion of validation activities, will focus on development-scale projects and will employ a team of over 50 experts before the end of the year. MaSTherCell has a growing customer base and offers a unique portfolio of capabilities and technologies that include the development and manufacture of autologous and allogeneic cell therapies, as well as a variety of related analytical services. Its experience includes therapies based on chimeric antibody receptor-engineered T cells (CAR-T), T cell receptors (TCR), tumor-infiltrating lymphocytes (TIL), and mesenchymal stem cells (MSC).

 

About Great Point Partners

 Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $2.0 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $306 million in committed capital) and public (BioMedical Value Fund family, approximately $1.5 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About Orgenesis

 Orgenesis (NASDAQ: ORGS) is a biopharmaceutical company specializing in the development, manufacturing and processing of technologies and services in the cell and gene therapy industry. The Company operates through two platforms: (i) a point-of-care (“POCare”) cell therapy platform (“PT”) and (ii) a Contract Development and Manufacturing Organization (“CDMO”) platform conducted through its subsidiary, Masthercell Global. Through its PT business, the Company’s aim is to further the development of Advanced Therapy Medicinal Products (“ATMPs”) through collaborations and in-licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes to bring such ATMPs to patients. The Company out-licenses these ATMPs through regional partners to whom it also provides regulatory, pre-clinical and training services to support their activity in order to reach patients in a point-of-care hospital setting. Through the Company’s CDMO platform, it is focused on providing contract manufacturing and development services for biopharmaceutical companies. Additional information is available at: www.orgenesis.com.

 

About SFPI-FPIM

The Belgian Federal Holding and Investment Company (Société Fédérale de Participations et d’Investissement / Federale Participatie- en Investeringsmaatschappij; SFPI-FPIM), was created on November 1, 2006 as a result of a merger between the Federal Participation Company and the Federal Investment Company. The Belgian federal government is SFPI-FPIM’s sole shareholder. SFPI-FPIM centrally manages the federal government’s shareholdings, cooperates with the government on specific projects, and pursues its own investment policy in the interests of the Belgian economy. The core business of SFPI-FPIM is as an investment company, to invest in companies with an attractive added value for society in one of the SFPI-FPIM priority sectors. As a holding company, it acquires equity in companies that are of strategic importance as far as federal policy is concerned, either making use of its own funds or by using funds that the state provides for a project.

 

About MaSTherCell Global, Inc.

MaSTherCell is dedicated to the industrialization and production of cell and gene therapies for leading biotech innovators. Its facilities enable cell therapy companies to benefit from state-of-the-art infrastructures and world-recognized experts, thus accelerating the arrival of cell therapies on the market. At the heart of MaSTherCell is a team of 240 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and substantial knowledge of the industry. MaSTherCell’s goal is to help customers providing innovative and affordable treatments to patients, in a fast and cost-efficient way.

 

Great Point Partners II Exits Investment in Corrona LLC, a Leading Provider of Clinical Real-World Evidence

Introduction

GREENWICH, CT and WALTHAM, MA – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, has exited its investment in Corrona to Audax Private Equity after accelerating the Company’s growth.  Corrona provides clinical real-world evidence to pharmaceutical and biotechnology companies by establishing and operating patient registries in the United States, Europe, and Asia.

Noah Rhodes, III, Managing Director at GPP commented, “We are very proud of what we accomplished with CEO Raymond Hill and the entire Corrona team. In 2014 we were looking for an investment in the clinical real-world evidence sector and were immediately impressed with the business that founder Dr. Joel Kremer had built.  Corrona expanded to six registries during our ownership and grew into related areas of UK electronic medical records and claims data and patient experience studies. We look forward to watching the Company continue to flourish under Ray’s leadership.”

“Great Point was an outstanding partner, providing insight gained from their extensive experience in the pharmaceutical services sector and supporting our search for related businesses to expand Corrona’s offerings with their dedicated sourcing team,” Raymond Hill, Chief Executive Officer at Corrona, stated.  “Additionally, through their deep network in the biopharmaceutical industry, Great Point recruited a talented board of directors that provided valuable guidance.”  Noted Jeff Greenberg, MD, CMO of Corrona, “GPP helped to enhance our capabilities in many areas, while ensuring we retained a strong focus on patients and our core investigator network.”

“We increased Corrona’s growth trajectory by providing capital to expand the number of registries the Company manages and completing two accretive acquisitions: Health iQ of London, England and HealthiVibe of Arlington, Virginia, which made Corrona a global business.  Corrona’s impressive growth is a significant achievement for the management team,” added Jeffrey Jay, Co-Founder and Managing Director at Great Point Partners.

Allen & Company LLC served as exclusive financial advisor to Corrona, and Morrison Cohen LLP served as the Company’s legal counsel.

 

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $1.9 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $306 million in committed capital) and public (BioMedical Value Fund family, approximately $1.4 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About Corrona

 Corrona provides real world evidence through syndicated registry data and analysis services, helping biopharmaceutical companies demonstrate the value of their products to clinicians, patients, payers, and regulators.  Corrona operates six major autoimmune registries across the US, Canada and Japan, collecting data from over 500 participating investigator sites.  In addition to supporting hundreds of manuscripts and abstracts, Corrona has supported post approval safety commitments for multiple advanced therapies approved for autoimmune conditions.  Corrona is headquartered in Waltham, MA.  Through its subsidiary Health iQ, Corrona has access to a broad range of UK and international data sets across primary and secondary care, as well as deep relationships with the NHS, Public Health England, and leading UK academic institutions.  The Company’s HealthiVibe business complements and strengthens Corrona’s strong presence in disease registries by providing market-leading expertise in supporting innovative, evidence-based patient engagement initiatives across the product lifecycle.  Learn more at www.corrona.org, or via email at info@corrona.org.

 

Great Point Partners-Backed Spine & Sport Physical Therapy Completes Acquisition of Wisdom Physical Therapy

Introduction

GREENWICH, CT and SAN DIEGO, CA – Great Point Partners’ (“GPP”) portfolio company, Spine & Sport Physical Therapy (“Spine & Sport”), a leading provider of outpatient physical therapy and rehabilitation services in San Diego, CA, has acquired Wisdom Physical Therapy (“Wisdom”).  Wisdom operates in El Centro, CA.

“We are excited to have Doug Wisdom and his team join Spine & Sport to further entrench ourselves in Imperial County,” said Mark Mathiesen, CEO of Spine & Sport. “Wisdom is one of the premier physical therapy providers in El Centro with a proven record of quality of care and strong referral network.”

“Spine & Sport’s treatment program, development resources, and vision for growth in Imperial County and beyond were key factors in our decision to join them,” said Doug Wisdom, founder of Wisdom.

The addition is the third acquisition Spine & Sport has made since Great Point’s investment in December 2018. It is a clear indication of Spine & Sport’s ability to execute its strategic plan, expansion and successful growth.  With the addition of Wisdom, Spine & Sport now has 22 locations.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $1.8 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $306 million in committed capital) and public (BioMedical Value Fund family, approximately $1.1 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Spine & Sport  

Spine & Sport Physical Therapy (“Spine & Sport”), headquartered in San Diego, CA is a leading provider of physical therapy and rehabilitation services in the San Diego metropolitan area. Spine & Sport was founded in 1999 and is currently operated by three entrepreneurs with significant experience in the outpatient multi-site healthcare space. The Company operates 22 owned outpatient physical therapy clinics as well as managing five additional locations in Northern California.  The Company’s outpatient clinics provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.  Spine & Sport’s rehabilitation programs and services help patients minimize physical and cognitive impairments and maximize functional ability so that they can return to competition, the workplace and / or their normal lifestyle. Reach Spine & Sport at 800-976-7544 or www.spineandsport.com/

Great Point Partners Closes Fund III at $306 Million

Introduction

GREENWICH, CT — Great Point Partners, a leading health care investment firm, today announced the closing of Great Point Partners III, L.P. (“GPP III”), a $306 million growth buy-out fund, at its hard cap. GPP III was oversubscribed and exceeded its target of $250 million.

GPP III will continue Great Point’s strategy of investing in growing, profitable health care companies that are led by management teams focused on achieving accelerated and sustainable growth. GPP III has already made three investments (representing approximately 30% of committed capital), all in growing pharmaceutical services companies, a core area of focus for the Firm.

“We are pleased to announce our final close,” said Jeffrey R. Jay, M.D., Co-Founder and Managing Director of Great Point Partners. “We were gratified to receive strong support from both our existing investors, many of whom have been invested with us since the inception of our private equity strategy in 2005, and a select group of new leading institutional limited partners.”

David Kroin, Co-Founder and Managing Director, added, “We see this success as a clear endorsement by our investors of our growth buy-out and growth recapitalization investing model, pro-active sourcing strategy and deep health care expertise.”

GPP III’s Limited Partners include leading endowments, foundations, family offices, banks and pension funds. The investment professionals and CEO Advisory Board at Great Point made a significant personal commitment to GPP III, approximately 8% of GPP III’s committed capital.

Morrison Cohen LLP acted as legal counsel for GPP III.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm, currently with approximately $1.8 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $306 million in committed capital) and public (BioMedical Value Fund family, approximately $1.2 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Great Point Partners-Backed VitaLink Research Completes Acquisition of Comprehensive Clinical Trials

Introduction

GREENWICH, CT and GREENVILLE, SC – VitaLink Research (“VLR”) today announced that it has acquired West Palm Beach, FL-based Comprehensive Clinical Trials (“CCT”).  CCT focuses on providing Phase II – IV clinical trials with a therapeutic focus in women’s health.  The addition of CCT enables VitaLink Research to provide high-quality clinical research to a greater number of patients throughout the Southeast.

“The partnership with Comprehensive Clinical Trials is a critical milestone in the company’s expansion into the growing field of women’s health,” said Nick Wright, CEO of VitaLink Research.  “The addition of CCT enables us to partner with the fantastic team that Dr. Ackerman has built throughout his distinguished career as a physician and Principal Investigator.  Additionally, I look forward to working with Dr. Ackerman to strategically grow our women’s health clinical research capabilities in existing VitaLink Research sites to increase the number of patients who can participate in these important research studies.  Dr. Ackerman’s expertise in clinical research is world renowned and he will continue to lead the CCT business.”

“I am excited to partner with the entire VitaLink Research team to further grow our combined business over the coming years,” said Dr. Ronald Ackerman, Founder of CCT.  “The strong infrastructure that VitaLink has established will enable CCT to focus exclusively on clinical research and expanding our women’s health expertise throughout the VitaLink network.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.8 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $288 million in committed capital) and public (BioMedical Value Fund, approximately $1.2 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About VitaLink Research

VitaLink Research (“VLR”) was founded in 2004 and has since become a leading dedicated clinical research site business with 13 locations in the U.S. Headquartered in Greenville, SC, VLR’s model is an effective method of research operations and management that consistently exceeds sponsor and FDA expectations during all quality audits while consistently ranking in the top 10% in global enrollment. The clustering of sites provides the opportunity for inter-site cross training, idea exchange, and standardization of operating procedures. With over ten years of shared experiences the company has developed best practices which continue to be the foundations of its successful U.S. operations. Learn more at www.vitalinkresearch.com.

 

Little Spurs Pediatric Urgent Care Expands into Dallas-Ft. Worth Through Its Acquisition of All Children’s Urgent Care

Introduction

GREENWICH, CT and SAN ANTONIO, TX – Great Point Partners’ portfolio company Little Spurs Pediatric Urgent Care (“Little Spurs”), a leading provider of pediatric urgent care services in Texas, has acquired Garland, Texas-based All Children’s Pediatric Urgent Care (“ACUC”). Together, Little Spurs and ACUC will continue to provide high-quality care to children throughout the Dallas-Ft. Worth (“DFW”) metro area.

Founded in 2014, ACUC has served the pediatric population of DFW by upholding the highest standard of care and commitment to clinical excellence. This reputation led a record number of DFW families to trust ACUC to treat their children, as the clinic had over 10,000 visits in 2018. “We are excited to partner with the ACUC team and look forward to expanding throughout Dallas to increase patient access to high quality pediatric urgent care,” said Dr. Tom Spurgat, CEO and Founder of Little Spurs.

“We have worked tirelessly since opening to provide DFW children with high-quality, flexible, and caring medicine. Our team is proud to have treated thousands of children and looks forward to continuing to expand our practice,” said Dr. Sameeh Zalloum, the Physician-Founder of ACUC. Dr. Zalloum will continue to practice medicine at ACUC.

Additionally, Little Spurs is pleased to announce that Hugh Greene, Jean Rush, and Don Tomasso have joined the Board of Directors. As the former CEO of Jacksonville Baptist Health System, Hugh Greene brings a wealth of knowledge on the provider side, while Jean Rush, a former Executive Vice President at Highmark Health, brings extensive payor experience. Don Tomasso, who has extensive multi-site healthcare services experience as the former President of Manor Care and former Chairman of the Board of Professional Physical Therapy, will serve as Chairman of the Board of Directors.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.8 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has $288 million in committed capital) and public (BioMedical Value Fund, approximately $1.2 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Little Spurs  

We created Little Spurs Pediatric Urgent Care because we realize that most patients waiting in the Emergency Room for treatment are not there for life threatening emergencies, yet still need care that is not available in most pediatric offices. We have assembled a skilled staff of pediatric emergency room experienced, board certified pediatricians, and experienced advanced practice practitioners who are highly qualified to take care of your child’s minor emergencies. Our Vision: To become the premier pediatric urgent care provider in Texas; offering care for all children in our communities. Our Mission: To provide excellent medical care to all pediatric patients; strive for high quality customer service, and become a destination workplace for medical professionals. Our Values: Compassion, Respect, Teamwork, Dedication, Communication and Quality Care.

Learn more at https://www.littlespurspedi.com/.

About All Children’s Urgent Care

 All Children’s Urgent Care clinic provides comprehensive health care for all children from routine office visit care to all urgent care needs such as injuries and lacerations. We know how difficult it can be for parents to schedule appointments and take off work to bring their children to the doctor’s office, that’s why we welcome walk-ins for parents any time. Every aspect of our clinic is designed with children in mind. Each member of our clinical staff is medically trained and every patient is seen by experienced board certified providers. Our vision is to provide faster, efficient, less expensive, and comprehensive health care for all children in the DFW area. Reach All Children’s Urgent Care at http://www.allchildrensurgentcareclinic.com/index.html.

 

Great Point Partners Recapitalizes SteriPack

Introduction

GREENWICH, CT and MULLINGAR, IRELAND — Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, today announced the growth recapitalization of SteriPack (“SteriPack” or the “Company”).  The Company is a leading contract manufacturing and value-added services company serving the medical device and pharmaceutical industries. SteriPack has been a continuous innovator in the markets that it serves and has grown both its breadth of services as well as geographic presence. From its original base of operations in Ireland, the Company extended its geographic footprint by adding facilities in Poland (2006), Malaysia (2009) and the United States (2012). SteriPack acts as a “one-stop-shop” solution for their customers by providing a full breadth of services from engineering through production and distribution.

“Since Garry Moore founded the business in 1994, SteriPack has been a constant innovator in the medical device contract manufacturing industry and the Company has continuously evolved to meet their clients’ needs through superior customer service and an uncompromising commitment to quality,” said Adam Dolder, Managing Director at GPP.

SteriPack has over 650 employees worldwide and is constantly looking to expand its capabilities and reach, through both organic growth and add-on acquisitions.  “Garry Moore (CEO), Aidan O’Brien (CFO), and the entire SteriPack team have done a phenomenal job leading the Company through two decades of growth. We look forward to helping them expand their global presence and accelerating that growth with an aggressive add-on acquisition strategy as we have done in many of our other successful investments,” added Bret Tenenhaus, Vice President at GPP.

“Great Point’s impressive track record of investing in the health care manufacturing industry and their experience with bolt-on acquisitions made them an ideal partner to help accelerate SteriPack’s growth,” said Garry Moore, founder and CEO of SteriPack. “We have built a great relationship with Great Point since 2015 and are excited to have them as partners, as we strive to better serve our customers around the world.”

As part of Great Point’s investment Robert Thomas of Great Point’s CEO Advisory Board will join SteriPack’s Board of Directors. Mr. Thomas is the former CEO of FoxHollow Technologies, which ultimately achieved a market capitalization of more than $1 billion prior to its sale to EV3.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $286 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $286 million in committed capital) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on (i) biopharmaceutical/medical device infrastructure, services and supplies, (ii) alternate site care, and (iii) healthcare technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About SteriPack

SteriPack is a leading contract manufacturing and value-added service provider to the medical device and pharmaceutical (primarily drug-device combination products) industries.  Serving some of the largest names in the medical device industry, the Company has experienced impressive customer retention and provides the highest quality and customer service. Headquartered in Ireland with 650 employees, SteriPack operates facilities in Poland, Malaysia, and the United States, a critical and differentiating element for its global client base. SteriPack’s international footprint, high quality products, and integrated services created a strong brand presence in the contract manufacturing market, allowing the company to develop long-standing relationships with blue chip device companies. For more information, please visit https://steripackgroup.com/

Great Point Partners Completes Growth Equity Investment in Tergus Pharma to Build New 100,000 Square Foot Manufacturing Facility for Topical Pharmaceuticals

Introduction

GREENWICH, CT and RALEIGH, NC — Great Point Partners (“GPP”) today announced a growth recapitalization of Raleigh, North Carolina-based Tergus Pharma, a leading contract development and manufacturing business for topical dermatology pharmaceuticals.  Tergus provides formulation development, in vitro permeating testing (IVPT), in vitro release testing (IVRT), skin biology, analytical services, and clinical manufacturing services for branded and generic dermatology products. Great Point’s investment will allow Tergus to build a state of the art commercial manufacturing facility in Raleigh, NC that will begin construction in July 2019. The new 100,000 square foot facility will have Clinical Trial Material (Phases I thru III) Supplies  and commercial manufacturing capabilities and expand current capacity by over 400%.

“Great Point’s expertise and successful track record growing pharmaceutical services companies was evident when they proactively approached us about a partnership. For years we have discussed building a commercial facility. The equity capital from GPP will enable us to do this and we will be able to better serve our customers by offering end-to-end services including commercial manufacturing,” said Vijendra Nalamothu, Ph.D., CEO of Tergus. “Great Point’s experience, network, and success in current and previous outsourced pharmaceutical services  investments was a true differentiator.”

“Tergus has differentiated itself as a leader in the complex topical dermatology development space that has been growing at ~15% per year,” said Rohan Saikia, Managing Director at Great Point Partners. “Tergus’ reputation within topical dermatology is unparalleled and we are thrilled that Tergus will now be a ‘one-stop-shop’ from clinical development to commercial manufacturing for all of their clients.”

 

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $286 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, pharmaceutical infrastructure, hospital outsourcing and alternate site care, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

 

About Tergus Pharma

Tergus, an end-to-end service provider for topical pharmaceutical research, drug development, testing and manufacturing company, has been an industry leader for several years with a state-of-the-art facility in Durham, North Carolina. The company has a long and stellar reputation for delivering quality results to clients from formulation through manufacturing, which is why people say, “Think Topicals, Think Tergus.” A systematic and scientific approach is used to thoroughly understand product components, processing, and finished product attributes to ensure high quality product throughout the course of development. Tergus helps its client achieve a balance between a fast-tracked program and quality science. For more information, please visit https://www.terguspharma.com/

Great Point Partners Makes $22 Million Equity Commitment to Bionova Scientific

Introduction

GREENWICH, CT and Fremont, CA — Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, today announced a $22 million equity commitment to Bionova Scientific, a leading specialized biologics contract development and manufacturing organization (“CDMO”). GPP funded $13.3 million at closing, with a commitment to fund an additional $9 million over the next two years. Founded in 2014 and based in Fremont, CA, Bionova helps clients manage all aspects of biologics development and manufacturing, from early stage research material generation to process development to contract manufacturing services. Great Point’s growth equity investment allows Bionova to complete the build out of a 57,000 square foot GMP facility in Fremont, CA with the capability to manufacture clinical grade protein therapeutics for its global customer base.

Bionova marks Great Point’s second investment in the biologics CDMO space, as GPP previously invested in Cytovance Biologics. “We are thrilled to once again invest in the biologics CDMO industry and look forward to replicating the success we had with Cytovance,” said Noah Rhodes, Managing Director at Great Point Partners. “We have known Amy, Chung, and the Bionova team for a number of years and look forward to helping them better serve their customers through the build out of a first-class biologics GMP facility in the Bay Area.”

“Great Point’s long track record of investing in the pharmaceutical services industry and their previous experience with Cytovance made them an ideal partner to help accelerate Bionova’s growth,” said Amy Kong, CEO of Bionova.

“We have built a great relationship with Great Point and are excited to have them as partners, as we strive to better serve our customers in the Bay Area and around the world,” added Chung Chun, COO at Bionova.

 

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $280 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $280 million in committed capital) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Bionova Scientific

Bionova Scientific is a dynamic, full service, biologics Contract Development and Manufacturing Organization (CDMO) on a mission to deliver the highest quality process development and manufacturing services to biologic drug development companies around the world. Bionova’s renowned scientific expertise and dedication to its customers helps life changing therapies arrive to the market faster and more efficiently. At the heart of Bionova is a team of highly dedicated experts combining strong experience in cGMP biologics manufacturing and process development, with a technology-focused approach and a deep knowledge of the industry. Their expertise covers the bioproduction of a broad array of biomolecules including recombinant glycoproteins, Mabs, Fabs, enzymes, Fc-fusions, and bi-specifics. From early stage research material generation to Process Development and GMP manufacturing, Bionova’s client-focused teams are fully committed to helping their clients fulfill their objectives in providing sustainable and affordable therapies for their patients. For more information, please visit http://bionovascientific.com/.

Great Point Partners Completes Growth Equity Investment in Axiom Real-Time Metrics

Introduction

GREENWICH, CT and TORONTO, CANADA – Great Point Partners (“GPP”) today announced a growth recapitalization of Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services that are used to enhance the efficiency of Phase I, II and III clinical trials and observational studies.  Axiom is a leading e-clinical technology company that focuses on Electronic Data Capture (“EDC”), Data Management (“DM”), Clinical Trial Management Systems (“CTMS”), Randomization (“IWRS”), Electronic Patient Reported Outcomes (“ePRO”) and other technology and service solutions for biotechnology and pharmaceutical sponsors conducting clinical trials.  Founded in 2001 and based in Toronto, Canada, the Company will leverage this funding to scale its technology system and superior customer service.

“From the beginning of our conversation when they proactively approached us about a partnership, Great Point demonstrated its expertise in the clinical trial service needs of biotechnology and pharmaceutical companies, Axiom’s core customer base. Their market knowledge and the depth of their experience investing in pharmaceutical services companies made them an ideal partner for Axiom as we enter our next phase of growth.  GPP’s investment will allow Axiom to increase the level of customer service and add additional technology solutions and services,” said Andrew Schachter, Founder and CEO of Axiom.

“We are excited to partner with the Axiom team and help them execute an accelerated growth plan,” said Noah Rhodes, Managing Director at Great Point Partners. “Andrew and his team have built an impressive business that has been growing at 56% per year over the last six years. We look forward to introducing Andrew to the biotechnology CEOs in our network, all of whom are either current or potential customers for Axiom’s products and services.”

“Our work in the trenches alongside drug developers over the last decade has proven that there is a huge need for Axiom’s solutions.  This need is reflected in their explosive growth and superb customer satisfaction reported to us by the CEOs who are their customers,” said Eddie Hjerpe, Senior Associate at Great Point Partners.

 

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.6 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP III, which has committed capital of $280 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III, $280 million in committed capital) and public equity funds (BMVF, approximately $1.1 billion). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Axiom Real-Time Metrics

Headquartered in Toronto, Canada, Axiom delivers intuitive, powerful and cost-effective eClinical solutions and services focused around your entire study. Services include: Data Management, Data Analytics, Biostatistics and Pharmacovigilance. Axiom’s eClinical suite, Fusion, delivers a powerful range of innovative end-user focused, unified functionality and more than 15 modules. Axiom serves as the Connected Hub for your entire clinical study data and operational needs. Fusion Delivers: EDC, DM, IWRS, CTMS, Inventory Management, IVR, Patient Portal, AE/SAE Tracking, Safety Database, Central Lab, Imaging, eTMF, and 24/7 Project and Clinical Data Reporting. For more information, please visit http://www.axiommetrics.com/.

Great Point Partners Completes Growth Recapitalization of Little Spurs Pediatric Urgent Care

Introduction

GREENWICH, CT and SAN ANTONIO, TX – Great Point Partners (“GPP”) today announced a growth recapitalization of Little Spurs Pediatric Urgent Care, a leading provider of pediatric urgent care services, operating 12 clinics in Texas.  The Company’s clinics treat children with acute illnesses or injuries in an urgent care setting, providing a convenient and cost-efficient alternative to emergency room treatment, while maintaining the highest quality of care.

“We first met Great Point in 2014 and we were immediately impressed with their deep knowledge of our market and health care expertise. Great Point’s unique insights into the pediatric urgent care market combined with their prior success in building leading health care services businesses make them the ideal partner for Little Spurs,” said Dr. Thomas Spurgat, CEO and Founder of Little Spurs. “With the help of the Great Point team, we are better positioned to achieve our goal of expanding our vital services to more patient populations, while maintaining the highest level of care for our patients and their families.”

“We are thrilled to form a partnership with Tom and the Little Spurs team to help accelerate their growth,” said Rohan Saikia, Managing Director at Great Point Partners. “Our partnership will allow the Company to grow its footprint and provide low cost and convenient access to more children in an urgent care setting.”

“Given the trend towards timelier access, higher quality, and lower costs within the U.S. health care system, the pediatric urgent care industry offers a strong value proposition to various constituents, especially children,” added Bret Tenenhaus, Vice President at Great Point Partners.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.5 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III which has over $275 million in committed capital) and public (BioMedical Value Fund, approximately $1.1 billion) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Little Spurs  

We created Little Spurs Pediatric Urgent Care because we realize that most patients waiting in the Emergency Room for treatment are not there for life threatening emergencies, yet still need care that is not available in most pediatric offices. We have assembled a skilled staff of pediatric emergency room experienced, board certified pediatricians, and experienced advanced practice practitioners who are highly qualified to take care of your child’s minor emergencies. Our Vision: To become the premier pediatric urgent care provider in Texas; offering care for all children in our communities. Our Mission: To provide excellent medical care to all pediatric patients; strive for high quality customer service, and become a destination workplace for medical professionals. Our Values: Compassion, Respect, Teamwork, Dedication, Communication and Quality Care.

Learn more at https://www.littlespurspedi.com/.

Great Point Partners Completes Growth Recapitalization of Spine & Sport Physical Therapy

Introduction

GREENWICH, CT and SAN DIEGO, CA — Great Point Partners (“GPP”) today announced a growth recapitalization of Spine & Sport Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services in the San Diego, CA metropolitan area, operating 16 owned outpatient physical therapy clinics as well as managing five additional locations in Northern California.  The Company’s outpatient clinics provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.

“Right from the initial conversation when they proactively approached us about a partnership, Great Point demonstrated its expertise in physical therapy and health care. Their prior successful experience with Professional Physical Therapy and market knowledge make them an ideal partner for Spine & Sport.  Our shared vision for growth is to continue to build Spine & Sport organically and through tuck-in acquisitions. We will do that while continuing to maintain the highest level of clinical care and providing more opportunities for our employees,” said Mark Mathiesen, CEO of Spine & Sport.

“We are excited to partner with the Spine & Sport team and help them execute an accelerated growth plan,” said Adam Dolder, Managing Director at Great Point Partners. “With our investment, directly relevant experience and shared vision, we believe it’s possible to transform the Company into the leading outpatient physical therapy provider in Southern California.  Our plan is similar to what we accomplished with Professional Physical Therapy in the New York metro area.”

“The founders of Spine & Sport, Mike Biggs, Mark Mathiesen and Joe Verna have done a tremendous job building the business over the past decade,” added Stephen Weaver, Principal of Great Point Partners.  “We are thrilled to partner with the team on the growth strategy by combining their experience and high-quality clinicians with our knowledge of the outpatient physical therapy sector and ability to source and execute tuck-in acquisitions.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.4 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III with a target of $250 million in committed capital) and public (BioMedical Value Fund strategy, approximately $800 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Spine & Sport  

Spine & Sport Physical Therapy (“Spine & Sport”), headquartered in San Diego, CA is a leading provider of physical therapy and rehabilitation services in the San Diego metropolitan area. Spine & Sport was founded in 1999 and is currently operated by three entrepreneurs with significant experience in the outpatient multi-site healthcare space. The Company operates 16 owned outpatient physical therapy clinics as well as managing five additional locations in Northern California.  The Company’s outpatient clinics provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.  Spine & Sport’s rehabilitation programs and services help patients minimize physical and cognitive impairments and maximize functional ability so that they can return to competition, the workplace and / or their normal lifestyle. Reach Spine & Sport at 800-976-7544 or www.spineandsport.com/

Great Point Partners Backed Citra Health Solutions Completes Acquisition of DataWing Software LLC

Introduction

GREENWICH, CT and RALEIGH, NC — Great Point Partners’ portfolio company, Citra Health Solutions (“Citra”), a trusted provider of benefit administration technology solutions and care management services, has acquired Portland, Oregon based DataWing Software LLC (“DataWing”). Together, Citra and DataWing will provide a comprehensive suite of technology products to value-based care providers.

For over 25 years, DataWing has offered software to help Managed Service Organizations (MSOs), Independent Physician Associations (IPAs), and other healthcare providers improve efficiencies and increase profitability. DataWing’s offering integrates with claims adjudication systems (including Citra’s EZ-CAP) to create additional value-added solutions. Additionally, DataWing products help healthcare providers obtain data from payor organizations to confirm the eligibility of patients to receive reimbursement for care. The acquisition of DataWing will extend Citra’s EZ-Suite set of software technologies and augment Citra’s capitation and eligibility management product offering.

“DataWing provides Citra with a complementary technology and service offering and a team with deep domain expertise,” said Scott Sanner, CEO of Citra Health Solutions. “The acquisition will enhance and strengthen Citra’s go-to-market strategy and offer our client base additional products to help with efficiency and cost savings.”

Jerry Porter, the founder of DataWing added, “We have been friends and partners of EZ-CAP since we began our business in the early 90s. We are excited to enhance Citra’s value proposition by combining our capabilities. The future is very bright for both DataWing and Citra customers alike.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Citra Health Solutions

Citra provides a one-contract, connected solution for clinical, financial and administrative requirements. Solving for the needs of providers, payers, health systems and employers in the transition to value-based care, Citra empowers clients with proven technology, population health, analytics, care management, and administrative services to lower the cost of care and improve quality. Citra currently serves 6 of the top 7 Health Plans, 7 Fortune 500 Companies, 50+ IPAs and MSOs managing commercial, Medicare and Medicaid populations, and 100+ Provider Groups, Hospitals, Universities and Integrated Delivery Networks throughout the United States and in Puerto Rico.

Great Point Partners II Sells Clinical Supplies Management to Clinigen

Introduction

GREENWICH, CT and MALVERN, PA – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, is pleased to announce that it has signed a definitive agreement to sell GPP II portfolio company, Clinical Supplies Management (“CSM”) after tripling revenue in less than two years. CSM is a leading provider of clinical trials drug packaging, labeling and logistics solutions to the global life science, pharmaceutical and biotechnology industries.

Rohan Saikia, Managing Director at GPP commented, “We are very proud of what we accomplished with CEO Scott Houlton and the entire CSM team in our two years of ownership. Our theme based investment approach, extensive executive network and internal sourcing team allowed us to recruit Scott Houlton as the CEO prior to our initial investment and complete two strategic European tuck-in acquisitions within the first three months of our ownership. These two tuck-in acquisitions transformed CSM into a global company that was better positioned to win new business and significantly increase sales.”

“Great Point’s expertise in pharmaceutical services and support for tuck-in acquisitions from sourcing through integration were critical components of our success, enabling us to build a high growth global company in a short period of time,” Scott Houlton, Chief Executive Officer at CSM, stated.  “Additionally, the talented Board of Directors recruited by Great Point offered invaluable insight and helped shape our strategy. This has been a highly rewarding partnership for the CSM team.”

“Due to Great Point’s extensive experience in pharmaceutical services and our dedicated acquisition sourcing team, we were able to identify tuck-in acquisition targets and potential areas of growth prior to our acquisition of CSM in 2016. With Scott’s leadership, these acquisitions helped us execute our strategy quickly and efficiently.  We transformed CSM from a company with operations at two U.S. sites only into a global company with operations also in Belgium and Germany that resulted in a dramatic acceleration of growth,” added Stephen Weaver, Senior Vice President at Great Point Partners.

 

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital, and GPP III with a target of $250 million in committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Clinical Supplies Management

 Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials. Some of CSM’s clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, as well as returns, reconciliation and destruction. Reach CSM in Malvern, PA at 866-487-3276 or www.csmondemand.com.

Great Point Partners Makes Growth Equity Investment in MaSTherCell Global

Introduction

GREENWICH, CT and CHARLEROI, BELGIUM — Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in MaSTherCell Global. Founded in 2011 (acquired by Orgenesis (NASDAQ: ORGS) in 2015) and based in Charleroi, Belgium, MaSTherCell leverages its world-class facilities, regulatory track record and technical expertise to maintain a leading position as a global manufacturer of cell and gene therapies. The growth equity investment by Great Point will allow MaSTherCell to pursue additional avenues of growth and capitalize on the rapidly expanding market of cell and gene therapies.

MaSTherCell (Manufacturing Synergies for Therapeutic Cells) offers clients process development and contract manufacturing services and is dedicated to all aspects of the cell therapy development and manufacturing process. From technology transfer to end logistics, the Company provides a wide range of services to help biotechnology companies develop and produce their novel drugs. MaSTherCell has facilities in Belgium, South Korea, Israel, and following the GPP investment, will build an additional facility in the United States.

“We are excited to make this investment in MaSTherCell,” Noah Rhodes, Managing Director at Great Point Partners, stated. “We have been pursuing a platform in the cell and gene therapy manufacturing market for some time and believe that MaSTherCell is well-positioned to take advantage of the tailwinds in the market.”

“Great Point’s long track record of investing in the pharmaceutical services industry made them an ideal partner to help accelerate MaSTherCell’s growth and achieve our vision for the company. We look forward to working together to pursue our common goals for expansion,” added Vered Caplan, Chairman of MaSTherCell.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About MaSTherCell

MaSTherCell is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations and speed up the arrival of their therapies onto the market. At the heart of MaSTherCell is a team of more than 90 highly dedicated experts combining strong experience in cGMP cell therapy manufacturing with a technology-focused approach and a substantial knowledge of the industry. From technology selection to business modeling, GMP manufacturing, process development, quality management and assay development, MaSTherCell’s teams are fully committed to helping their clients fulfill their objective of providing sustainable and affordable therapies to their patients. The company operates in a validated and flexible facility located in the strategic center of Europe within the Walloon healthcare cluster, Biowin. For more information, visit www.masthercell.com.

Great Point Partners Backed United Claim Solutions Completes Acquisition of Zebu Compliance Solutions

Introduction

GREENWICH, CT and PHOENIX, AZ — Great Point Partners (“GPP”) today announced that United Claim Solutions (“UCS”), a GPP II portfolio company, has acquired Portsmouth, Ohio-based Zebu Compliance Solutions (“Zebu”). Zebu is a software enabled business, providing payment integrity and ongoing credentialing solutions to payors, clearinghouses, and provider organizations across the United States. The acquisition of Zebu brings additional resources and capabilities to UCS, augmenting its suite of payment integrity solutions and expanding its customer base.

“UCS and Zebu have had a strong working relationship over the past seven years. Formalizing our partnership with Zebu enhances our service offering and technology capabilities, enabling us to better serve our clients’ needs,” Josh Carder, CEO of UCS, stated. “Zebu brings us an experienced and talented team, led by industry veteran Francesca Hartop, Zebu’s Founder and CEO. Francesca has deep industry knowledge that has helped establish a comprehensive suite of tools across both payor and provider markets.”

“The addition of Zebu provides UCS with added scale and access to over 1,000 new customers. Zebu’s technology, knowledge base and product suite will help UCS continue to improve its payment integrity solutions,” added Noah Rhodes, Managing Director at Great Point Partners.

“The Zebu-UCS platform will facilitate high-value integrated and complementary services to better serve our existing customers and further extend our product offerings into new customer segments. Our goal is to create efficiency and integrity across the health care landscape. Zebu’s partnership with UCS creates a comprehensive suite of health care claims management and compliance solutions,” commented Ms. Hartop.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About United Claim Solutions

United Claim Solutions (“UCS”) is an innovative payment integrity solutions company providing cutting edge and customizable solutions for TPAs, self-insured groups, labor and trust organizations, stop-loss carriers and health plans. Since its founding in 2004, UCS has placed emphasis on quality and efficient service, optimal savings and timely solutions for its clients. UCS provides payment integrity services in all 50 states, bringing innovative solutions to its clients to generate additional savings, support their client retention and facilitate their business growth. For further information, please contact UCS at (866) 762 4455 or www.unitedclaimsolutions.com.

Great Point Partners-Backed Softbox Systems Completes Third Acquisition in The Last Year – Acquiring Cold Tech Systems in Panama

Introduction

GREENWICH, CT and LONG CRENDON, U.K. — Great Point Partners (“GPP”) today announced that Softbox Systems (“Softbox”), a GPP II portfolio company, has acquired Panama-based Cold Tech Systems (“Cold Tech”), the exclusive Softbox licensee in Latin America for several years. This establishes Softbox as the leading supplier of high-quality temperature control packaging systems for the region’s pharmaceutical cold chain industry.

The acquisition of Cold Tech Systems enhances Softbox’s ability to distribute its innovative temperature control packaging systems directly to the Latin American market and meet the increasing demand for local innovation as well as local production, inventory, and technical and quality assurance support.

Noah Rhodes, Managing Director at GPP, said “Softbox continues to grow rapidly, and revenue has more than tripled since our investment in 2014. The pharmaceutical industry today is global, and we are committed to building a matching geographic footprint to serve our customers. The acquisition of Cold Tech further expands our reach and augments our position as the global leader in the passive temperature-controlled packaging industry.”

Wayne Langlois, President of Softbox, commented “With the acquisition of Tempack in 2017 and now Cold Tech Systems, we have become an even stronger and simpler solution in Latin America, and I believe our combined companies, will provide the market’s best products, service and support to our customers.”

Alfredo N. Ratmiroff, President of Cold Tech Systems, added: “The integration with Softbox significantly strengthens Cold Tech’s ability to supply its customers in Latin America with the best-in-class cold chain solutions. Softbox’s acclaimed client-driven innovations and Cold Tech’s client-centric product and service customizations are combining to offer the most effective temperature protection with packaging that maximizes logistic efficiency.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $675 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Softbox Systems

Softbox Systems based in Long Crendon, U.K. is an award winning temperature control packaging innovator that has been designing and producing high performance passive temperature control packaging solutions for over 20 years. The Company offers consistent quality to our clients from our strategically located global manufacturing sites throughout Europe, North America, Latin America and Asia Pacific.

Softbox has formed long standing partnerships with the world’s leading biotech, pharmaceutical, clinical research and logistics companies, and apply innovative thinking to overcome the challenges that our clients face in managing the Cold Chain when shipping temperature sensitive clinical trial and commercialised products. For more information on Softbox please visit www.softboxsystems.com.

Great Point Partners Backed Citra Health Solutions Appoints Scott Sanner as Chief Executive Officer

Introduction

GREENWICH, CT and JACKSONVILLE, FL — Great Point Partners II portfolio company, Citra Health Solutions, a trusted provider of benefit administration technology solutions and care management services, announced today the appointment of Scott Sanner as Chief Executive Officer effective immediately. Mr. Sanner brings nearly 30 years of relevant industry experience to this new role having previously held positions at Change Healthcare including oversight of Communication & Payment Services, as well as Senior Vice President & General Manager of Accountable Care where he grew the ACO business by over 30 percent. Prior to that, Sanner was the Senior Vice President and General Manager of Technology Services at MED3000, Inc. and was responsible for the growth of MED3000’s Technology and Physician Services divisions. Sanner began his career at Misys Healthcare where he ultimately led the commercial operations of that business.

“We welcome Scott’s experience and leadership to Citra,” said Adam Dolder, Managing Director at Great Point Partners. “Scott’s background, industry relationships and vision make him well-equipped to extend the Company’s history of innovation and growth. We are delighted to find someone with his passion and record of accomplishments to join and lead the Company.”

“I am excited to join Citra as CEO where we will continue to create innovative solutions for healthcare payers and providers,” said Mr. Sanner. “Given my prior experience, I personally know the value of Citra’s technology and services platform, and look forward to delivering an enhanced experience to Citra customers. To remain relevant and competitive amidst unprecedented changes in today’s health care market, payers and providers alike will need a partner with their best interest in mind and that will be our mission.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital currently under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million of committed capital) and public (BioMedical Value Fund strategy, approximately $750 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternate site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Citra Health Solutions

Citra provides a one-contract, connected solution for clinical, financial and administrative requirements. Solving for the needs of providers, payers, health systems and employers in the transition to value-based care, Citra empowers clients with proven technology, population health, analytics, care management, and administrative services to lower the cost of care and improve quality. Citra currently serves 6 of the top 7 Health Plans, 7 Fortune 500 Companies, 50+ IPAs and MSOs managing commercial, Medicare and Medicaid populations, and 100+ Provider Groups, Hospitals, Universities and Integrated Delivery Networks throughout the United States and in Puerto Rico.

Great Point Partners Backed American Surgical Professionals Continues Nurse Staffing Expansion through Acquisition of Chesapeake Medical Staffing

Introduction

GREENWICH, CT and and HOUSTON, TX — Great Point Partners (“GPP”) today announced that American Surgical Professionals (“ASP”), a GPP I portfolio company, has acquired Lutherville-Timonium, MD-based Chesapeake Medical Staffing (“CMS”). CMS focuses on providing nurse staffing and allied health services to acute and post-acute care facilities throughout the East Coast. The addition of CMS will enable ASP to provide a comprehensive set of outsourced healthcare staffing solutions to its existing client base of over 250 hospitals and health systems and provide infrastructure support to CMS’ current and future clients.

“The acquisition of Chesapeake Medical Staffing enables American Surgical Professionals to further establish itself as a leading provider of outsourced staffing services for hospitals and health systems nationwide,” said Tom Kirk, CEO of ASP. “The addition of CMS enables us to partner with the fantastic team that Jeff McClure and Terri Weller have built and collectively provide a greater set of service offerings to ASP and CMS’ existing clients.”

“This transaction is a clear demonstration of ASP’s commitment to expanding its breadth of service offerings for our clients,” said Rohan Saikia, Managing Director at Great Point Partners. “ASP will continue to partner with leading nurse staffing and allied health businesses throughout the United States to further solidify its position as a leading provider of outsourced health care staffing solutions.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital under management and 28 professionals, investing in the United States, Canada and Western Europe. GPP is currently making new private equity investments from GPP II, a $215 million fund. Great Point Partners manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $675 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. For further information, please contact Great Point Partners at 203-971-3300 or www.gppfunds.com.

About American Surgical Professionals

Founded in 1993 and headquartered in Houston, TX, American Surgical is the nation’s leading provider of professional surgical assistant services to hospitals, clinics (ASC), surgeons and patients. The Company offers custom tailored solutions to perioperative staffing situations. These include providing surgical specialists on an outsourced, as needed or contract basis. In addition to being Joint Commission certified, ASP’s professionals are experienced in all state-of-the-art technologies such as robotics and current medical techniques such as endoscopic vein harvesting. The utilization of ASP’s services results in a reduction of staff management complexities, enhanced economics and improved outcomes for surgical procedures. For more information, please visit www.amerisurg.com or call 713-779-9800.

Great Point Partners Exits Autism Learning Partners

Introduction

GREENWICH, CT and GLENDALE, CA — Great Point Partners (“GPP”) is pleased to announce that it exited its investment in GPP I portfolio company, Autism Learning Partners (“ALP”). ALP is the leading provider of Applied Behavior Analysis (“ABA”) and other services for children and adults with Autism Spectrum Disorders (“ASD”).

Noah Rhodes, Managing Director at GPP commented, “We are very proud of what we have achieved working together with Jeffrey Winter, CEO, and Gina Chang, COO, who we recruited to the Company. Our partnership with ALP began seven years ago when we recapitalized a sole proprietorship that had 300 employees operating in California, Texas and New Mexico. After executing an aggressive growth strategy consisting of organic expansion into new markets as well as six tuck-in acquisitions, ALP now provides services to clients in 9 states (3-fold increase) through its dedicated workforce of over 2,600 employees (9-fold increase).”

Adam Dolder, Managing Director at GPP stated, “Together with Jeff and the team, as well as co-investors, we built ALP into the leading provider of autism therapy in the country, a significant achievement for all of us.”

Jeffrey Winter, Chief Executive Officer of ALP, said, “Great Point was a dedicated partner that was instrumental in the growth of ALP. GPP sourced 4 of the 6 acquisitions, and helped execute all of the tuck-in acquisitions we made during their investment period. They also recruited a talented Board of Directors, including Karen Ajmani, President of Healthcare Services at Progyny, who helped transform ALP into the success it is today.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1.1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $675 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing and alternative site care, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Autism Learning Partners

Headquartered in Glendale, California, Autism Learning Partners is a leading provider of therapy to children with Autism Spectrum Disorders. ALP’s services include ABA, speech, occupational, and physical therapies. The Company utilizes custom-tailored treatment programs, licensed professionals, and experienced staff to address the unique treatment needs of children with ASD. ALP provides services in 9 states, with a client base that includes commercial insurance beneficiaries, behavioral health agencies, school districts, private pay clients, and military families. Autism Learning Partners was backed by Great Point Partners, LLC, Jefferson River Capital LLC, and Scopia Capital Management LP. Visit www.autismlearningpartners.com for more information.

Great Point Partners Backed VitaLink Research Completes Acquisition of Upstate Pharmaceutical Research

Introduction

GREENWICH, CT and GREENVILLE, SC — Great Point Partners (“GPP”) today announced that VitaLink Research (“VLR”), a GPP II portfolio company, has acquired Greenville, SC-based Upstate Pharmaceutical Research (“UPR”). UPR focuses on providing Phase II – IV clinical trials with a respiratory therapeutic focus. The addition of UPR will enable VitaLink Research to provide high-quality clinical research to a greater number of subjects throughout the Carolinas.

“The acquisition of Upstate Pharmaceutical Research enables VitaLink to further establish itself as the leading wholly-owned clinical research site company in the Carolinas,” said Steve Clemons, Co-Founder of VitaLink Research. “The addition of UPR enables us to partner with the fantastic team that Dr. Krishna Pudi mentored throughout his career. Dr. Pudi has a record of exceptional subject recruitment and retention while adhering to highest quality standards.”

“This transaction is a clear demonstration of VitaLink’s ability to execute on its strategic plan of acquisitive growth,” said Stephen Weaver, Senior Vice President at Great Point Partners. “VitaLink will continue to acquire and partner with clinical research sites throughout the United States to become the leading independent clinical research site business.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada and Western Europe. GPP is currently making new private equity investments from GPP II, a $215 million fund. Great Point Partners manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $600 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. For further information, please contact Great Point Partners at 203-971-3300 or www.gppfunds.com.

About VitaLink Research

VitaLink Research (“VLR”) was founded in 2004 and has since become a leading dedicated clinical research site business with 11 locations in the Southeastern U.S. Headquartered in Greenville, SC, VLR’s model is an effective method of research operations and management that consistently exceeds sponsor and FDA expectations during all quality audits while consistently ranking in the top 10% in global enrollment. The clustering of sites provides the opportunity for inter-site cross training, idea exchange, and standardization of operating procedures. With over ten years of shared experiences the company has developed best practices which continue to be the foundations of its successful U.S. operations. Learn more at www.vitalinkresearch.com.

Great Point Partners Backed Softbox Systems Completes Tempack Acquisition – Adding Operations in Spain, Germany, and Latin America

Introduction

GREENWICH, CT and and LONG CRENDON, U.K. — Great Point Partners (“GPP”) today announced that Softbox Systems (“Softbox”) a GPP II Portfolio company has acquired Tempack Packaging Solutions (“Tempack”) based in Barcelona, Spain. Tempack focuses on the development and manufacturing of packaging solutions for the transportation of high value temperature-sensitive pharmaceutical products. The addition of the Tempack’s operations increases Softbox’s footprint in Europe and Latin America and brings additional packaging solutions for its customers.

Wayne Langlois, President of Softbox, stated, “Softbox will leverage the customer relationships and distribution channels established by Alex Vila and his team at Tempack to expand its operations, offer current and future Softbox products, and provide innovative temperature-controlled packaging products across Europe and the Americas.”

Noah Rhodes, Managing Director at Great Point Partners added, “Global expansion is a key objective of our strategic plan for Softbox and the acquisition of Tempack will allow us to better serve our customers through an expanded presence in both the European and Latin American markets.”

Tempack currently has two offices in Europe (Spain, Germany) and four offices in Latin America. Softbox has offices in the U.K, United States, India, and Singapore. Together both companies will offer greater global coverage while providing existing customers with improved capabilities, production capacity and quality of customer support.

Alex Vila, Tempack CEO, commented, “Tempack can now offer an expanded product portfolio to our customers. Together we will continue to grow and to serve additional markets with the most comprehensive and cost effective cold chain shipping solutions.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $600 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Softbox Systems

Softbox Systems is an award winning temperature control packaging innovator that has been designing and producing high performance passive temperature control packaging solutions for over 20 years. We offer consistent quality to our clients from our strategically located global manufacturing sites throughout Europe, North America, Latin America and Asia Pacific.

We have formed long standing partnerships with the world’s leading biotech, pharmaceutical, clinical research and logistics companies, and apply innovative thinking to overcome the challenges that our clients face in managing the Cold Chain when shipping temperature sensitive clinical trial and commercialised products.

In 2014, Great Point Partners, a leading health care investment firm, recapitalized Softbox to provide growth financing for the Company to continue to execute on its expansion, innovation and global investment strategy to support its clients around the globe.

Softbox – Enabling Cold Chain Packaging Excellence

For more information about Softbox Systems and its innovative packaging, visit www.softboxsystems.com.

Great Point Partners Backed United Claim Solutions Completes Acquisition of INETICO

Introduction

GREENWICH, CT and PHOENIX, AZ — Great Point Partners (“GPP”) today announced that United Claim Solutions (“UCS”), a GPP II portfolio company, has acquired Tampa, Florida-based INETICO. INETICO focuses on providing health care cost containment services to self-funded, third party administrator (“TPA”) and stop-loss clients across the United States and Puerto Rico. The addition of INETICO brings additional resources and capabilities to UCS and will augment its suite of payment integrity solutions.
“UCS’ acquisition of INETICO expands our service offering and further deepens our commitment to the highest level of customer service when addressing our clients’ needs,” Josh Carder, CEO of UCS, stated. “The addition of INETICO brings us a great team, led by Founder, CEO, and industry veteran, Joe Hodges. Joe has a record of exceptional service, products and quality in the payment integrity industry.”

“UCS and INETICO joining forces will help drive innovation in the payment integrity market. The addition of INETICO will add care management and new repricing services to UCS, and will help UCS continue to drive down health care costs for our clients,” added Noah Rhodes, Managing Director at Great Point Partners.

“We believe that together, our two companies will create a leader in payment integrity solutions. Our goal is to work with our self-insured, TPA and stop-loss clients to create a one-stop shop for their cost containment needs. UCS’ savings rates and innovative solutions combined with INETICO’s care and negotiation services will be a driving force in the industry,” commented Joe Hodges, Founder of INETICO.

In conjunction with this acquisition announcement, UCS is also unveiling NX Health Network, its high-performance custom network solution for self-insured groups that reduces medical costs and increases patient and provider satisfaction. For more information on NX Health Network, please visit www.nxhealthnetwork.com or call (800) 834 2312

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada and Western Europe. GPP is currently making new private equity investments from GPP II, a $215 million fund. Great Point Partners manages capital in private (GPP I, $156 million and GPP II, $215 million) and public (BioMedical Value Fund, approximately $600 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. For further information, please contact Great Point Partners at 203-971-3300 or www.gppfunds.com.

About United Claim Solutions

United Claim Solutions (“UCS”) is an innovative payment integrity solutions company providing cutting edge and customizable solutions for TPAs, self-insured groups, labor and trust organizations, stop-loss carriers and health plans. Since its founding in 2004, UCS has placed emphasis on quality and efficient service, optimal savings and timely solutions for its clients. UCS provides payment integrity services in all 50 states, bringing innovative solutions to its clients to generate additional savings, support their client retention and facilitate their business growth. For further information, please contact UCS at (866) 762 4455 or www.unitedclaimsolutions.com.

Clinical Supplies Management Completes Second European Acquisition — Acquires B&C Group in Brussels, Belgium

Introduction

GREENWICH, CT and MALVERN, PA — Great Point Partners (“GPP”) today announced that that Clinical Supplies Management (“CSM”) a GPP II Portfolio company has acquired B&C Group (“B&C”) based in Brussels, Belgium. B&C focuses on providing clinical trial supplies and biomedical sample services. The addition of the B&C operations increases CSM’s footprint to two full-service facilities in Europe and brings additional capabilities in biomedical sample services.

“CSM will leverage the custom systems architecture Phillipe Van der Hofstadt, CEO, and his team developed for B&C across our global network, providing customers with a seamless, world-class operating partner that is scaled to meet their needs and offers flexible solutions and customer service,” said Scott Houlton, CSM Chief Executive Officer.

Steve Weaver, Senior Vice President at Great Point Partners added, “European expansion is a core part of our strategic plan for CSM and this acquisition, which marks the second in Europe within two months, will help CSM better serve all of our pharmaceutical clients in joint U.S. and European clinical trials.”

CSM’s December 2016 acquisition of the Theorem Clinical Supply business in Frankfurt will naturally complement the B&C Group operations in Brussels and offer customers increased capabilities, capacity and provide disaster recovery backup within three hours of each location. Philippe Van der Hofstadt, B&C CEO, will lead the European operations for CSM.

Philippe Van der Hofstadt commented, “B&C is very excited to join CSM and formalize what has been a strong partnership relationship. We believe that CSM, working with Great Point, a leading global health care private equity firm, is perfectly poised to grow and change the industry. The on-demand packaging and direct-to-patient solutions are examples of how CSM is adding value to customers.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $560 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Clinical Supplies Management

Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials. Some of CSM’s clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, as well as returns, reconciliation and destruction. Reach CSM at 866-487-3276 or www.csmondemand.com

Great Point Partners I exits its partnership with Portfolio Company — Professional Physical Therapy

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that it exited its partnership with GPP I portfolio company, Professional Physical Therapy (“ProPT”). ProPT is the leading outpatient physical therapy service provider in the New York Tri-State market, operating 107 facilities across New York, Connecticut and New Jersey.

Adam Dolder, Managing Director at GPP commented, “We are very proud of what we achieved working with Adam Elberg, and the entire ProPT team. Our partnership began five years ago when ProPT operated only 10 facilities in a single state and had approximately 300 employees. After executing an aggressive growth strategy that involved making 21 tuck-in acquisitions and opening 16 de novo units, the company now serves patients in more than 100 locations across three states and employs over 1,200 people.”

In discussing his company’s explosive growth, Adam Elberg, CEO and co-founder of ProPT, said, “In 2011, the founders of ProPT partnered with Great Point Partners to build the leading physical therapy company in the New York Tri-State market. GPP was instrumental in developing our acquisition and integration platform, and surrounded the management team with a talented Board of Directors that helped guide our growth to date.” Mr. Elberg added, “It has been a highly rewarding partnership with GPP and I am excited about the next stage in ProPT’s growth.”

Rohan Saikia, Principal at GPP, stated “This success is a testament to the outsourced business development expertise GPP brought to the collaboration with ProPT. During our partnership, we sourced nine of the Company’s 21 acquisitions that accounted for nearly 80 operating sites, supported Adam Elberg in strengthening the management team, and grew revenue by a compound annual growth rate of over 35%.”

This marks the fourth successfully exited investment in the last 14 months for GPP I, with three of the four generating a gross multiple of invested capital of five times or greater.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of assets under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, a $215 million fund. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $500 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Physical Therapy, headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy, hand therapy and rehabilitation services throughout the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional Physical Therapy operates 107 outpatient physical and hand therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a STACK Sports Performance Center, one inside a Golf & Fitness Academy, one inside Chatham Club, one inside Strive Fitness, and 86 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Professional Physical Therapy also operates a 20,000 square foot sports performance training facility in Garden City, NY, as well as four fitness centers in Stamford, Wilton, Southport, CT, and Copiague, NY. www.professionalpt.com

Clinical Supplies Management Begins Global Expansion Through Acquisition of Theorem Clinical Research – Clinical Supplies in Frankfurt, Germany

Introduction

GREENWICH, CT and MALVERN, PA — Clinical Supplies Management (“CSM”), a Great Point Partners (“GPP”) portfolio company, today announced it has acquired the assets of Frankfurt, Germany based Theorem Clinical Research – Clinical Supplies (“TCS”). TCS was previously a subsidiary of Chiltern International and focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across Europe. With the acquisition of TCS, CSM has expanded to Western Europe and will be able to better serve the needs of its global clients.

“In pharmaceutical services, global capabilities matter — and we are building our business to ensure that we are providing the geographic scope of services our pharmaceutical clients demand,” said Scott Houlton, CSM CEO. “TCS has invested in a world-class facility that serves a diversified multi-national, European pharmaceutical client base. The business will continue to grow under CSM ownership and we look forward to working closely with them on global clinical trials.”

Rohan Saikia, Principal at Great Point Partners said, “The acquisition of TCS allows CSM to increase its global presence and add a world-class European team led by TCS’ Executive Director, Rüdiger Weber. This acquisition solidifies CSM’s position as a worldwide service provider in the clinical trials market.”

Weber added “CSM has delivered superb just-in time customer service and high quality solutions to the clinical trial packaging and labeling market for the last twenty years. Having access to their North American facilities will also allow us to service our current and future clients globally.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $525 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Clinical Supplies Management, Inc.

Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials. Some of CSM’s clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, as well as returns, reconciliation and destruction. Reach CSM at 866-487-3276 or www.csmondemand.com

Great Point Partners Completes Growth Recapitalization of Clinical Supplies Management

Introduction

GREENWICH, CT and MALVERN, PA — Great Point Partners (“GPP”) today announced a growth recapitalization of Clinical Supplies Management (“CSM” or the “Company”). CSM is a leading provider of clinical trials drug packaging, labeling and logistics solutions to the global life science, pharmaceutical and biotechnology industries. CSM was founded in 1997 by Gerald Finken, a pharmacist with over 35 years of experience in the clinical supplies industry. CSM has grown from a niche provider of returns and reconciliations, to a full service solutions provider able to manage the full spectrum of a pharmaceutical company’s needs for clinical trials materials management.

“CSM has a superb reputation in the clinical trial management industry and is constantly evolving to meet the needs of their clients,” said Rohan Saikia, Principal of Great Point Partners. “Our investment and partnership with CSM will enable the Company to invest further in its infrastructure and management team as well as execute on an accelerated growth strategy including expanded service offerings overseas to meet the needs of CSM’s global clients. As part of our partnership with CSM, Gerald will become Chief Scientific Officer and industry veteran Scott Houlton will join as CEO.” Scott Houlton most recently served as President of Development and Clinical Services at Catalent and prior to Catalent, Mr. Houlton held leadership roles at Aptuit and Quintiles Transnational.

“Gerald has done a phenomenal job leading CSM through two decades of growth” added Stephen Weaver, Vice President of Great Point Partners. “Great Point’s knowledge in outsourced pharmaceutical services and ability to source and execute strategic tuck-in acquisitions will help transform the business into a worldwide leader in clinical trial packaging and labeling.”

“We are very pleased to partner with Great Point Partners and leverage their industry expertise to grow CSM” said Gerald Finken. “Our goal of delivering CSM’s On-Demand services worldwide will now become a reality.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $500 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Clinical Supplies Management, Inc.

Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all projects regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials. Some of our CSM’s clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, returns, reconciliation and destruction. Reach CSM at 866-487-3276 or www.csmondemand.com

Aris Radiology Continues National Expansion Through Acquisition of US Teleradiology

Introduction

GREENWICH, CT and ATLANTA, GA — Aris Radiology, a Great Point Partners (“GPP”) portfolio company, today announced it has acquired Atlanta-based US Teleradiology (“UST”). Founded in 2001, UST is a physician-owned radiology practice that provides professional radiology services to hospitals and other medical facilities across 25 states. With the acquisition of UST, Aris now has more than 250 radiologists who interpret approximately 2.5 million studies annually across 400 client sites in over 30 states.

“We are extremely excited about the combined expertise and resources of UST and Aris Radiology,” said Carl Kozlowski, Aris President and CEO. “UST has built a strong network of highly trained radiologists and esteemed clientele, and we look forward to expanding on UST’s hospital system relationships.”

Rohan Saikia, Principal at Great Point Partners and Board member of Aris Radiology said, “UST is Aris’ third strategic acquisition since our investment. This acquisition solidifies Aris’ position as one of the premier national radiology providers and a leader in the consolidation of the radiology market.”

UST CEO, Francis Ferraro, MD added, “we have been dedicated to providing the highest level of service to the hospitals and organizations we serve, and the partnership with Aris will allow us to now also provide the Aris’ 24 hours per day, seven days a week full subspecialty coverage to our clients.”

Dr. Ferraro will join Aris as a member of its physician leadership team serving as Director of Physician and Clinical Relations and Chief Medical Officer for Aris’ California operations. As part of the continued national expansion, Aris will open an executive office in Atlanta, GA.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $500 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Aris Radiology, LCC

Founded in 2007 and headquartered in Hudson, OH, Aris provides professional radiology services to patients, surgeons and healthcare institutions. The Company is a Joint Commission certified radiology services company. Aris works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 sub specialty coverage, 24/7 operations support, and quality assurance data. Aris’ breadth of service and discipline allows it to deliver high quality patient care in a cost-effective manner to the hospitals, and other health care payors. Visit www.arisradiology.com for additional information.

Great Point Partners Completes Growth Recapitalization of Alliance Biomedical Research

Introduction

GREENWICH, CT and GREENVILLE, SC — Great Point Partners (“GPP”) today announced a growth recapitalization of Alliance Biomedical Research (“ABR” or the “Company”). ABR is a leading clinical trial research site business focused on Phase II — IV clinical trials with 11 locations throughout the Southeastern U.S. ABR was founded in 2004 by Dr. Greg Feldman, Dr. Joe Boscia, Anna Buice, Steve Clemons and Haley Williams and has organically grown its footprint from a single location to 11 sites over the last 12 years. Pharmaceutical, biotechnology companies or Clinical Research Organizations hire ABR to work on a clinical study, create operational workflows that comply with protocol requirements, recruit qualified patients to test the study drug, monitor the drug’s effects, adhere to tight regulatory standards, and report their findings to the client.

“ABR has an unparalleled track record of meeting or exceeding patient enrollment targets in clinical trials addressing one of the leading causes of trial delays,” said Stephen J. Weaver, Vice President of Great Point Partners. “Our investment in and partnership with ABR will enable the Company to further improve its infrastructure and execute on an accelerated growth strategy of de novo facility expansion and tuck-in acquisitions. The clinical research site sector is highly fragmented and falls squarely within the outsourced pharmaceutical services vertical, a core area of focus for GPP.”

“We founded ABR with the vision to become the leading clinical research site company and substantially improve the efficiency of the clinical trial process,” said Dr. Greg Feldman, Founding Principal of ABR. “We were impressed with GPP’s prior investment experience in outsourced pharmaceutical services, the robust acquisition pipeline they had developed prior to our first meeting and their deep industry knowledge. We have an exceptional team at ABR and are excited to partner with GPP to accelerate growth and work towards our original vision.”

“ABR is a compelling opportunity to invest in a leader in the market of clinical trial site management,” added Adam B. Dolder, Managing Director at Great Point Partners. He concluded by saying, “The Company has a proven track record in clinical trial execution and importantly, patient recruitment and enrollment, a key differentiator in the marketplace and the ’holy grail’ in the pace of a clinical trial.”

Mr. Jim Petrilla, Founder of BioAgilytix, will serve as CEO while Mr. Richard Vaillant, former CFO of GPP I portfolio company Cytovance Biologics, will serve as CFO of the Company.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of assets under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $500 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Alliance Biomedical Research Holdings, LLC.

R’s model is an effective method of research operations and management that consistently exceeds sponsor and FDA expectations during all quality audits while consistently ranking in the top 10% in global enrollment. The clustering of sites provides the opportunity for inter-site cross training, idea exchange, and standardization of operating procedures. With over ten years of shared experiences the company has developed best practices which continue to be the foundations of its successful U.S. operations. Learn more at www.alliancebiomedical.com

Professional Physical Therapy Acquires Sports Training Physical Therapy

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that GPP I portfolio company Professional Physical Therapy (“ProPT”) has acquired Sports Training Physical Therapy. This acquisition adds nine new clinics in Millburn, Newark, Hazlet, Spring Lake, Newton, Haskell, Chatham, East Hanover, and Morristown and enables ProPT to give patients convenient access to a total of 31 locations throughout 8 counties in New Jersey.

According to Stephen Weaver, Vice President at Great Point, “The transaction is a clear demonstration of ProPT’s ability to execute on its strategic plan and is the ninth acquisition ProPT has closed in 2016 alone. ProPT now operates 98 outpatient physical therapy centers, up from 10 at the time of our investment in 2011, making it the largest provider in the Northeast.” Maureen Wilhelm, Owner of Sports Training Physical Therapy, stated, “In partnering with Professional Physical Therapy, we’re confident that we’ve aligned ourselves with a company that shares that same commitment to patient care that has been the cornerstone of our practice. They are known for developing high quality programs and providing individualized care and attention to their patients and staff.”

Donald Demay, Partner and Chief Operating Officer at ProPT added, “The team from Sports Training Physical Therapy not only complements our expertise and values, but also enhances some of the more niche specialties, such as hand therapy and pediatric specialty programs tailored to children with orthopedic injuries.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $500 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy, headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional Physical Therapy now operates 78 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a STACK Sports Performance Center, and 60 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Additionally, Professional Physical Therapy operates a 20,000 square foot sports performance training facility in Garden City, New York. www.professionalpt.com

Professional Physical Therapy Acquires Achieve Sports Medicine & Rehab and PRO Physical Therapy

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that GPP I portfolio company Professional Physical Therapy (“ProPT”) has acquired Achieve Sports Medicine & Rehab and PRO Physical Therapy. These two acquisitions add three new clinics in Waldwick, Wyckoff and Randolph, New Jersey, and now give patients access to 21 physical therapy locations throughout six counties in New Jersey.

According to Rohan Saikia, Principal at Great Point, “The transactions with Achieve Sports Medicine & Rehab and PRO Physical Therapy are the sixth and seventh tuck-in acquisitions ProPT has closed in just the first seven months of 2016 alone. ProPT now operates 88 outpatient physical therapy centers, making it the largest provider in the Northeast.” Jeff De Bellis, Partner and Vice President of Clinical Operations at ProPT stated, “The strategic additions of Achieve Sports Medicine & Rehab and PRO Physical Therapy to Professional affirm our strategy of creating strong partnerships with highly respected regional practices and renowned practitioners.”

Jodi DeVincentis, President of PRO Physical Therapy agrees, “We have implemented some unique and cutting-edge programs at PRO Physical Therapy, however, our reach was limited. Professional Physical Therapy’s superb reputation in the industry, expert clinical education program, and myriad of opportunities for professional advancement made this the best choice for Pro Physical Therapy and our clinicians. ” Richard Sica, co-founder of Achieve Sports Medicine & Rehab states, “I am confident that with the combined expertise of our physical, occupational and hand therapists, we will successfully continue to help our patients achieve the highest level of function and independence possible.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $475 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy, headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional Physical Therapy now operates 88 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a Golf Fitness Academy, one located in a STACK Sports Performance Center, and 69 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Additionally, Professional Physical Therapy operates a 20,000 square foot sports performance training facility in Garden City, New York www.professionalpt.com.

Great Point Partners I Sells Portfolio Company – Biotronic NeuroNetwork

Introduction

GREENWICH, CT and ANN ARBOR, MI — Biotronic NeuroNetwork, a Great Point Partners I (GPP I) portfolio company, today announced that it has been acquired by NuVasive for $98 million in cash.

Rohan Saikia, a Principal at GPP stated, “We are very proud of the business we have built along with Bill Gecsey, CEO and the entire Biotronic team. During our partnership, we led a number of organic and inorganic initiatives which grew EBITDA at a compounded annual growth rate in excess of 12.5%, including driving operational improvements, sourcing tuck-in acquisitions, performing debt refinancing and a dividend recapitalization.”

William Gecsey, President and Chief Executive Officer of Biotronic said, “Great Point was a hardworking and dedicated partner for Biotronic that was very accessible to us. They sourced inorganic opportunities, helped recruit a top-flight management team and provided generous economic participation for the team associated with our growth and profitability.”

“For more than 35 years, the team at Biotronic has built a phenomenal business focused on providing the highest quality of intraoperative neural monitoring services designed to provide patient safety and deliver economic benefit for hospitals and surgeons. I am confident that the combination with NuVasive will further build out service offerings that drive improvements in patient care.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $450 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Biotronic NeuroNetwork

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 350 administrative, support and clinical staff, including over 300 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. www.biotronic.com.

Biotronic NeuroNetwork Acquires NuWave Monitoring

Introduction

GREENWICH, CT and HOMEWOOD, IL — Great Point Partners (“GPP”) today announced that GPP I portfolio company Biotronic NeuroNetwork (“Biotronic”), the nation’s largest intraoperative neuromonitoring company, has acquired NuWave Monitoring.

NuWave Monitoring is an intraoperative neuromonitoring company providing highly trained and certified technologists and servicing patients, surgeons, and health care facilities in Illinois and Indiana. NuWave will benefit from Biotronic’s industry-leading infrastructure including training, clinical management, and quality assurance program.

“Biotronic provides intraoperative neuromonitoring services across the United States, and now is also the leading provider in the Midwest,” said Rohan Saikia, Principal at Great Point Partners.

“Biotronic and NuWave are a natural fit for each other,” said William J. Gecsey, CEO of Biotronic NeuroNetwork, “both organizations share a commitment to quality and service. With the acquisition, Biotronic expands its presence and reach from Chicago through northwestern Indiana.”

The NuWave Monitoring team will continue working with their surgeons and hospitals and will comply with Biotronic’s Joint Commission accredited quality assurance program.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $450 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Biotronic NeuroNetwork

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 250 administrative, support and clinical staff, including over 200 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. www.biotronic.com

Professional Physical Therapy Expands Further in New Jersey

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that GPP I portfolio company Professional Physical Therapy (“ProPT”) has acquired Princeton Physical Therapy Group. With the addition of these five clinics, patients will have even greater access to seasoned and knowledgeable physical therapists who are dedicated to improving patient outcomes.

The transaction with Princeton Physical Therapy is the fifth tuck-in acquisition ProPT has closed in 2016 and represents its 11th tuck-in acquisition over the last 12 months. ProPT now operates in 83 outpatient physical therapy centers, making it the largest provider in the Northeast. Jeff De Bellis, Partner and Vice President of Clinical Operations at ProPT stated, “The expertise, community focus, and operational strengths of the team at Princeton align exceptionally well with our stated goal of continued growth and development.”

“With this acquisition ProPT has grown four-fold in size from the October 2011 date of our investment. We are proud of the impact our capital and tuck-in acquisition expertise has had at ProPT,” said Stephen Weaver, Vice President at Great Point Partners.

“Our primary goals at Princeton are to ensure that patients improve with each treatment, restore movement, and achieve their clinical goals. After meeting with the team at Professional Physical Therapy, it was quickly evident that their patient-centric values are similar to ours,” said David Del Vecchio, Chief Executive Officer of Princeton Physical Therapy.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $450 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy, headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional Physical Therapy now operates 83 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a STACK Sports Performance Center, and 65 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Additionally, Professional Physical Therapy operates a 20,000 square foot sports performance training facility in Garden City, New York. www.professionalpt.com

Professional Physical Therapy Expands in Connecticut with Acquisition of Six Clinics

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that GPP I portfolio company Professional Physical Therapy (“ProPT”) has acquired Moore Physical Therapy & Fitness. The addition of the Moore Physical Therapy’s six clinics affords Pro PT’s patients a broader team of accomplished licensed physical therapists, occupational therapists, and sports rehabilitation experts dedicated to providing best-in-class, evidence based treatment plans.

The transaction with Moore Physical Therapy & Fitness is the fourth tuck-in acquisition ProPT has closed in 2016 and represents its 10th tuck-in acquisition over the last 12 months. ProPT now operates 78 outpatient physical therapy centers, making it the largest provider in the Northeast. Adam Elberg, Founder, President & CEO of ProPT stated, “We are executing our strategic plan ahead of plan and we are thrilled to be able to continue to partner with the best-in-class providers in our respective markets.”

“Acquiring Moore solidifies ProPT as the leading provider of physical therapy in the tri-state market,” added Rohan Saikia, Principal at GPP.

“Through this acquisition, we will have the opportunity to partner with the largest outpatient physical therapy provider in the northeast and the best provider in Fairfield County,” said Charlie Byrd, Partner and Vice President of Clinical Operations in Westchester and Connecticut at ProPT.

“At Moore, our focus is on what is best for the patient. By joining the ProPT family, we feel we can continue to provide best-in-class care,” said Bob Moore, CEO and Founder of Moore Physical Therapy & Fitness. “After 25 years of service, this next step feels right. Not only will our patients see the benefit, but our staff will as well.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy, headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional Physical Therapy now operates 78 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a STACK Sports Performance Center, and 60 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Additionally, Professional Physical Therapy operates a 20,000 square foot sports performance training facility in Garden City, New York. www.professionalpt.com

Citra Health Solutions Announces Acquisition of SironaHealth

Introduction

GREENWICH, CT and JACKSONVILLE, FL — Citra Health Solutions (“Citra”), a Great Point Partners II (“GPP”) portfolio company, announced the acquisition of SironaHealth (“Sirona”), a Portland, Maine based company delivering a full spectrum of clinical care management services. Citra purchased SironaHealth as the next step in an on-going plan to extend its integrated population health solutions in the value-based market.

For nearly 20 years, Sirona has provided outsourced nurse triage, clinical care coordination, and patient care & case management services across the United States. Sirona utilizes its propriety technology platform and clinical call center resources to help health insurers, hospitals, providers, and other health care focused organizations engage patients with personalized care and connect patients to the appropriate resources and care settings.

“By managing the health of populations, including disease management, care management and wellness, Sirona will fit into Citra’s holistic approach to drive increased member engagement, reduce health care costs and improve the quality of care,” said Howard Buff, CEO and Founder of Citra Health Solutions. “e;The integrated health care model will provide a service and technology enabled platform that supports a multitude of payment models and risk arrangements for providers and health systems.” “The acquisition of Sirona brings to Citra a robust clinical infrastructure and a proven track record of excellence in nurse triage and patient engagement solutions,” added Adam Dolder, Managing Director at GPP. “The combined offerings of Citra and Sirona further entrench Citra as a preeminent player in evolving value-based care models.”

About Great Point Partners

Great Point Partners (“GPP”) is a leading health care investment firm with approximately $900 million of equity capital under management investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which closed on $215 million in 2013. Great Point manages both private and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies and the private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Citra Health Solutions

Citra Health Solutions is a leading health care services and technology firm that solves for the needs of providers, hospital systems and payers in the transition to value-based care. In this new era of payment and delivery, Citra empowers clients with proprietary technology, population health, analytics and care management services to strategically expand market opportunity, diversify revenue streams and reduce the cost of care. To learn more, visit www.citrahealth.com.

Professional Physical Therapy Acquires Wilutis Hand Therapy and Advanced Hand Therapy

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners I (“GPP I”) today announced that Professional Physical Therapy (“ProPT”) has acquired Wilutis Hand Therapy and Advanced Hand Therapy, leaders in the fields of hand therapy and occupational therapy. With these two tuck-in acquisitions, ProPT augments its services to include occupational therapists, enhances its existing hand therapy services and adds six new locations on Long Island. ProPT now has 67 facilities throughout New York, New Jersey, and Connecticut.

Stephen Weaver, Vice President at Great Point Partners, said, “ProPT’s ability to grow organically and acquisitively is unparalleled in the New York, New Jersey and Connecticut markets. These acquisitions mark the 12th and 13th tuck-ins since GPP’s investment in October 2011 and are a clear indication of ProPT’s ability to execute on its strategic growth plan.”

Unifying the two most prominent Occupational Therapy hand practices on Long Island is the most unique transaction ProPT has completed to date. “Partnering with Robert Wilutis of Wilutis Hand Therapy and Richard Scalise of Advanced Hand Therapy enables us to dramatically broaden the hand therapy product offerings across the entire company,” said Adam Elberg, President and CEO of ProPT.

“As leaders in hand and occupational therapy, we sought to join an organization with the same dedication to its patients and exceptional treatment outcomes that has defined our business,” added Robert S. Wilutis, owner of Wilutis Hand Therapy. “I was impressed when ProPT was recognized as one of the top three physical therapy providers in the nation, so joining this award-winning company not only ensures the continuation of our promise to be the best in the industry, but also allows us the opportunity to provide hand therapy services across the entire Tri-State area.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“ProPT”), headquartered in Uniondale, New York, is an award-winning, leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, ProPT now operates 67 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, five located in Blink Fitness facilities, one located in a STACK Sports Performance Center, and 49 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with orthopedic and sports injuries and other medical conditions. Additionally, ProPT operates a 20,000 square foot sports performance training facility in Garden City, New York. www.professionalpt.com

Great Point Partners I Sells Portfolio Company – Equian

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Equian, a Great Point Partners I (GPP I) portfolio company, today announced that it has been acquired by New Mountain Capital, LLC for $225 million in cash. Equian is a leading provider of health care payment integrity solutions to payors of medical claims.

Noah F. Rhodes, III, Principal of Great Point Partners and Board member of Equian stated, “We are very proud of the business that we have built with Scott Mingee, CEO, and the entire Equian team over the past eight years. During our partnership, we sourced and executed eleven add-on acquisitions, arranged multiple debt financings for acquisitions as well as a dividend recapitalization, grew revenue by a compound annual growth rate of over 31%, and increased EBITDA more than ten-fold. We know that Equian will continue to thrive, and look forward to seeing the business’ continued success.”

“The partnership that started in 2007 between the two co-founders Russ Sherlock and John Ansay and Great Point Partners has exceeded the goals we set for ourselves in terms of corporate growth and enhanced market position,” said Jeffrey R. Jay, M.D., Managing Director of Great Point Partners. “The Equian sale is also a milestone for GPP I, which had $156 million of committed capital. With the Equian distribution, gross distributions from GPP I during 2015 alone now exceed $165 million.”

“In 2007, the founders of Equian partnered with Great Point Partners to help us create a leading provider of payment integrity solutions,” said Russell W. Sherlock, Equian’s Co-Founder and Chairman. “We have had an incredible journey growing Equian into the market leading business it is today, and I am thankful to Great Point Partners for their partnership and confidence in our vision. Together, we built a great company that will continue to thrive for many years to come.”

“We are excited about this transaction and the opportunity that it represents for Equian.” said Scott Mingee, Chief Executive Officer of Equian, Inc. “We will continue to serve our clients with the same level of attention and customer service that we have in the past, and we will now be able to offer them an expanded product offering through our combination with Trover Solutions.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Equian

Equian is a health care information services company providing solutions throughout the United States that ensure each health care interaction is paid accurately, and at the lowest possible cost. Equian was backed by Great Point Partners, LLC, a leading health care investment firm, and is recognized nationally by Inc. Magazine and Modern Healthcare as a leading high-growth company in health care. Visit www.equian.com for more information.

PitchBook Names Great Point Partners Top Investor in Pharma & Biotech Infrastructure Since 2010

Introduction

GREENWICH, CT – Great Point Partners (“GPP”) today announced that PitchBook, the leading provider of data on private equity transactions, named GPP as one of the most active pharma and biotech infrastructure investors since 2010.

Note: All platform and add-on investments from 2010 – November 17, 2015
Investor Deals
Lincoln Park Capital 10
Great Point Partners 9
TPG Capital 9
Warburg Pincus 9
Ardian 8

Great Point Partners’ first fund, GPP I, has realized three highly successful pharmaceutical and biotechnology supply chain investments. These were Caprion Proteomics, an international leader in biomarker services based in Montreal, Mediatech, a manufacturer of proprietary cell culture media, and Cytovance Biologics, the fastest growing contract manufacturer of protein and anti-body drugs in the United States. Equity investment appreciation in these companies ranged from approximately 3.4-fold to 7.4-fold.

GPP sourced two tuck-in acquisitions for Caprion Proteomics to accelerate its growth and solidify its dominant market position. As noted previously by others, GPP sources more tuck-in acquisitions per portfolio company than any other health care private equity firm.

To date GPP II, Great Point’s second growth buy-out fund, has made two pharmaceutical and biotech supply chain investments in Corrona, a leader in patient registries for post approval drug surveillance, and Softbox, a leader in temperature controlled packaging for biologics, vaccines, and active pharmaceutical ingredients. Both of these companies have been growing revenues over 20% per year since GPP’s investment.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Citra Health Solutions Announces $11.2 Million in Client Savings for Managed ACOs

Introduction

GREENWICH, CT and JACKSONVILLE, FL – Great Point Partners (“GPP”) today announced that GPP II portfolio company Citra Health Solutions (“Citra”) helped two of its managed Accountable Care Organizations (“ACOs”) achieve a total savings of $11.2 million in 2014. American Health Alliance and ACO Health Partners were part of only 27% of ACOs nationwide receiving 2014 bonuses from the Centers for Medicare & Medicaid Services (“CMS”).

Final reports from the CMS Shared Savings Program, which were made available on September 2, 2015, show ACO Health Partners’ savings as $6,476,300 and American Health Alliance with $4,756,401 in savings for the 2014 year. The Shared Savings Program allows physicians to share in up to 60% of the savings they generate, incentivizing providers to utilize population health management programs to deliver higher quality and lower cost care. In addition to these savings, both ACOS exceeded quality requirements by over 80% and showed significant improvement in patient satisfaction thresholds.

“These results prove that, with the necessary resources, ACOs are a great stepping stone to health care reform. Technology and infrastructure are critical in delivering superior support and clinical care to patients,” said Howard Buff, Citra’s Founder & Chief Executive Officer. Citra is known as a market leader in value-based care through signature care programs such as Chronic Care Management and Transitional Care Management.

“The transition to value-based reimbursement presents a unique set of challenges and opportunities for health care providers,” stated Adam B. Dolder, Managing Director at GPP. “Citra is an integral partner for providers in this transition enabling them to leverage Citra’s extensive value-based enablement capabilities. The shared savings we were able to help our clients achieve, combined with the significant outperformance on quality measures, validate Citra’s position as one of the preeminent providers of value-based care programs.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Citra Health Solutions

Citra Health Solutions is a leading health care services and technology firm that solves for the needs of providers, hospital systems and payers in the transition to value-based care. In this new era of payment and delivery, Citra empowers clients with proprietary technology, population health, analytics and care management services to strategically expand market opportunity, diversify revenue streams and reduce the cost of care. To learn more, visit www.citrahealth.com.

Great Point Partners I Portfolio Company, Cytovance Biologics, Is Acquired by Hepalink USA

Introduction

GREENWICH, CT and OKLAHOMA CITY, OK – Cytovance® Biologics, Inc. (“Cytovance”), a Great Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it has been acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash.

Through the Cytovance acquisition, Hepalink USA Inc. and its parent company Shenzhen Hepalink Pharmaceutical Co., Ltd. add a leading biologics CDMO to its current U.S. operations. Cytovance manufactures protein and antibody drugs for biotechnology and pharmaceutical companies throughout the world.

“This transaction expands our ability to develop and grow both our domestic and international businesses and will accelerate our current expansion plans in our Oklahoma City facilities,” said Mr. Darren Head, President and Chief Executive Officer of Cytovance. He added, “Great Point Partners has been an outstanding private equity partner that arranged debt financings enabling growth, helped us recruit senior executives, and that provided Dr. Bernhard Hampl, former CEO of Sandoz USA, from their CEO Advisory Board as Co-Chairman.”

Noah Rhodes, a Principal at GPP and Board member of Cytovance, stated, “When we invested in Cytovance in 2011 it was a relatively unknown company that had all of the right ingredients to become an industry leading CDMO, and our equity investment and relationships with senior lenders enabled the company to execute on an accelerated growth strategy. Since our investment four years ago, Cytovance has grown its revenue at a compound annual growth rate of 45% and is now considered one of the preeminent biologics contract manufacturers in the world.”

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Cytovance® Biologics Inc.

Cytovance® Biologics is a contract development manufacturing company specializing in the cGMP production of therapeutic proteins and antibodies from mammalian cell culture, microbial fermentation, transgenic processes, and small scale “flex suite” programs. In addition, Cytovance offers process development services, cell line development, purification development, stability testing, and regulatory support services – all from its Oklahoma City state-of-the-art facilities. Cytovance partners with clients to provide integral pathways in converting novel protein discoveries into lifesaving therapies and diagnostics.

About Hepalink

Hepalink, together with its U.S. subsidiary SPL, is one of the largest suppliers of heparin sodium API in the world, distributing its products to the global market and to internationally renowned pharmaceutical companies. Hepalink was established in 1998 and was listed on the Shenzhen Stock Exchange on May 6, 2010. Hepalink’s headquarters are located in the Shenzhen High-Tech Park. More information is available at www.hepalink.com/en.

Biotronic NeuroNetwork Acquires Southern California Based Neurowave Monitoring

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the nation’s leading intraoperative neurophysiological monitoring (“IONM”) company, is pleased to announce the acquisition of Neurowave Monitoring (“Neurowave”), a California-based provider of technical IONM services.

Since 1995, Neurowave has been a premier provider of IONM services in Los Angeles and Orange counties, earning the respect and trust of regional hospitals and surgeons. “Biotronic is an ideal partner for Neurowave” said Paul Sowa, President of Neurowave. “Their infrastructure and commitment to patients will help the combined entity grow in southern California.” William J. Gecsey, President and CEO of Biotronic NeuroNetwork commented, “The acquisition will allow Biotronic to further serve its client base in southern California and leverage a strong team of technologists.”

“This is Biotronic’s 7th tuck-in acquisition” added Scott Davidson, Managing Director at GPP. “Biotronic is the largest national provider of IONM services, and this further solidifies the company’s leadership position.”

IONM utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) and organs in real-time during surgeries such as neurological, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 250 administrative, support and clinical staff, including over 200 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. Please see www.biotronic.com/chatstat for more news. For more information on Biotronic please visit www.biotronic.com.

Professional Orthopedic and Sports Physical Therapy Completes Three Tuck-in Acquisitions Expanding Long Island Footprint

Introduction

GREENWICH, CT and UNIONDALE, NY – Professional Orthopedic and Sports Physical Therapy (“Professional”), a Great Point Partners I, L.P. portfolio company, has acquired Bi-County Physical Therapy & Rehabilitation, Flynn Physical Therapy and S.M.A.R.T. Physical Therapy, continuing its rapid growth on Long Island in an effort to provide the most convenient and highest quality care to its patients. With these three acquisitions, Professional adds six locations in the Long Island/Queens area, now totaling 63 facilities throughout New York, New Jersey and Connecticut.

“It’s amazing that we are able to add three additional high caliber clinically-based companies right on the heels of our acquisition of Premier Physical Therapy,” stated Tim Mauro, Professional’s Partner and Regional VP of Clinical Operations on Long Island.

Adam Elberg, Professional’s Founding Partner, President & CEO, added, “These three tuck-in acquisitions further strengthen Professional’s footprint and strategic position as the largest orthopedic outpatient physical therapy company in the New York, New Jersey and Connecticut tri-state area.”

According to Stephen Weaver, Vice President at Great Point Partners, Professional has now completed eleven tuck-in acquisitions since GPP’s investment in October 2011 and has completed six tuck-in acquisitions thus far in 2015. Professional continues to execute on its strategic plan of successful growth while maintaining an exceptional staff of physical therapists and delivering the highest quality of care to its patients.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“Professional”), headquartered in Uniondale, New York, is a leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional now operates 63 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, four located in Blink facilities, one located in a STACK Velocity Sports Performance Center, and 46 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and other medical conditions. Additionally, Professional operates a 20,000 square foot sports performance training facility in Garden City, New York.

Professional Physical Therapy Becomes Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness

Introduction

GREENWICH, CT and UNIONDALE, NY — Great Point Partners (“GPP”) today announced that its GPP I portfolio company, Professional Orthopedic and Sports Physical Therapy (“Professional”), acquired Premier Physical Therapy & Wellness (“Premier”) with 13 state-of-the-art clinics in Manhattan, Westchester, and Connecticut.

“Our acquisition of Premier Physical Therapy & Wellness establishes Professional as the largest provider of outpatient physical therapy services in the Northeast,” said Adam Elberg, Professional’s Founding Partner, CEO, & President. “Expanding our footprint in New York City and Westchester, while entering Fairfield County, Connecticut has tremendous benefits to our referral sources, patients, and employees. This is an exciting and transformative acquisition for Professional.”

“Premier grew to be the second largest New York City-based provider of physical therapy,” said John J. Benke, a Premier owner. “My partners, Laura Benke and Joseph Tatta, and I recognized the current consolidation in health care and our need to achieve greater scale by joining forces with Professional. Their best-in-class therapist educational programs are second-to-none. These will enable our employees to thrive.”

This marks the 8th tuck-in acquisition that Professional has completed since GPP’s investment in October 2011 and third tuck-in acquisition thus far in 2015. Professional now offers added convenience by operating 57 clinics throughout Manhattan, Queens, Bronx, Brooklyn, Long Island, Westchester, Rockland, New Jersey, and Connecticut. Professional’s ability to execute on its strategic plan of successful growth and provide an exceptional staff of physical therapists that offer top-of-the-line treatment, meeting each patient’s needs, is extraordinary.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

About Professional Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“Professional”), headquartered in Uniondale, New York, is a leading provider of physical therapy and rehabilitation services in the New York metropolitan area, New Jersey and Connecticut. Founded in 1998, Professional now operates 57 outpatient physical therapy centers: 12 located within Equinox Fitness Centers, four located in Blink facilities, one located in a STACK Velocity Sports Performance Center, and 40 standalone. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and other medical conditions. Additionally, Professional operates a 20,000 square foot sports performance training facility in Garden City, New York.

PitchBook Names Great Point Partners Top Investor in Health Care for 2015 for Third Straight Year

INTRODUCTION

GREENWICH, CT — Great Point Partners (“GPP”) today announced that PitchBook named it as one of the most active health care investors since 2010.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Dr. Barry Straube, Formerly of CMS, to Join Board of Directors for Great Point Partners' Citra Health Solutions

Introduction

GREENWICH, CT and JACKSONVILLE, FL — Great Point Partners (“GPP”) today announced that Dr. Barry M Straube, M.D., formerly the Chief Medical Officer of CMS (Center for Medicare and Medicaid Services), has agreed to join the Board of Directors of its GPP II portfolio company Citra Health Solutions (“Citra”). The Jacksonville-based company provides tools and services that allow the health care industry to succeed in the emerging value-based environment and in the growth of ACO’s (“Accountable Care Organizations”).

“Our mission is to equip our health care partners with the best possible solutions, enabling them to deliver quality care, improve population health management and increase efficiency,” said Howard Buff, Chief Executive Officer at Citra. “With the exciting addition of Dr. Straube to our board, we take another important step in building a team that is capable of fulfilling these ambitions. Dr. Straube’s impressive track record will validate and further enhance the value of our programs.”

Dr. Straube brings to Citra extensive physician executive and clinical leadership experience in the physician-hospital, managed care, technology & innovation and federal/state health care sectors. Previously, he served as Chief Medical Officer for CMS for six years as well as the Director of the CMS Office of Clinical Standards & Quality (OCSQ). He currently serves as Director with The Marwood Group, a health care advisory and financial services firm headquartered in New York City.

Prior to his government service, Dr. Straube served in a number of senior physician management positions for Foundation Health Systems and Health Net, where he held the roles of Vice President, Quality Improvement and Senior Medical Director.

Dr. Straube received an A.B. magna cum laude and Phi Beta Kappa from Princeton University and an M.D. from the University of Michigan Medical School.

“Citra has had record quarterly sales and we welcome the immediate contributions that Dr. Straube can make to the Company’s value-based programs,” added Adam Dolder of Great Point Partners.

About Citra Health Solutions

Citra Health Solutions (“Citra”) aligns the needs of providers and patients with a focus on better health and more efficient value-based management. By combining scalable services with technical solutions, Citra enables its partner to optimize business practices while improving health outcomes for patients. Visit www.citrahealth.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Aris Radiology Expands Coverage through Acquisition of Optimal Radiology

Introduction

GREENWICH, CT and HUDSON, OH — Great Point Partners (“GPP”) today announced that its GPP I portfolio company Aris Radiology has acquired Optimal Radiology (“Optimal”), a Tennessee-based professional radiology company that provides 24/7 coverage of hybrid (onsite radiologist staffing and teleradiology) services to hospitals and health systems across five states. The acquisition will allow Aris to expand its national footprint to now cover 30 states, as well as increase radiologists on staff to 160—creating capacity to interpret an estimated 1.5 million exams annually.

Carl Kozlowski, Chief Executive Officer of Aris, commented, “The acquisition of Optimal and its client base establishes Aris as the premier provider of onsite and offsite professional radiology services to hospitals and health systems nationwide. We are excited to continue providing the highest level service to Optimal’s existing clients, working closely with our new Chief Medical Officer, Dr. Chad Calendine, formerly of Optimal.”

“Aris’ hybrid radiology model and dedication to providing the highest quality service to their clients made them an obvious partner for Optimal,” said Dr. Chad Calendine. I am eager to work with Carl and the rest of the Aris team to expand premier sub-specialty radiology coverage to Optimal providers and others which have had difficulty obtaining reliable subspecialty radiology coverage.”

Optimal will continue to provide the same superior coverage to its numerous hospital and health system contracts. As part of the company’s continued expansion and the Optimal acquisition, Aris will open an executive office in Nashville, TN, according to Rohan Saikia, a Principal at Great Point Partners.

About Aris Radiology, LLC

Founded in 2007 and headquartered in Hudson, OH, Aris provides professional radiology services to patients, surgeons and health care institutions. The Company is a Joint Commission certified radiology services company. Aris works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 subspecialty coverage, 24/7 operations support, and quality assurance data. Aris’ breadth of service and discipline allows it to deliver high quality patient care in a cost-effective manner to the hospitals, and other health care payors. Visit www.arisradiology.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, and information technology. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Great Point's Equian Starts the Year Enhancing Payment Integrity through Acquisition of The Assist Group

Introduction

GREENWICH, CT and INDIANAPOLIS, IN — Equian, a Great Point Partners (“GPP”) I portfolio company and a leader in health care reimbursement analysis and payment integrity, today announced the completed acquisition of The Assist Group (“TAG”) effective January 2015. The transaction kicks off the year furthering Equian’s commitment to the payment integrity market and advancing the company’s pre-payment clinical claims review and resolution solutions.

TAG, based in Lakewood, Colorado, is a pre-payment technology and solutions company with extensive clinical and claim resolution processes that identify improper costs and yield significant savings to payers. TAG’s deep clinical domain experts coupled with their detailed technology platform provide health care payers substantiated findings to avoid reimbursement of inappropriate costs on a pre-payment basis.

“TAG’s forensic review process of identification and resolution which results in a reduction of claim billing errors is impressive and has saved payers tens of millions,” says Scott Mingee, CEO of Equian. “Our acquisitions in the last 12 months were focused on post payment expertise, and with the addition of TAG’s pre-payment capabilities we further our vision as an end to end payment integrity company. Our customers are looking for a partner to help them along the entire continuum of post payment, pre-payment and ultimately prevention. TAG has a unique approach along with new rules which enhances our ability to lower the cost of care for our customers.”

“We identified pre-payment solutions as a large and underpenetrated market in the commercial and government managed care sector,” added Brett Carlson, Principal at Great Point Partners. “Through primary research in talking with customers, TAG emerged as the top target on our acquisition wish list.”

About Equian

Equian is a health care information services company providing solutions throughout the United States that ensure each health care interaction is paid accurately, and at the lowest possible cost. Equian is backed by Great Point Partners, LLC, a leading health care investment firm, and is recognized nationally by Inc. Magazine and Modern Healthcare as a leading high-growth company in health care. Visit www.equian.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Former IMS Health and InVentiv Health Executive Raymond H. Hill Joins Corrona as Executive Chairman of the Board of Directors

Introduction

GREENWICH, CT and SOUTHBOROUGH, MA — Corrona, a Great Point Partners (GPP”) II portfolio company and a leader in observational data and consulting in the auto-immune field, today announced that Raymond H. Hill has been elected Executive Chairman of Corrona’s board of directors.

As President at InVentiv Health Clinical, a leading contract research organization (CRO), Mr. Hill was instrumental in driving EBITDA growth, securing key strategic partnerships, and re-positioning the company. Prior to that, as President at IMS, Mr. Hill spearheaded work in portfolio strategy, pricing and market access, launch excellence, managed markets, sales force effectiveness, and commercial outsourcing. Mr. Hill also served as the CEO of Pharmaceutical Product Development Inc.

“I am thrilled that Ray Hill will be joining the Corrona team. He is an immensely wise, talented, and experienced executive who will help us excel in many areas in coming years”, said Dr. Joel Kremer, founder and Chief Medical Officer of Corrona.

“Ray will be an invaluable resource to the company”, said Noah Rhodes, Principal at Great Point Partners. “His experience managing both clinically oriented and data oriented firms in the health care field will serve us well. We look forward to his counsel on matters relating to health care data, the use of data for pharmaceutical marketing, in satisfying post approval FDA requirements, and leveraging real world data to improve health outcomes.”

“I am excited to be leading the board and advising the team at this most interesting time in health care,” said Mr. Hill. “Corrona is doing innovative work in real world patient and clinical data for autoimmune diseases. With access to over 40,000 patients and 10 years of longitudinal data, Corrona is very well positioned to help biopharmaceutical companies understand how their drugs are used and how to optimize outcomes in the real world.”

About Corrona

Corrona was founded in 2000 by leading physicians dedicated to advancing and improving the care of patients with chronic diseases. Our mission is to advance research and improve the quality of patient care through world class observational cohorts. Corrona provides data and research results to all biopharmaceutical companies with an interest in our therapeutic areas of coverage. Our data is used to assist in trial design, comparative effectiveness, patterning and to satisfy post market safety reporting. We are proud to be advised by experienced academic and clinical physicians throughout the country with a wide range of experiences. www.corrona.org.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO

Introduction

GREENWICH, CT and ANN ARBOR, MI — Biotronic, a Great Point Partners I portfolio company and the nation’s leading intraoperative neurophysiology monitoring (“IONM”) company, today announced the promotion of Bill Gecsey, President and CFO, to the position of Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic in 2010 as CFO, was promoted to President and CFO in 2013 and has been an integral part of Biotronic’s continued growth and success.

“Bill’s efforts and achievements since joining the company in 2010 have been consistently outstanding and have positively impacted every aspect of the business,” said Charles Orsatti, Chairman of the Board of Directors. “Since his promotion to President and CFO last year, his expanded role and responsibilities have directly contributed to the company achieving historical highs in both growth and profitability. We are excited about continuing to work with Bill over the next growth phase for the business.”

Bill Gecsey, CEO of Biotronic, commented “I am honored and excited after four years at Biotronic to become the Chief Executive Officer. I look forward to continuing to build on Biotronic’s commitment to providing the highest quality IONM services in the United States and continuing our trajectory of rapid growth.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 250 administrative, support and clinical staff, including over 200 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. www.biotronic.com

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Completes Growth Recapitalization of Softbox Systems

Introduction

GREENWICH, CT and LONG CRENDON, UK — Great Point Partners, a Greenwich-based health care investment firm, today announced a growth recapitalization of Softbox Systems, Ltd. (“Softbox”). Softbox is a leading provider of temperature controlled packaging (“TCP”) solutions for the biotechnology and pharmaceutical industries. The Company’s products play a critical role in maintaining the integrity of temperature-sensitive drugs, vaccines and active pharmaceutical ingredients (“API”) during the distribution process.

The investment will enable Softbox to expand its global geographic footprint, diversify its product offering, and continue to invest in superior customer service for its clients.

“We are very excited about the opportunity to partner with Great Point. We were impressed with their rolodex of customer relationships in the biotechnology industry, the robust acquisition pipeline they had developed, and their deep industry knowledge. We are confident that their resources will allow us to achieve a higher level of growth by tapping into new markets, broadening our product line, and expanding our customer base. We believe that we will solidify our market leading position in this rapidly growing industry,” said Richard Jones, Chief Executive Officer of Softbox.

“Softbox presented a compelling opportunity to invest in a global leader in the market of TCP solutions for the biopharmaceutical industry,” said Adam B. Dolder, Managing Director at Great Point Partners. “Management’s deep domain knowledge and commitment to innovation of new solutions for their customers have created a unique platform in the industry. Richard and Edwin Tattam, Founder, have developed a company with extraordinary customer satisfaction and durable, long-term relationships with its customers.”

As part of Great Point’s investment, Dr. Jeffrey R. Jay and Noah F. Rhodes, III will join Mssrs. Tattam, Jones and Dolder on Softbox’s Board of Directors. In addition, Dr. Bernard Hampl of Great Point Partners CEO Advisory Board will also serve as Co-Chairman of the Board along with Mr. Tattam. Dr. Hampl is also Co-Chairman of the Board of Cytovance Biologics and a Director of Chemwerth Inc., a leading API provider to the pharmaceutical industry. Previously, Dr. Hampl was CEO of Eon Labs from 1996 to 2005 until the acquisition by Novartis at which time he became the CEO of the Sandoz US-division of Novartis.

About Softbox Systems, Ltd.

Softbox was founded in 1995 in order to take advantage of increasing focus on temperature controlled packaging by the biopharmaceutical industry and global regulatory bodies. The company currently supplies a line of packaging solutions (“PolyBox”, “TempCell”, “SilverPod”, etc.), and currently serves more than half of the world’s 50 largest pharmaceutical companies. Softbox has a global presence, with headquarters in the United Kingdom, and additional locations in the United States, India, Singapore, and Australia. Learn more at www.softboxsystems.com.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Professional Orthopedic and Sports Physical Therapy Acquires 13 New York Metro Clinics

Introduction

GREENWICH, CT and UNIONDALE, NY — Professional Orthopedic and Sports Physical Therapy (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company, has acquired the 13 Sports Physical Therapy of New York’s (“SPTNY”) downstate locations. Through this acquisition, Professional will provide broader New York City and Queens coverage, as well as expand its services into Brooklyn, Rockland County and the Bronx.

“The SPTNY acquisition is one of the most compelling deals we’ve done to date,” said President, CEO & Founding Partner Adam Elberg. “With 13 additional locations, we’ll be able to provide patients and physicians with greater flexibility of choice for treatment, as well as more career opportunities for our employees. We’re looking forward to integrating SPTNY’s team into the Professional family, as we continue to provide the best physical therapy care in the New York-Metropolitan area. Our priorities will always be excellent, individualized patient care and promoting an environment where employees can thrive.”

When asked about the sale of SPTNY’s downstate clinics to Professional, Lynn Steenberg, owner of SPTNY said, “It was critically important for us to find a company that would continue to emphasize the values we have created at Sports PT of New York. Because Sports PT will continue to service the upstate region of NY from Saratoga to Buffalo, it was important to divest our downstate business to a company that would provide the highest quality support to the staff, patients, and medical community. Professional can meet that high bar.”

Rohan Saikia, Senior Vice President of Great Point Partners and Board member of Professional added, “Since our partnership in 2011, the Company has grown rapidly from 10 facilities to over 40 facilities through a combination of starting new locations as well as 5 strategic and accretive acquisitions. The Company has truly differentiated itself as the most scalable, preeminent and highest quality provider in the region.”

About Professional Orthopedic and Sports Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“Professional”), headquartered in Uniondale, New York, is a leading provider of Physical Therapy and Rehabilitation Services in the New York-metropolitan area and New Jersey. Professional was founded in 1998, and now operates 40 outpatient Physical Therapy centers: 11 of which are located within Equinox Fitness Centers, four located in a Blink facility, one located in a Velocity Sports Performance Center, and 24 standalone. Additionally, Professional operates a 20,000 square foot sports performance training facility in Garden City, New York. The company’s outpatient Physical Therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and various other medical conditions. Visit www.professionalpt.com for more information. www.professionalpt.com.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $400 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, and specialty pharmaceuticals. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Equian Acquires AfterMath Claim Science and Enhances Its Payment Integrity Capabilities

Introduction

GREENWICH, CT and INDIANAPOLIS, IN — Equian completed the acquisition of AfterMath Claim Science, Inc. effective June 11, 2014. The transaction builds upon Equian’s commitment to the payment integrity market and accelerates Equian’s strategy of expanding its capabilities through advanced data mining and analytics.

Based just outside of Chicago, IL, AfterMath Claim Science is a post-payment recovery services company that identifies and eliminates medical claim payment errors. Since its inception in 2003, AfterMath Claim Science has been developing overpayment solutions for the nation’s leading health care payors. The Company’s investment and commitment to their data mining technology (ClaimScopeR) was an attractive element of the transaction for Equian.

“The AfterMath Claim Science acquisition further expands our capabilities and footprint in post-payment services and analytics,” says Scott Mingee, CEO of Equian. “It builds on our last acquisition, The Reclaim Group, by adding new types of waste we identify, recover and ultimately eliminate for our clients. We are constantly looking for new ways to reduce our clients’ cost of care and remain committed to our focus on innovation, growth and capability expansion – AfterMath Claim Science checks all those boxes for us and our clients.”

“Post-payment services and analytics is highly scalable and a tremendous growth opportunity for Equian. With Equian’s rock solid management team, technological prowess, and deep payment knowledge they are delivering a powerful value proposition,” says Jeffrey R. Jay, M.D., Managing Director of Great Point Partners and a member of the Equian Board of Directors.

“AfterMath Claim Science has been delivering significant cost savings to several of the largest and most sophisticated health insurers in the country for the past 10 years,” added Brett Carlson, Senior Vice President at Great Point Partners. “We look forward to building upon their decade of success”.

About Equian

Equian (formerly known as Health Systems International) is a health care information services company providing solutions throughout the United States—and around the world—that ensure each health care interaction is paid accurately, and at the lowest possible cost. Equian is backed by Great Point Partners, a leading health care investment firm, and is recognized nationally by Inc. Magazine and Modern Healthcare as a leading high-growth company in health care. Visit www.equian.com.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $750 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Growth Recapitalization Investment in Corrona

Introduction

GREENWICH, CT and SOUTHBOROUGH, MA — Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth recapitalization investment in Corrona, Inc. (“Corrona”). Corrona is an observational registry founded in 2000 by Dr. Joel Kremer and is the leading provider of clinical real world data obtained prospectively from both physicians and patients at the time of a routine clinic visit. The Company has a very large and robust dataset for rheumatoid arthritis, psoriatic arthritis, spondyloarthopathy and gout, and is branching out to other autoimmune and chronic diseases.

The equity investment will fund growth in the Company’s infrastructure in IT, epidemiology and biostatistical support, pharmacoeconomics, and enhanced project management capabilities and will also fund the Company’s expansion to other autoimmune and chronic diseases.

Dr. Joel Kremer, Founder and CMO of Corrona stated, “Through the partnership with Great Point Partners, Corrona will realize its full potential to lead the nation in reporting clinical results which make a difference to patients, physicians, and society. We are pleased and enormously flattered that GPP has chosen to invest in Corrona. Working together with GPP, Corrona will be able to explore and achieve its full potential to become a world leader in health care research and post-market approval drug surveillance for chronic diseases.”

“Corrona has grown rapidly with an impressive customer base because the Company is uniquely positioned with the most detailed and informative patient disease registries”, said David Kroin, Managing Director of Great Point Partners. “Corrona is uniquely positioned at the intersection of biopharmaceutical development and health care information technology with an emphasis on research and science, each of which is a core focus area for Great Point’s private equity efforts. This transaction will provide the Company with the growth capital and resources necessary to realize Dr. Joel Kremer’s vision of a fully integrated real world evidence company.”

“Great Point demonstrated their potential value to Corrona during our first meeting and stood out from other potential private equity partners,” added James Cavan, President and COO of Corrona. “The team was impressively knowledgeable about the business of clinical drug monitoring and research. Corrona will benefit from their new insights and experiences along with additional working capital to address our growth goals. As a result of this investment, our expected growth to new therapeutic areas and geographic representations will accelerate which will benefit our clinicians, subscribers, researchers and most importantly patients.”

As part of their investment, Great Point Managing Directors Dr. Jeffrey R. Jay and David Kroin, Principal Noah F. Rhodes, III and Senior Associate Stephen Weaver will join Corrona’s Board of Directors along with Kirk Grosel, Principal of Blockbuster Strategy and from Corrona, Dr. Joel Kremer, Jim Cavan, Dr. Jeffrey Greenberg and Robert Lento.

About Corrona

Corrona was founded in 2000 by leading rheumatologists dedicated to advancing and improving the care of patients with rheumatic and other chronic diseases. CORRONA’s mission is to advance medical research and improve the quality of patient care has expanded based upon the success of its research to include planned new therapeutic areas of dermatology, GI, SLE, and MS Corrona operates independent disease cohorts without any ownership links to the pharmaceutical industry. Learn more at www.corrona.org.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $750 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Investment in Orange Health Solutions to Finance the Acquisition of MZI HealthCare

Introduction

GREENWICH, CT and JACKSONVILLE, FL — Great Point Partners, LLC (“GPP”), a health care focused private equity firm based in Greenwich, CT, announced a significant investment in Orange Health Solutions (“Orange”), a Jacksonville, FL based technology enabled health care services company, from its second private equity fund GPP II. The primary use of the proceeds was to finance Orange’s acquisition of MZI HealthCare (“MZI”), which has developed the EZ-CAP health benefit management solution suite. The purchase of MZI enhances Orange’s core product and service offerings to more effectively meet the evolving needs of their customers as the US health care industry migrates to value-based reimbursement structures.

Orange was formed in December 2012 by a team of former UnitedHealth Group executives, Howard Buff and Nicole Bradberry, both with significant experience in the payer and consumer driven health care industries, and who will continue to lead the merged company as CEO and President, respectively. Orange offers solutions to health care providers that allow them to deliver higher quality coordinated care, improve population health management capabilities and increase efficiency while positively impacting their own financial success.

“The combination of Orange’s service solutions and the synergistic technology platforms of MZI pulls together a comprehensive solution that enables providers to manage medical cost and quality, while at the same time address the growing need for patient engagement and health care consumerism,” said CEO Howard Buff.

The combined offerings of Orange and MZI enable providers to capitalize on the opportunities presented by provider risk-sharing models. Orange’s service offerings allow providers to outsource the non-clinical population health management services necessary to partake in value-based contracts. The product suite of MZI gives its clients benefit administration and claims adjudication capabilities allowing them to more effectively manage the health care spending of their patient populations. The business combination represents a unique value proposition by offering a single source vendor across payment and benefit administration, population health technology and service offerings.

“Building out the necessary technology and human capital based infrastructure to succeed as ACOs or other value-based reimbursement models is not cost-effective for the vast majority of the market,” said Brett Carlson, Senior Vice President at Great Point Partners, “Orange Health, in combination with MZI, provides an integrated one-stop solution that allows providers to solve their technology and service needs.”

About Orange Health Solutions

Orange Health Solutions (“Orange”) provides innovative solutions to its health care partners, allowing them to deliver higher quality coordinated care, improved population health management, increased efficiency and positively impact financial success. Orange delivers the products and services necessary for health care providers to meet the demands of a value-based health care system while retaining their independence. Visit the Orange Website at www.orangehealth.net.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $750 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

About MZI Healthcare

MZI HealthCare, LLC (“MZI”), with offices in Longwood, Florida and Valencia, California, is a provider of health care software solutions designed to meet new clinical and performance requirements for accountable care and health care reform. The MZI enterprise health care solution suite includes EZ-CAP, EZ-CARE, EZ- ANALYTICS, and consulting services. MZI products and services help health care organizations harness clinical, financial and administrative information, giving them a unique perspective to make smarter decisions about patient care and payment, resource allocation, provider and contract management and more. Visit the MZI website at www.mzihc.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Rebrands Company as Equian Amid Record Growth

Introduction

GREENWICH, CT and INDIANAPOLIS, IN — Health Systems International, a Great Point Partners I, L.P. (“GPP I”) portfolio company, announced it is changing its name to Equian. The new name unifies the meaning behind the payment integrity solutions the company offers.

Key elements that were integrated as the foundation of the new name include: Equity (fair and accurate payments), Quality (best outcomes and pay for performance model), Insight (research, data and development in the changing health care environment), and Analytics (actionable data for informed business decisions).

“In 2004, Health Systems International began delivering medical cost management solutions to payors throughout the health care and workers’ compensation markets,” said Scott Mingee, CEO. “With all the changes and complexities in the health care market, we saw a lot of opportunity to increase the value we provide to customers by accelerating our investment and focus on the payment integrity market. Our core platform in pre-payment, post-payment, and data analytics provides a unique solution to our markets. With a 100% focus on driving the best financial outcomes for our clients in all areas of the reimbursement cycle, we decided to re-align our name to match our mission.”

“Since our growth recapitalization in 2007, Equian has grown revenue approximately seven-fold over six years,” added Jeffrey R. Jay, MD, Managing Director of Great Point Partners. “Equian has the highest quality products and best customer service in the world, which is why they are experiencing such phenomenal growth. We are pleased to be their partner.”

About Equian

Equian is health care information services company focused on lowering the cost of care by eliminating waste. Our nation’s most pressing challenge is the rising cost and affordability of health care, and Equian’s efforts are dedicated to that challenge. The Company provides pre-payment, post-payment, and data analytic solutions for payors to ensure health care interactions are paid accurately at the lowest possible cost. www.equian.com

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $750 million of equity capital under management and 26 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million, and GPP II) and public (BMVF, approximately $370 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Professional Orthopedic and Sports Physical Therapy Acquires Gold Coast Physical Therapy

Introduction

GREENWICH, CT and UNIONDALE, NY — Professional Orthopedic and Sports Physical Therapy (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Gold Coast Physical Therapy & Sports Training (“GCPT”) with four state-of-the-art clinics in Suffolk County. This marks Professional’s fourth tuck-in acquisition since GPP’s investment in October 2011.

“We’re thrilled to welcome Gold Coast to the Professional family,” said Adam Elberg, President and CEO of Professional. “Gold Coast is one of the premiere physical therapy providers in Suffolk County with a similar outlook on excellent service standards and company values. We know this is the beginning of a great future together. I’m also pleased to announce that Joseph Kozlowski, Robert Shapiro, Scott Donop, Glenn Bitran, and Richard Ferriggi are joining the Professional family as partners. Everyone is looking forward to working with them and growing together.”

“Professional’s superior commitment to producing high-quality outcomes and consistently achieving outstanding service value were key factors in our considerations for partnering with them,” said Robert Shapiro, Partner and Co-Founder of GCPT. “As we continue to demonstrate our best-in-class clinical protocols, it’s exciting to join Professional and further benefit our stakeholders — our patients, referral sources, and employees. I’m looking forward to this new chapter and am especially eager to work alongside Professional’s Chief Clinical Officer Rob Panariello in Professional Seminars — the renowned continuing education program for physical therapists, physical therapist assistants, athletic trainers, and strength and conditioning specialists.”

“Gold Coast’s exceptional commitment to patient care is a perfect fit with Professional,” said Tim Mauro, Vice President of Clinical Operations at Professional. “Together, we’ll be able to provide unsurpassed treatment and service across Long Island.”

The addition is a clear indication of Professional’s ability to execute on its strategic plan, continuing its rapid expansion and successful growth. Through best-in-class treatment and protocols, Professional continues to recruit and train top-tier physical therapists, and scale to its growing number of facilities throughout New York and New Jersey. With the addition of GCPT, Professional now has 27 locations.

About Professional Orthopedic and Sports Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“Professional”), headquartered in Uniondale, New York is a leading provider of physical therapy and rehabilitation services in the New York metropolitan area and New Jersey. Professional was founded in 1998 and now operates 27 outpatient physical therapy centers: nine of which are located within Equinox Fitness Centers, four located in a Blink facility, one located in a Velocity Sports Performance Center, and thirteen standalone. Additionally, Professional operates a 20,000 square foot sports performance training facility in one of its locations. The company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and various other medical conditions. www.professionalpt.com

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management and 24 professionals. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million and GPP II) and public equity (BMVF, approximately $340 million) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

iVantage Health Analytics® Acquires Galloway Consulting

Introduction

GREENWICH, CT and PORTLAND, ME — iVantage Health Analytics (“iVantage”), a Great Point Partners (“GPP”) II portfolio company and a leading provider of health analytic solutions, announced today that they have acquired Galloway Consulting, a strategic advisor to hospitals. This is the third acquisition that iVantage has completed since GPP’s initial investment in May of 2013.

Galloway specializes in helping hospital groups, physicians, and providers improve their operations, outcomes and profits. The firm was founded by Mitchell Galloway in 1998 and has assisted over 450 clients, including academic medical centers, national and regional hospital systems, as well as individual hospitals in rural and urban markets.

“Galloway Consulting has been a partner with iVantage for the past two years and we have seen compelling evidence that combining business intelligence and advisory services offers great benefits to our health care clients,” commented Mitchell Galloway, President and CEO of Galloway Consulting. “The dynamics of the new health care have generated market demand for an integrated source of advanced business analytics and expert counsel. Adding our advisory services and deep industry expertise to the integrated VantagePoints platform will offer the industry the best of both worlds.”

Brett Carlson, a Senior Vice President of Great Point Partners commented “We are proud of what iVantage has achieved to this point, and we believe that that this next chapter with Galloway Consulting will enhance the range of solutions offered to iVantage’s customers.”

About Galloway Consulting

Galloway Consulting is a consulting services company specializing in Accelerated Health Care Transformation; a proprietary model ensuring rapid results for hospitals. The company uses proven methods and extensive experience to help health care organizations improve every dimension of performance in a sustainable way – quality, safety, service, volume, revenue, cost, and patient flow. They employ renowned professionals with decades of practical understanding and skills in accelerated turnaround and transformation to support a broad array of advisory services.

About iVantage Health Analytics

iVantage, a Great Point Partners II portfolio company, is a leading provider of health care informatics and business analytics solutions that transform complex data into actionable business intelligence. The VantagePoints platform is used by hospital management teams to drive empirical and evidence based decision making with cloud-based applications. These products are positioned to meet the needs of a today’s health care market, which requires meaningful data to support new compliance based requirements and the operational challenges of the Patient Protection and Affordable Care Act (“PPACA”).

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management and 23 professionals. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million and GPP II) and public equity (BMVF, approximately $325 million) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

Pitchbook Names Great Point Partners The Top Healthcare Investor of 2013

Introduction

 

Biotronic NeuroNetwork Acquires Neurophysiology Associates

Introduction

GREENWICH, CT and ANN ARBOR, MI — Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the nation’s leading intraoperative neurophysiological monitoring (“IONM”) company, today announced that it has acquired Neurophysiology Associates, LLC (“NPA”), a premier regional IONM provider based in Athens, GA.

Greg W. Sasso, Chief Executive Officer of Biotronic NeuroNetwork commented, “We welcome all of Neurophysiology Associates’ team members and customers to the Biotronic team. This partnership will serve to strengthen Biotronic’s leadership position in the IONM market segment and clearly expands our national service footprint by providing an excellent entry in the attractive markets of South Carolina and Georgia. We employ over 200 Neurophysiologists servicing over 425 hospital customers and over 1,100 surgeon customers in 32 States. Additionally, the Biotronic team will monitor over 40,000 surgical cases during 2014.”

Biotronic continues to have double-digit organic procedure growth, and is now the market share leader in IONM services. The high organic growth, acquisitions, and successful integrations, clearly demonstrate the Company’s ability to execute on its strategic plan. The acquisition will allow Biotronic to expand its client base to the southeast, as well as add additional skilled technicians to its staff.

IONM utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) and organs in real-time during surgeries such as neurological, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 250 administrative, support and clinical staff, including over 200 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world. www.biotronic.com

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management and 23 professionals. GPP is currently making new private equity investments from GPP II, a $215 million fund. Great Point manages capital in private (GPP I, $156 million and GPP II) and public equity (BMVF, approximately $325 million) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

Great Point Partners Closes $215 Million Health Care Buy-Out Fund

Introduction

GREENWICH, CT — Great Point Partners, a leading health care investment firm focused on growth investing, today announced the closing of Great Point Partners II, L.P. (“GPP II”), a $215 million growth buy-out fund. This new fund is larger than the firm’s prior fund, GPP I which was $156 million and exceeds the firm’s $200 million fund raising target. GPP II, like Great Point’s prior fund will invest in lower middle market, growth health care companies.

“We are pleased to announce our final close,” said Jeffrey R. Jay, M.D., Managing Director of Great Point Partners. “This successful fundraise was driven by strong support from both existing and new investors in the United States, the United Kingdom and continental Europe. We see this success as a clear global endorsement by our investors of our growth buy-out and growth recapitalization investing model.”

GPP II’s Limited Partners include leading endowments, foundations, family offices, banks and pension funds. A significant number of the new investors are from outside of the United States. The firm held its final close of the fund without extension and above its original target, as planned.

According to Adam Dolder, Managing Director, “GPP II will continue to pursue a strategy the firm has followed for a decade – partnering with management teams to build market-leading health care companies through a combination of organic growth and the aggressive pursuit of accretive tuck-in acquisitions. While growth is always a core aspect of our investment theses, we add value by placing members of our CEO Advisory Board as Operating Chairmen or Lead Directors on portfolio company boards and by assigning a team to research, source and close tuck-in acquisitions.” The firm invests in most areas of health care with particular emphasis on the outsourcing sector, the pharmaceutical and biotechnology supply chain, health care information technology and devices and diagnostics.

“We believe that our strong track record and continuing ability to both make and exit investments that generate attractive rates of return, regardless of the difficulty of the economic cycle, is a testament to the firm’s focus on building durable companies that lower the cost of health care and enhance the efficiency in production and delivery, “ said David Kroin, Managing Director of Great Point Partners.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management and 23 professionals. GPP is currently making new private equity investments from GPP II, which has closed on $215 million in commitments. Great Point manages capital in private (GPP I, $156 million and GPP II) and public equity (BMVF, approximately $300 million) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

Media Contact
Ron Panzier, 203-971-3307 rpanzier@gppfunds.com

iVantage Health Analytics Acquires Xylem Consulting, Inc.

Introduction

GREENWICH, CT and PORTLAND, ME — iVantage Health Analytics (“iVantage”), a Great Point Partners II, (“GPP”) portfolio company and a leading provider of health analytic solutions, announced today that it has acquired Xylem Consulting, Inc., a strategic advisor to hospitals.

Xylem Consulting, Inc. specializes in bundled payment and risk-based contract negotiations, strategy development and optimal pricing of health services. The firm was founded by Jack Wolf, CPA, MHA, and provides data-driven financial decision-making support to large hospital systems, academic medical centers, community hospitals and ancillary health care providers. The addition of Xylem complements iVantage’s recent acquisition of Professional Data Services (PDS) and enables clients to leverage both robust business intelligence and advisory services to drive contract negotiations and combat the eroding margins associated with the health care reform reimbursement mandates.

“I’m thrilled to have Xylem join iVantage and be able to tap its robust portfolio of actionable analytic services to further assist hospitals in creating a healthier bottom line,” commented Wolf. “Joining iVantage, we can now further empower our clients with a centralized financial, strategic, operations and compliance platform and improve their contract negotiations with any at-risk entity.”

Brett Carlson of Great Point Partners commented, “Xylem Consulting is the 2nd tuck-in acquisition completed by iVantage this year, and is consistent with our strategy to complement iVantage’s strong technology capabilities with an equally strong services offering.”

About Xylem Consulting, Inc.

Xylem Consulting, Inc. provides strategic advisory services to hospitals nationwide. The firm has a proven track record of working with hospitals to achieve their contracting goals. The firm understands how to manage the data and prepare hospitals for successful negotiations. Established in 2007, Xylem supports hospital decision-makers on the development of managed care portfolio strategies and pricing targets and achievement of successful payor negotiations.

About iVantage Health Analytics

iVantage is a leading provider of health care informatics and business analytics solutions that transform complex data into actionable business intelligence. Its VantagePoints™ platform is used by hospital management teams to drive empirical and evidence based decision making. These products are positioned to meet the needs of a today’s health care market, which requires meaningful data to support new compliance based requirements and the operational challenges of the Patient Protection and Affordable Care Act (“PPACA”). In May of 2013, iVantage received a significant equity investment from Great Point Partners.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management and 23 professionals. GPP is currently making new private equity investments from GPP II, which has closed on approximately $200 million in commitments. Great Point manages capital in private (GPP I, $156 million and GPP II) and public equity (BMVF, approximately $300 million) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

Great Point Partners Named a Top Healthcare Investor by Pitchbook 2 Years in A Row

Introduction

Pacific Child & Family Associates Acquires Autism Intervention Specialists

Introduction

GREENWICH, CT and GLENDALE, CA — Pacific Child & Family Associates (“PCFA”), a Great Point Partners I, L.P. (“GPP”) portfolio company and a leading provider of applied behavior analysis (“ABA”) and other services for children and adults with autism spectrum disorders (“ASD”), today announced that it has acquired Autism Intervention Specialists (“AIS”), a premier ABA provider located in Worcester, Massachusetts.

AIS provides services to clients in the northeastern U.S. and has been rapidly expanding since inception due to its reputation for high quality services. AIS also offers complementary therapies, such as social skills groups and community based programs. The acquisition will allow Pacific Child to extend its geographical presence, as well as provide additional services to augment its clinical capabilities. AIS’ senior management team, led by President and Founder Nassim Auode, Executive Director Tenney Hajnal, and Regional Clinical Director Dr. Jeffrey Skowron, will continue to play an integral role in management of the combined entity going forward. Great Point Partners also welcomed Scopia Windmill Fund, LP (“SWF”) as a co-investor in this transaction. David Wittels, Head of Private Equity of SWF’s investment manager, Scopia Capital Management LLC, is also a member of Autism Speaks’ National Board of Directors, and brings to PCFA a wealth of experience in the field of autism services and advocacy.

Mark Dorenfeld, Chief Executive of Pacific Child commented, “Our acquisition of Autism Intervention Specialists marks a new era for Pacific Child and Family Associates’ network of programs. The AIS clinic model allows us to build upon AIS’s strengths and affords the opportunity to replicate and showcase our interdisciplinary model including speech and language therapy, occupational therapy, and physical therapy. We view this as a time for innovation and an opportunity to be the paragon for the delivery of services to children with Autism Spectrum Disorders and their families.”

This transaction marks the third acquisition that the company has closed since Great Point’s initial investment. PCFA now provides access to over 1,000 therapists in more than 30 states.

About Pacific Child & Family Associates

Headquartered in Glendale, California, Pacific Child & Family Associates is a leading provider of therapy to children with autism spectrum disorders. PCFA’s services include ABA, speech, occupational, and physical therapies. The Company utilizes custom-tailored treatment programs, licensed professionals, and experienced staff to address the unique treatment needs of children with ASD. PCFA provides services in 30 states, with a client base that includes commercial insurance beneficiaries, behavioral health agencies, school districts, private pay clients, and military families. Pacific Child & Family Associates is backed by Great Point Partners, LLC, a leading health care investment firm. Visit www.pacificchildandfamily.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. GPP is currently investing from GPP II, which is targeted at $200 million. Great Point manages capital in private and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, diagnostics, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Acquires The Reclaim Group

Introduction

GREENWICH, CT and INDIANAPOLIS, IN — Health Systems International (“HSI”), a global provider of payment effectiveness solutions and a Great Point Partners I portfolio company, today announced the acquisition of The Reclaim Group (“TRG”), a medical post-payment recovery services company, based in Bethesda, Maryland. TRG is a leading provider of facility claims overpayment identification and recovery services to various health care clients in the United States, and is experiencing rapid growth and demand for its services. The acquisition further expands Health Systems International’s suite of payment effectiveness products.

“As we look to deliver analytics and full service payment integrity solutions to our clients, TRG expands our offering into post payment recovery,” said Scott Mingee, CEO of HSI. “Technology-based, analytics solutions are a perfect match with our business.”

HSI’s strong revenue growth rate in excess of 40% per year since Great Point Partners invested in 2007 clearly demonstrates its ability to successfully meet the existing and future needs of its customers. Noah Rhodes, a Principal of Great Point Partners stated, “With the acquisition of TRG, HSI now offers both pre-payment and post-payment services to its large and growing customer base. Instead of building this functionality over time, HSI can immediately deliver these services to its more than 400 payor clients.”

About Health Systems International

Health Systems International lowers health care costs for clients through payment integrity solutions and analytics. The company serves organizations located throughout the U.S. and internationally, and is recognized nationally by Inc. Magazine and Modern Healthcare as a leading high-growth health care company. Health Systems International is backed by Great Point Partners, LLC, a leading health care investment firm. Visit www.us-hsi.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management. GPP is currently making new private equity investments from GPP II, which has closed on approximately $200 million in commitments. Great Point manages capital in private (GPP I and GPP II) and public equity (BMVF) funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

iVantage Health Analytics Acquires Professional Data Services

Introduction

GREENWICH, CT and PORTLAND, ME — iVantage Health Analytics Inc., a Great Point Partners II, L.P. (“GPP”) portfolio company and a leading provider of health analytic solutions, today announced the acquisition of Professional Data Services (“PDS”). PDS offers managed care analytics, internal/external payment benchmarking solutions to support payor negotiations, and strategic planning/execution.

The addition of PDS represents the continued expansion of the iVantage Health Analytics solution suite and enables the company’s hospital clients to make more informed business decisions, critical as they face an increasingly regulated health care marketplace.

PDS provides a SaaS based analytic tool developed for hospitals at the Hospital Association of Southern California (HASC). The SaaS products provide hospital revenue optimization and benchmarking using proprietary paid claims data. PDS’ hospital clients benefit from market analytics that empower contract negotiation and optimized revenue management.

“The key to constant improvement is reliable and timely measurement against benchmarks,” said Jim Barber, CEO of HASC and PDS. “Health plan contract performance, properly benchmarked with relevant peer groupings, provides PDS clients with invaluable financial information they cannot get elsewhere. As one of the largest hospital associations in the US, our membership demands top notch solutions. We are so impressed with the organization’s capabilities that, as part of this transaction, we will now become a shareholder of iVantage.”


About iVantage Health Analytics

iVantage is a leading provider of health care informatics and business analytics solutions that transform complex data into actionable business intelligence. This platform is used by hospital management teams to drive empirical and evidence based decision making. These tools are positioned at the center of a large market opportunity due to increased demand for meaningful data, driven by new compliance based requirements and operational challenges of the Patient Protection and Affordable Care Act (“PPACA”). iVantage has been growing at approximately 50% per year.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management. GPP is currently investing from GPP II, which has closed on approximately $200 million in commitments. Great Point manages capital in private and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, devices and diagnostics, health care services, hospital outsourcing, information technology, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Professional Orthopedic and Sports Physical Therapy Closes Two New York City Tuck-In Acquisitions

Introduction

GREENWICH, CT and WHITESTONE, NY — Professional Orthopedic and Sports Physical Therapy (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company, today announced that it has acquired The Sports Physical Therapy Group (“East Side/West Side”) and Joint Effort Physical Therapy (“Joint Effort”) both of which are located in Manhattan.

Adam Elberg, Founder, and Chief Executive Officer of Professional commented, “I am very excited about this latest expansion of our footprint in New York City. Not only are we now able to provide better access for our patients in parts of Manhattan that complement our existing presence, but we are joining forces with some of the most respected physical therapists in the area. Anthony Saraniti (East Side/West Side) and Lloyd Hines (Joint Effort) have been serving their communities with the highest quality physical therapy care for over 30 years. Together, the combined knowledge and expertise of our companies will only enhance the treatment quality for all our patients.”

Anthony Saraniti, owner of The Sports Physical Therapy Group stated, “In exploring a strong NYC partner, it was clear that Professional was the optimal group with which to team up. Entering the next phase of my company’s growth, alongside the management team of Professional, is a very exciting and positive step.”

And Lloyd Hines, owner of Joint Effort, added, “Professional has a highly regarded academic and clinical reputation. I have had the opportunity to get to know their leadership over many years. Clinical leaders like Robert Panariello, their Chief Clinical Officer, make Professional an ideal fit with Joint Effort’s core values of providing outstanding patient care. I look forward to working closely with all the “professionals” at Professional!”

These acquisitions are a clear indication of Professional’s ability to execute on its strategic plan, continuing its rapid expansion and successful growth. Through best-in-class treatment and protocols, Professional continues to recruit and train top tier physical therapists, and scale its growing number of facilities throughout New York and New Jersey. With the addition of East Side West Side and Joint Effort, Professional now has 21 locations.

About Professional Orthopedic and Sports Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“Professional”), headquartered in Whitestone, NY is a leading provider of physical therapy and rehabilitation services in New Jersey and New York metropolitan areas. Professional was founded in 1998 and operates 21 outpatient physical therapy centers: eight of which are located within Equinox Fitness Centers, one located in a Blink facility, one located in a Crunch Fitness, one located in a Velocity Sports Performance Center, and six standalone. Additionally, Professional operates a 20,000 square foot sports performance training facility in one of its locations. The Company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and various other medical conditions.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. GPP is currently investing from GPP II, which is targeted at $200 million. Great Point manages capital in private and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, diagnostics, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

American Surgical Assistants Acquires ProAssist Surgical Associates

Introduction

GREENWICH, CT and HOUSTON, TX — Great Point Partners (“GPP”) today announced that GPP I portfolio company, American Surgical Assistants has acquired Dallas-based ProAssist Surgical Associates, a premier provider of surgical physician assistant (“PA”) services. ProAssist primarily focuses on providing highly qualified surgical and physician assistants for surgery and surgical assistant billing services.

Tom Kirk, Chief Executive Officer of American Surgical commented, “We are thrilled with the acquisition of ProAssist. The skill, expertise, quality and outcomes that they have historically generated match those that American Surgical has consistently provided. This combination is operationally and strategically compelling from multiple perspectives.”

The acquisition will allow American Surgical to extend its services to the expanding Dallas Fort Worth market and to incorporate a surgical physician assistant offering within its existing core business units. “We are excited about our new partnership,” says Mike Fuller, owner of ProAssist. “The sharing of ideas, technology and support will undoubtedly continue to allow ProAssist to lead the way for surgical first assistant services throughout the DFW metroplex and the region”.

This is the fifth acquisition for the company since the Great Point investment, and it further solidifies the American Surgical Assistants’ commitment to growth in its home state of Texas in addition to nine other states. The combined company now serves over 235 clients nationwide. Great Point played the lead role in sourcing and negotiating the acquisition and will continue to assist American Surgical in effectively integrating the acquisition.

About American Surgical Assistants

Founded in 1999 and headquartered in Houston, TX, American Surgical is the nation’s leading provider of professional surgical assistant services to patients, surgeons and health care institutions. The Company is a Joint Commission certified surgical assistant services company. Its services result in cost savings for patients, insurance carriers, hospitals, surgeons, and health care institutions while maintaining quality of service. Visit www.americansurgicalassistants.com or call 713-779-9800 for additional information.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $650 million of equity capital under management. The American Surgical investment was made from GPP I, a fully committed $156 million lower middle market health-care buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million, and focuses on growth recapitalizations health care companies with $1 to 10 million of EBITDA.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Connecture Continues to Achieve Rapid Growth Amid Increased Demand For Online Health Insurance Marketplaces

Introduction

GREENWICH, CT and BROOKFIELD, WI — July 13, 2013 – Connecture, Inc., the leading provider of Web-based information systems used to create health insurance marketplaces, today reflected on major performance milestones achieved by the company in the first six months of 2013. Connecture continues to grow rapidly amid increased demand for the marketplaces, exchanges and information systems needed to effectively distribute health insurance.

“There is universal agreement throughout the commercial insurance industry and the government marketplace that selecting, purchasing and enrolling in the right health plan is often far more complex and costly than it needs to be,” said Doug Schneider, CEO of Connecture. “Connecture’s continued and rapid growth is a direct reflection of just how effective our information systems are at eliminating waste and empowering Americans to choose the best health coverage with confidence.”
Some of the many notable performance milestones achieved by Connecture in the first half of 2013 include:

  • The acquisition of DRX: With the acquisition of DRX in January of this year, Connecture acquired competencies that will increasingly be required to create platforms and systems that span the commercial insurance industry and the government marketplace for health coverage. With the acquisition, Connecture is also ideally qualified to address the unique needs of those over and under 65 years of age.
  • Revenue growth: Connecture is forecasting revenue growth of more than 80 percent this year to revenues in excess of $90 million.
  • New customer signings and expanded engagements: Connecture signed nine new customers in the first half of this year and expanded its engagements with 25 customers.
  • Job creation and investment in skilled employees: Excluding employees that joined the company as a direct result of the acquisition of DRX, Connecture increased the number of employees who serve its customers by more than 20 percent. Today, the company employs 438 people.
  • New facilities: Connecture opened a new facility in Raleigh, N.C. and expanded its headquarters in Brookfield, Wis. The company also expanded its offices in Atlanta and Farmington, Conn.
  • Product innovations and consumer research: Connecture unveiled numerous product enhancements in the past six months. The company also continued to aggressively invest in consumer research, testing and surveys that deliver the real-world perspective needed to make the company’s products intuitive for the public. Notably, Connecture conducted a survey of more than 1,700 consumers in April. The resulting data helped to further refine Connecture’s decision-support tools, including an Out-of-Pocket Cost Calculator that enables consumers to quickly gauge the annual cost of health plans they wish to consider.
  • Accolades: Connecture received a number of accolades, including a Eureka Award for creativity, innovation and progress in business from the Business Journal Serving Greater Milwaukee – which also placed the company in its Fastest Growing Firms ranking. The company also received an IQ (Innovation Quotient) Award from BizTimes Milwaukee and was named a Top Workplace by the Milwaukee Journal Sentinel.

These performance milestones complement an already enviable track record of success. Most of the nation’s largest carriers, and more than half of all Blue Cross & Blue Shield plans, rely on modules of Connecture’s InsureAdvantage product – a highly customizable, Web-based suite of solutions that streamline insurance distribution across all lines of business, including health, dental, life, vision, short-term disability and more. The company also continues to expand rapidly in the market for private exchanges – offering both multi-payer and single-payer platforms.

In the public sector, modules of Connecture’s StateAdvantage suite of products comprise the shopping and enrollment functions of Affordable Care Act exchanges being built in Maryland, Minnesota and Washington, D.C., while in the federal market 75 percent of Americans who enroll in Medicare Part D, and 70 percent of all Medicare Plan Sponsors, rely on plan comparison and enrollment systems created by Connecture’s DRX division that power functions within Medicare.gov. DRX’s drug comparison tools are also used by half of the 10 largest pharmacy benefit managers in the U.S.

“Our employees should be very proud of the work we are doing to make healthcare more affordable and accessible,” added Schneider. “Our growth and Connecture’s importance in this market will only increase in the months and years to come as our systems enable stakeholders to expand and retain membership while simultaneously achieving readiness for reform in a rapidly changing marketplace.”

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The Connecture investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

About Connecture

Connecture is the leading provider of Web-based information systems used to create health insurance marketplaces and exchanges. Its industry-proven solutions enable consumers – both over and under age 65 – employers and brokers to more easily shop for, purchase and renew health insurance while minimizing back-office administrative expenses for health plans. Connecture’s solutions include a wide range of proven distribution platforms for the commercial insurance industry and the public sector and are provided to health plans, state insurance marketplaces, the federal government, private exchanges and insurance brokers. More than 33 million Americans shop for their health insurance through systems built by Connecture, and more than half of the nation’s 20 largest plans rely on them to sell, administer and manage their plans and products effectively. For more information, visit www.connecture.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

American Surgical Assistants Announces New CEO Tom Kirk

Introduction

GREENWICH, CT and HOUSTON, TX — Great Point Partners I portfolio company, American Surgical Assistants (“ASA”), the nation’s leading provider of outsourced surgical assistant services, announced today the appointment of Tom Kirk as chief executive officer effective June 3rd, 2013. Mr. Kirk brings more than 30 years of relevant industry experience to this new role having previously served as President & COO, and eventually CEO, of Hanger, Inc. Mr. Kirk succeeds Zak Elgamal, American Surgical’s co-founder and President, who has served as chief executive officer since the Company was founded in 1999. Mr. Elgamal will remain on the Company’s Board of Directors and continue his leadership role as an advocate for the surgical assistant industry for various national organizations.

“American Surgical has built an outstanding reputation based on reliable and high quality services,” commented Mr. Kirk. “By focusing on providing comprehensive solutions to the surgical assistant needs of hospitals, physicians/surgeons and health care institutions, it has added value and flexibility to its client partners in a cost efficient manner. I am honored and enthusiastic to be part of the Company, and I plan to expand their offering to new venues and additional geographic areas. As we look to the future we will build upon the solid foundation of employee dedication, responsive and clinically excellent service and cooperative relationships with other care providers and payers developed over the last fourteen years.”

“Tom Kirk’s leadership, accomplishments, extensive experience, and proven expertise are tremendously appreciated. I look forward to having him at the helm of ASA, and I am confident that he will lead American Surgical Assistants to the next level.” said Mr. Elgamal.

About American Surgical Assistants

Founded in 1999 and headquartered in Houston, TX, American Surgical provides professional surgical assistant services to patients, surgeons and health care institutions. The Company is a joint commission certified surgical assistant services company. Its services result in cost savings for patients, insurance carriers, hospitals, surgeons, and health care institutions while maintaining the quality of service. Visit www.americansurgicalassistants.com for additional information, or call 713-779-9800.

About Great Point Partners

Great Point Partners (“GPP”), based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The American Surgical investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes $10 Million Growth Recapitalization Investment in iVantage Health Analytics

Introduction

GREENWICH, CT and PORTLAND, ME — Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a $10M growth recapitalization investment in iVantage Health Analytics (“iVantage”) from its second private equity fund GPP II. iVantage was formed in August 2011 through the merger of four existing and established health care informatics companies and is a leading provider of health care business analytics solutions to hospitals. The Company is led by a highly credentialed management team including:

  • Hud Connery, Jr., former COO of HealthTrust and CEO/Founder of Essent Healthcare;
  • Thomas Day, former Vice President and Corporate Officer of health care at Bain & Company and former CFO of the Advisory Board Company;
  • John Morrow, former SVP at Healthgrades and HCIA/Solucient/Thomson Reuters Healthcare; and
  • Thomas S. Hutchinson, former SVP at HealthStream Research

iVantage’s solutions help transform complex clinical and financial data into actionable business intelligence, and this platform is used by hospital management teams to drive empirical and evidence based decision making. The differentiated solution is able to displace incumbent siloed data solutions by providing hospitals with an integrated product suite across clinical, functional, and population/market analytics. These tools are positioned at the center of a large market opportunity due to increased demand for meaningful data driven by new compliance based requirements and operational challenges of the Patient Protection and Affordable Care Act (“PPACA”).

The equity investment will fund expanded sales and marketing efforts, additional investment in technology infrastructure and personnel expansion.

“Great Point demonstrated intimate knowledge of the analytics sector since our initial meeting”, said Hud Connery, CEO of iVantage. “Their deep network, industry insight, and capital investment will allow us to accelerate our next phase of growth. We are pleased to have an investor of the caliber and reputation of Great Point Partners join us as a shareholder.”

“We’ve been in constant dialogue with hospital executives since the passing of health care reform”, said Brett Carlson, Senior Vice President at Great Point Partners. “The widespread consensus is that clinical, functional, and market analytics are necessary and will provide users significant competitive advantages in navigating the complexities of the new environment.”

Jeffrey Jay M.D. Managing Director added, “iVantage will utilize the funding to execute its long-term growth strategy and deliver innovative solutions as the Company expands into new markets and develops and/or executes new products.”

About iVantage Health Analytics

iVantage is a leading provider of health care informatics and business analytics solutions that transform complex data into actionable business intelligence. This platform is used by hospital management teams to drive empirical and evidence based decision making. These tools are positioned at the center of a large market opportunity due to increased demand for meaningful data driven by new compliance based requirements and operational challenges of the Patient Protection and Affordable Care Act (“PPACA”). iVantage has been growing at approximately 50% per year. Visit www.ivantagehealth.com for additional information or call John Morrow at 207-218-2058.

About Great Point Partners

Great Point Partners (“GPP”), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. GPP is currently investing from GPP II, which is targeted at $200 million. Great Point manages capital in private and public equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biologics and pharmaceutical infrastructure, diagnostics, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Announces the Addition of Robert W. Thomas to the Firm’s CEO Advisory Board

Introduction

GREENWICH, CT and SAN FRANCISCO, CA — Great Point Partners (“GPP”) announced the addition of seasoned medical device executive Robert W. Thomas to the firm’s CEO Advisory Board. CEO Advisory Board members at Great Point Partners act as Operating Chairmen and Lead Directors of the firm’s private equity portfolio companies.

From March, 2000 through December, 2006, Mr. Thomas served as President and CEO of FoxHollow Technologies, having previously served as the company’s Vice President of Operations. Under Mr. Thomas’ leadership, FoxHollow executed one of the most successful product launches in the history of the medical device industry, completed its IPO, and ultimately achieved a market capitalization of more than $1.2 billion prior to its sale to EV3 in 2007.

Mr. Thomas will be working closely with GPP Managing Director Scott R. Davidson to source and execute medical device buyouts, recapitalizations and carve-outs for GPP’s Great Point Partners II (“GPP II”) private equity fund. In addition to joining the GPP CEO Advisory Board, Mr. Thomas will be making a significant personal investment in GPP II. Mr. Thomas and Mr. Davidson are currently working together on an initial investment for GPP II in the medical devices space; the carve-out of a health care products business from within a larger enterprise.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, pharmaceutical infrastructure, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Announces New CEO Scott Mingee

Introduction

Greenwich, CT and Indianapolis, IN — Great Point Partners I portfolio company, Health Systems International (“HSI”), a trusted leader in payment integrity solutions, announced today the appointment of Scott Mingee as chief executive officer effective April 8, 2013. Mr. Mingee brings more than 22 years of relevant industry experience to this new role having previously served as group president, health care provider solutions at Xerox Services. Prior to Xerox, he worked as chief information officer of Outsourced Administrative Systems (OASYS) and held a variety of positions within the Anthem Blue Cross Blue Shield family of companies. Mr. Mingee replaces Russell W. Sherlock, Health Systems International’s co-founder and chairman of the board, who has served as chief executive officer since April 2004.

“We welcome Scott’s experience and leadership to Health Systems International,” said Mr. Sherlock. “Scott’s background, industry relationships and vision make him well-equipped to extend our track record of industry leading growth and innovation. We are delighted to find someone with his passion and record of accomplishments to join and lead our company.”

“Health Systems International is at the forefront of ensuring accuracy in health care reimbursements. Over 400 industry payers utilize our solutions to lower their health care spend and ensure cooperative relationships with the providers who serve their members,” said Mingee. “I am excited to be part of Health Systems International and building on our core solutions, data and technology to extend our vision into payment integrity through analytics, avoidance and payment transparency. To remain relevant and competitive amidst unprecedented changes in today’s health care market, payers and providers alike will need a partner with their best interest in mind. Our holistic approach, pay-for-performance model and capacity for advanced analytics combined with the speed and scale to deliver, makes HSI a natural partner for any health care business.”

About Health Systems International

Health Systems International lowers health care costs for clients through payment integrity solutions and analytics. The company serves organizations located throughout the U.S. and internationally. Health Systems International is backed by Great Point Partners, LLC, a leading health care investment firm and is recognized nationally by Inc. Magazine and Modern Healthcare as a leading high-growth company in health care. Visit www.us-hsi.com for more information.

About Great Point Partners

Great Point Partners (“GPP”), based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The HSI investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Aris Acquires Pediatric Radiology of America and Expands its Pediatric Radiology Capabilities

Introduction

GREENWICH, CT and HUDSON, OH — Great Point Partners (“GPP”) today announced that its GPP I portfolio company, Aris Teleradiology has acquired Pediatric Radiology of America (“PRA”), a premier pediatric radiology services company that provides extensive pediatric subspecialty coverage. Many of the PRA radiologists are subspecialty experts in areas such as neuro-pediatrics and cardiac pediatric radiology.

Carl Kozlowski, Chief Executive Officer of Aris commented, “Aris is excited to join hands with PRA. The team at PRA has top pediatric radiologists that are vetted through a strict recruiting and quality control process. The acquisition of PRA and its client base provides Aris with the most complete portfolio of sub-specialty pediatric radiology services of any national radiology company. As Aris continues to grow nationally as a premier professional radiology services company, we will continue to differentiate ourselves by adding value. PRA like Aris is accredited by The Joint Commission and their dedication to quality first and foremost, made them the most natural fit for Aris.”

Shehnaz Pancholi, CEO and Founder of PRA added, “We are excited to join Aris and help grow their pediatric subspecialty nationally. Aris is the leading quality brand in the professional radiology space.”

PRA will be integrated into Aris and offer a deeper pediatric radiology subspecialty to all current and new Aris clients. As a part of Aris, PRA will continue to provide the same superior coverage to numerous US hospitals and continue to attract hospitals and imaging centers that are interested in furthering their pediatric subspecialty expertise. The combined company will provide teleradiology and outsourced professional radiology services to more than 125 clients in 31 states.

About Aris Teleradiology, LLC

Founded in 2007 and headquartered in Hudson, OH, Aris provides professional radiology services to patients, surgeons and healthcare institutions. The Company is a Joint Commission certified radiology services company. Aris works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 sub specialty coverage, 24/7 operations support, and quality assurance data. Aris’ breadth of service and discipline allows it to deliver high quality patient care in a cost-effective manner to the hospitals, and other health care payors. Visit www.arisradiology.com for additional information.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The Aris investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Connecture Acquires DRX, A Leading Provider of Information Systems for Medicare

Introduction

Acquisition Brings Together the Competencies Needed to Create an Integrated Online Health Plan Distribution Platform That Simultaneously Meets the Needs of the Commercial Insurance Industry and Government Health Plan Marketplaces, including Medicare

GREENWICH, CT and BROOKFIELD, WI — Jan. 17, 2013 — Connecture, Inc., a Great Point Partners portfolio company and the leader in sales automation technology for the health insurance industry, today announced it acquired DRX (formerly known as DestinationRx), a provider of Web-based information systems used to compare and enroll in Medicare health plans, as well as those used to compare name brand pharmaceuticals with therapeutic alternatives. DRX powers the Medicare.gov PlanFinder and Online Enrollment Center and serves many of the nation’s largest health plans, pharmacy benefit managers, brokers and senior advocacy groups like AARP. The company is based in Los Angeles.

“This acquisition brings together the people and skills required to create an integrated distribution platform for health plans that is able to simultaneously address the needs of the commercial insurance and government health plan marketplaces, for the first time,” said Doug Schneider, CEO of Connecture. “Both companies share a commitment to make it less expensive to compare plans and enroll in the right one. Now that expertise can be combined to help even more Americans, whether it’s to compare plans offered by many payers in a private exchange, consider similar products on a carrier’s website, shop for the best plan in a state exchange, or select the right Medicare plan and pharmaceuticals.”

The acquisition builds on a natural synergy between the two companies. Connecture is a leader in the commercial insurance market for individual and small group plans, as well as private exchanges, and is one of the first companies to create the shopping and enrollment systems for state and federal partnership exchanges. DRX is a leader in the federal arena and Medicare, the comparison of therapeutic pharmaceuticals, and in multi-payer private exchanges used by large groups.

“Two undeniable trends attracted us to DRX,” said Brett Carlson, Board Member at Connecture and Vice President at Great Point Partners. “We’ve been watching the acceleration of senior enrollment into managed care and the increasing utilization of competitive marketplaces for insurance purchasing in the private sector. DRX strengthens our technological capability and value proposition for our clients in both of these key strategic areas.”

Each company’s information systems enjoy widespread use. More than 25 million Americans have shopped for their health insurance online using systems created by Connecture. And today more than half of the nation’s 20 largest health plans, and nearly 50 percent of all Blue Cross & Blue Shield plans, rely on the company’s information systems to effectively sell their products. Connecture is also supplying the core shopping and enrollment functions for the state exchanges being built in Maryland and Minnesota to meet the requirements of the Patient Protection and Affordable Care Act.

DRX is the leading provider of plan comparison and enrollment solutions for Medicare. To date, DRX solutions processed more than 11 million Medicare applications. In addition to powering the Medicare.gov PlanFinder and Online Enrollment Center, DRX systems are also in use within numerous federal agencies, including the Centers for Medicare and Medicaid, and among leading Medicare sponsors, including Aetna, Cigna, and United Healthcare.

Health care is changing and together, all of us at DRX and Connecture, have an amazing opportunity to make a positive impact, not only for our customers, but also the Americans they serve,” added Dan Maynard, President and Co-Founder of Connecture.

About Connecture

Connecture is the leading provider of Web-based information systems used to create health insurance marketplaces and exchanges. Its industry-proven solutions enable consumers, employers and brokers to more easily shop for, purchase and renew health insurance while minimizing back-office administrative expenses for health plans. Connecture’s solutions are provided to health plans, state insurance exchanges, private exchanges and insurance brokers. More than 25 million Americans shop for their health insurance through systems built by Connecture, and more than half of the nation’s 20 largest plans rely on them to sell, administer and manage their plans and products effectively. For more information, visit www.connecture.com.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The Connecture investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

Connecture Achieved 100% Growth in 2012 as the Demand for Health Insurance Exchanges Explodes

Introduction

GREENWICH, CT and BROOKFIELD, WI — Great Point Partners I Portfolio Company, Connecture, Inc., the leader in sales automation technology for the health insurance industry, announced the significant milestones achieved by the company and its employees in 2012. The company more than doubled its sales in a year marked by dramatic growth.

“In the 15 years since the founding of Connecture, our commercial off-the-shelf information systems earned a reputation among the nation’s health plans for uncompromising reliability, the flexibility for customization they need, and the ease of use consumers demand when purchasing health insurance online,” said Dan Maynard, President and co-founder of Connecture. “Now we’re doing the same thing in the marketplace for public exchanges.”

More than 25 million Americans shop for health insurance on information systems built by Connecture. Some of the many milestones achieved by Connecture this year include:

  • Sales growth: Connecture more than doubled its sales in 2012 – closing the year with sales of $87 million. The company expects to continue on a similar trajectory in 2013.
  • Significant growth investment: In August, Great Point Partners, LLC, a Greenwich, CT-based private equity firm focused on the health care industry, completed a $20 million growth recapitalization of Connecture.
  • New customer signings: Connecture signed several new carriers to its growing customer base, which now includes health plans in all 50 states that cumulatively comprise nearly half of the country’s health insurance industry. In addition, Connecture won contracts to provide the core shopping and enrollment functions for the state exchanges in Maryland and Minnesota – two of the first states to move forward with the creation of exchanges that fulfill the requirements of the Affordable Care Act.
  • New support for Blue Cross & Blue Shield plans: In August, Topaz Shared Services, LLC, (Topaz) announced it would use Connecture’s InsureAdvantage in its shared services offering.
  • Product innovations: Connecture introduced InsureAdvantage for Private Exchanges – a Web-based platform that empowers health plans to help employers lower the costs associated with health benefits– all while making it possible for consumers to shop for and enroll in the right plan with confidence. Connecture also introduced a new Health Plan Management module of StateAdvantage, the company’s commercial off-the-shelf product suite that enables states to efficiently create and operate consumer-friendly health insurance exchanges.
  • Job creation: In 2012, Connecture hired 100 people and continues to fill openings for numerous new positions at all of its locations, including Atlanta, Georgia, Brookfield, Wisconsin and Farmington, Connecticut. Available jobs can be viewed at http://www.connecturejobs.com.
  • Investment in talent: Connecture appointed Doug Schneider, a veteran executive with nearly two decades of experience leading high-growth healthcare companies – including Medstat, Thomson Healthcare, and Thomson Reuters Healthcare – as CEO.

“Whether you’re a health insurance payer, a state, a corporation, a small business, a broker or a consumer, there’s universal agreement that the health insurance purchasing process is needlessly expensive and complex,” said Schneider. “Our Web-based platforms remove the unnecessary costs and friction. Health insurance is by its nature complex – one size does not fit all – but buying and selling it doesn’t have to be.”

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The Connecture investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

About Connecture

Connecture is the leading provider of Web-based information systems used to create health insurance marketplaces and exchanges. Its industry-proven solutions enable consumers, employers and brokers to more easily shop for, purchase and renew health insurance while minimizing back-office administrative expenses for health plans. Connecture’s solutions are provided to health plans, state insurance exchanges, private exchanges and insurance brokers. Half of the nation’s 20 largest plans rely on Connecture to sell, administer and manage their plans and products effectively. For more information, visit www.connecture.com.

Professional Orthopedic and Sports Physical Therapy Acquires Millennium Physical Therapy

Introduction

GREENWICH, CT and WHITESTONE, NY — Great Point Partners (“GPP) today announced that its GPP I portfolio company, Professional Orthopedic and Sports Physical Therapy (“ProPT”), has acquired Millennium Physical Therapy (“Millennium”), a premier physical therapy company with four locations in northern New Jersey.

Adam Elberg, Founder and Chief Executive Officer of ProPT commented, “I am very excited to rejoin forces with Millennium. The partners of ProPT and Millennium have a long history of working together and share a common vision of providing excellent patient care. Allan Roth, Jeff Debellis & Michael Implicito have long been respected leaders in the field of Physical Therapy, and we are proud to call them our partners via this transaction. This significantly strengthens the ProPT footprint in New Jersey. Together, we look forward to providing the highest quality of care in the tri-state area.”

Allan Roth, Co-Founder of Millennium added, “We are thrilled about the combination of Millennium and ProPT and what it will mean in terms of added value for our patients. Both companies provide high quality physical therapy services and care deeply about everyone we work with. Our expertise in New Jersey, along with ProPT’s vision, will make a powerful contribution to the industry”.

The acquisition is a clear indication of ProPT’s ability to execute on its strategic plan, continuing its rapid expansion and successful growth. Through best-in-class treatment and protocols, ProPT continues to recruit and train top tier physical therapists, and scale to its now 17 facilities throughout New York and New Jersey.

About Professional Orthopedic and Sports Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“ProPT”), headquartered in Whitestone, NY is a leading provider of physical therapy and rehabilitation services in New Jersey and New York metropolitan areas. ProPT was founded in 1998 and operates 17 outpatient physical therapy centers: nine of which will be located within Equinox Fitness Centers, one located in a Blink facility, one located in a Velocity Sports Performance Center, and six standalone. Additionally, ProPT operates a 20,000 square foot sports performance training facility in one of its locations. The Company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, and various other medical conditions.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The ProPT investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Completes Dividend Recapitalization of Health Systems International

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Great Point Partners (“GPP”) announced that its GPP I portfolio company Health Systems International (“HSI”), has successfully completed a dividend recapitalization. This transaction was an attractive opportunity for HSI’s shareholders, which include HSI Management and GPP’s Limited Partners, to receive a significant return on their investment in the company. After taking into account the dividend recapitalization, HSI still possesses ample borrowing capacity and will continue to pursue attractive acquisition opportunities in 2013.

This recapitalization occurred only five months after GPP I’s successful sale of Caprion Proteomics for 3.4x invested capital.

About Health Systems International

HSI is one of America’s fastest growing health care companies and has been recognized as an Inc. 500 private company. HSI is a leading provider of outsourced medical cost management solutions for self-insured corporations and insurance companies and is backed by Great Point Partners, LLC, a private investment firm focused on health care companies. Since 1987, HSI has utilized proprietary technology and medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The HSI investment was made from GPP I, a fully committed $156 million lower middle market buy-out fund. GPP is currently investing from GPP II, which is targeted at $200 million.

Great Point manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic NeuroNetwork Adds Biomet Inc. founder Dane Miller to Board of Directors

Introduction

GREENWICH, CT and ANN ARBOR, MI – September 12, 2012 – Great Point Partners I portfolio company, Biotronic NeuroNetwork (“Biotronic”), today announced the appointment of Dane A. Miller, Ph.D., former CEO and Founder of Biomet Inc., to its Board of Directors. Dr. Miller served as President and CEO of Biomet since its inception in 1978 until retiring in March of 2006. With Dr. Miller at the helm, Biomet grew from $17,000 in sales its first year into one of the leading musculoskeletal companies in the world – with annual sales exceeding $2.7 billion and grew from eight employees to more than 10,000 globally. Dr. Miller continues to serve on Biomet’s Board of Directors.

Greg W. Sasso, CEO of Biotronic, expressed excitement at Dr. Miller’s appointment, “As we expand our industry leading services across the nation, we wanted to add an admired executive and visionary person with unparalleled industry expertise to the board. We are honored to have Dr. Miller join our Board of Directors.”

Dr. Miller added, “Biotronic is committed to providing the highest quality intra-operative neuromonitoring services and delivering real value to their customers and their patients. I am excited to become a Board member of Biotronic.”

Adam B. Dolder, Managing Director of Great Point Partners and Chairman of Biotronic, said, “We are thrilled to have Dr. Miller join the board of Biotronic. Dr. Miller is a luminary in the industry and has an unparalleled track record of success in building, and helping build, great companies. His experiences will serve the Company exceptionally well.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 225 administrative, support and clinical staff, including over 160 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 450 hospitals and 1,200 surgeons annually. www.biotronic.com.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, biotechnology and life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Leads $12 Million Growth Equity Investment in Streamline Health

Introduction

GREENWICH, CT and CINCINNATI, OH – August 16, 2012 – Streamline Health Solutions Inc. (NASDAQ: STRM), a leading provider of enterprise content management and business analytics solutions for health care organizations, completed a $12 million growth equity investment led by Great Point Partners (“GPP”) of Greenwich, CT. As part of this investment, the company issued convertible preferred stock that can be converted into common stock on a one for one basis at $3 per share, and warrants to purchase common stock. In addition, the company issued convertible notes, which, upon shareholder approval, will convert into the same series of convertible preferred stock.

“We chose Great Point Partners for their expertise and deep network in the health care information technology (HCIT) space. GPP’s expertise will be of great assistance with our growth plans going forward,” said Robert E. Watson, President and CEO of Streamline Health.

Rohan Saikia of Great Point Partners said, “As a growing, highly scalable and well-positioned, leading provider of health care information technology solutions, Streamline Health exemplifies the very type of company that Great Point Partners seeks for investment. We’re pleased to partner with Streamline Health and support their growth into new and adjacent markets.”

This transaction closed only two weeks after GPP closed another HCIT investment in Connecture, an online health insurance process automation software solution. “We have been active in both the provider-focused and managed care information technology sectors. You will see us play an active role here in the years to come,” added Brett Carlson from Great Point.

Streamline Health Solutions also announced the acquisition of New York City-based Meta Health Technology, Inc. (“Meta”) a leading provider of health information management solutions for hospitals, clinics, physician group practices and long-term care facilities across the U.S. and Canada. Meta has a pending release of a computer-assisted coding (“CAC”) solution which, combined with Streamline Health’s current offerings, will place Streamline Health at the core of addressing the complexities of the ICD-10 transition.

About Streamline Health

Streamline Health provides solutions that help hospitals and physician groups improve efficiencies and business processes across the enterprise to enhance and protect revenues. Our comprehensive suite of health information solutions include enterprise content management, business analytics, and integrated workflow systems. Our solutions offer a flexible, customizable way to optimize the clinical and financial performance of any healthcare organization. www.streamlinehealth.net.

About Meta Health Technology

Meta is a full-service provider of health information management and Clinical Documentation Improvement (CDI) solutions for hospitals, physician group practices and long-term care facilities. The company has served the healthcare industry exclusively for over 30 years. Meta’s clients range from small community hospitals to many of the largest and most prestigious medical facilities across North America. www.metahealth.com.

About Great Point Partners

Great Point Partners, based in Greenwich, CT and founded in 2003, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private (Great Point Partners I) equity funds. GPP has provided growth equity, growth recapitalization, and buyout financing to more than 100 health care companies with outstanding management teams, strong growth, and market leadership. The private equity fund invests in profitable companies across all sectors of the healthcare industry. The firm pursues a proactive and proprietary approach to sourcing investments. Reach out to Great Point at 203.971.3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Connecture Announces Growth Recapitalization from Great Point Partners to Fuel Continued Expansion

Introduction

GREENWICH, CT and BROOKFIELD, WI – Connecture, the leader in sales automation technology for the health insurance industry, today announced that Great Point Partners, LLC, a Greenwich, CT.-based private investment firm focused on the health care industry, has led a growth recapitalization in Connecture. The investment will enable Connecture to meet the demand from states for the creation of health insurance exchanges as mandated by the Patient Protection and Affordable Care Act, in addition to supporting Connecture’s ongoing investment in software innovation in the health plan, broker, and insurance exchange markets.

In addition to projected revenue growth in excess of 50% for 2012, this investment adds additional business momentum to Connecture, which recently announced its role in the development of health insurance exchanges in Maryland and Minnesota, an effort which requires it to hire more than 100 Java developers and its move to a larger facility in Brookfield, Wisconsin. Since its founding in 1997, Connecture has established itself as the leading developer of software designed to streamline and simplify the health insurance distribution process. More than half of the nation’s 20 largest health insurance plans use Connecture’s technologies and more than 25 million Americans purchase their health insurance on systems built by Connecture.

“The Great Point team has the health care technology and payer sector domain expertise to complement and support our strategic vision as a company, which is to eliminate the friction in the health insurance purchasing process,” said Doug Schneider, Connecture CEO. “In the immediate term, this investment will enable Connecture to accelerate building out its capacity and help states, brokers and health plans meet the deadlines associated with health care reform with the best sales automation products in the market.”

As part of the investment, the following Great Point team members will join Schneider on Connecture’s board of directors: David Kroin, Managing Director; Adam Dolder, Managing Director; Joe Pesce, Managing Director; and Brett Carlson, Vice President.

“Connecture has developed tools for the modern day health plan,” said Brett Carlson of Great Point Partners. “With the depth of their product offering and leadership position in the sales automation market, Connecture’s technology effectively connects consumers, health plans, employers and brokers to the new health insurance marketplaces being developed by the States and in the private sector.”

About Great Point Partners

Great Point Partners, based in Greenwich, Conn., is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203.971.3300 or www.gppfunds.com.

About Connecture

Connecture is the leading provider of Web-based technologies used to create health insurance marketplaces and exchanges. Its industry-proven solutions effectively assist consumers and employees with the health insurance shopping and purchasing process and minimize back-office administrative tasks, such as workflow and health plan management, application processing, renewal processing and integration with health plans and state and federal programs. More than 25 million Americans purchase their health insurance through systems built by Connecture and more than half of the nation’s 20 largest plans rely on Connecture’s technologies and services to sell, administer and manage their plans and products effectively. For more information, visit www.connecture.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Announces sale of Caprion Proteomics

Introduction

GREENWICH, CT and MONTRÉAL, QUEBEC – Great Point Partners, LLC today announced the sale of Caprion Proteomics, Inc., a Great Point Partners I portfolio company. Caprion is a leading provider of proteomic services to the pharmaceutical industry that include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) in-vitro diagnostics development. Under Great Point’s stewardship, Caprion completed two tuck-in acquisitions, enhanced its management team and grew EBITDA by over 300x. The growth was primarily driven by strong organic revenue growth, operating improvements and accretive tuck-in acquisitions.

Caprion’s differentiated and proprietary services offer a unique value proposition to global pharmaceutical and biotechnology clients, such as GlaxoSmithKline, Johnson & Johnson, and Merck by helping them achieve accelerated proof-of-concept by accurately identifying biomarkers at the protein level in pre-clinical and clinical studies across an array of disease indications. Biomarkers can lower the cost of drug development by reducing failure rates in clinical trials. With over 100 projects for 45 clients completed since 2008, the Company is recognized as a leader in its industry and a trusted partner by its clients.

The sale is a continuation of GPP I’s string of successful exits and occurs only seven months after its exit of Mediatech in December 2011 for 4.1x invested capital.

“This transaction represents a very successful outcome for Caprion’s current shareholders, as well as tangible evidence of the highly productive and synergistic partnership we have established with Great Point Partners over the past five years. Our partnership with Great Point played a central role in the strong performance and growth that Caprion achieved during this period, and in positioning the company for sustained future growth under new ownership as we continue to capitalize on the growing demand for proteomics services in the area of drug discovery and development.” said Martin LeBlanc, President and CEO of Caprion.

Adam Dolder, Managing Director of Great Point Partners and former Chairman of Caprion, stated “We could not be more thrilled with the successful outcome of our investment in Caprion. This transaction is a testament to the vision that we shared with Martin and a compliment to his excellent leadership in bringing that vision to reality. Caprion is a truly differentiated company that capitalizes on the major needs of its pharmaceutical and biotech clients and the value achieved in the transaction proves that point.”

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (Great Point Partners I, LP). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. For more information, please visit www.gppfunds.com.

About Caprion Proteomics

Caprion Proteomics is a world leading provider of proteomics-based biomarker services and immune monitoring solutions to the pharmaceutical and biotech industries. Caprion’s proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has over a decade of experience providing large-scale proteomics biomarker and drug target discovery and validation services for over 50 major clients in the pharmaceutical, biotech and public sectors. Caprion also conducts internal programs aimed at discovering and developing novel in-vitro diagnostics markers for a variety of indications, including metabolic and infectious diseases and oncology, while serving as a biomarker center of excellence for the U.S. Government/NIH-NIAID for Biodefense research.Caprion entered into a worldwide strategic marketing and distribution alliance for biomarker services with Covance, Inc. (NYSE:CVD) in 2008. Caprion also acquired PPD Biomarker Discovery Sciences, LLC from PPD Inc. in 2010, and the assets of the National Immune Monitoring Laboratory in 2011. Caprion Proteomics, a privately-held company, is majority owned by Great Point Partners, LP. For more information, please visit www.caprion.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Named a Top Healthcare Investor by Pitchbook

Introduction

Aris Teleradiology Adds Paul M. Black as Chairman of the Board

Introduction

GREENWICH, CT and HUDSON, OH – Great Point Partners I portfolio company, Aris Teleradiology (“Aris”), today announced the appointment of Paul M. Black, the former COO of Cerner, as Chairman of Aris Teleradiology. From 1994 to 2007, Cerner grew from $120 million in sales to $1.5 billion. During the ten years he was responsible for top line growth, the 10 year revenue CAGR was 21% and the 10 year EPS CAGR was 25%. Mr. Black is also Chairman of the Board at Truman Medical Centers, an Adjunct Professor of Business at the University of Missouri – Kansas City and a Board member of Great Point Partners I portfolio company Biotronic NeuroNetwork, an outsourced provider of intraoperative neuromonitoring services.

Carl Kozlowski, CEO of Aris indicated, “Aris has been experiencing rapid business growth since its founding in 2007, and the equity financing from Great Point Partners will help accelerate this growth plan. As we expand our geographic footprint and service offerings, we wanted to add an executive with an understanding of the use of health care information technology (“HCIT”) at hospitals and a track record in driving organic growth in sales to hospitals.”

Mr. Black added, “Aris is committed to providing the highest quality professional radiology services and is well-positioned to accelerate its growth plan. I am excited to become the Chairman of Aris and help the Company transition to a national provider of professional radiology services.”

About Aris Teleradiology, LLC

Founded in 2007 and headquartered in Hudson, OH, Aris provides professional radiology services to patients, surgeons and healthcare institutions. The Company is a Joint Commission certified radiology services company. Aris works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 sub specialty coverage, 24/7 operations support, and quality assurance data. Aris’ breadth of service and discipline allows it to deliver high quality patient care in a cost-effective manner to the hospitals, and other health care payors. Visit Aris Teleradiology, LLC for additional information.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners I Portfolio Company, Mediatech Inc., is Acquired by Corning Incorporated

Introduction

GREENWICH, CT – Great Point Partners today announced that Great Point Partners I portfolio company, Mediatech, Inc., was acquired by Corning Incorporated (NYSE:GLW) in an all-cash transaction. Mediatech is now a wholly-owned subsidiary of Corning and will be integrated into Corning’s Life Science segment.

Mediatech develops, manufactures and sells a broad range of high quality cell culture media and molecular biology reagents related to tissue and cell culture applications, including culture media, basal salt solutions, antibiotics, sera, specialty media and flexible packaging systems, under the cellgro® brand.

David Kroin, Managing Director of Great Point Partners, said “From our original thematic review of the biologics manufacturing supply chain, we identified cell culture media as an attractive sector for investment and sought out Mediatech as a leading player in this segment. Corning’s acquisition of Mediatech has confirmed the validity of our thesis and we are thrilled with the combination. Mediatech’s loyal customer base, and the strength of the cellgro® brand name in the U.S., underpin its strategic value.”

“By providing customers worldwide with greater access to Mediatech’s cellgro® product portfolio, this acquisition supports Corning’s ongoing commitment to supply its customers with a comprehensive line of laboratory research tools” said Richard Eglen, General Manager Corning Life Sciences.

Mediatech’s wide array of culture media and molecular biology reagents are complementary to the general labware, cell culture, lab equipment, and HTS/Assay products offered today by Corning. In addition, the acquisition enables Corning to continue to improve its strategic balance by strengthening its Life Sciences segment.

James DeOlden, co-founder of Mediatech, will serve in an advisory capacity during the leadership transition. Regarding this transaction, DeOlden said, “I am very happy to be working with the Corning organization to expand the market access for Mediatech’s high quality products and solutions.”

About Corning Incorporated

Corning Incorporated (www.corning.com) is the world leader in specialty glass and ceramics. Drawing on 160 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications, and life sciences. Corning’s products include glass substrates for LCD televisions, computer monitors, and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy, and metrology.

About Mediatech, Inc.

Mediatech, Inc., (www.cellgro.com) is a leading Life Science company providing products, services and solutions to support its customer’s research, development and production. Mediatech’s academic, biotechnology, and pharmaceutical customers use their products in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. In addition to a broad product line of bottled products, Mediatech also develops, manufactures and supplies custom cell and tissue culture products to meet specific customer needs. Mediatech is a cGMP facility, certified to FDA Regulations 21 CFR Part 820, as well as ISO 13485:2003.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Growth Equity Investment in Aris Teleradiology

Introduction

GREENWICH, CT and HUDSON, OH – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced a growth equity investment in Aris Teleradiology, LLC (“Aris”). Founded in 2007 and headquartered in Hudson, OH, Aris is a leading outsourced national provider of professional radiology services to hospitals, imaging centers, and radiology groups.

The Company works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution by providing high quality radiologist, 24/7 sub specialty coverage, 24/7 operations support and quality assurance data to clients. Aris’ breadth of services allows it to deliver high quality patient care in a cost effective manner to the hospitals, and other health care payors.

The equity investment will fund the sales and marketing efforts, infrastructure and personnel expansion which will position the Company to accommodate and win new hospital contracts. Since its inception in 2007, the company has grown rapidly through new client wins.

“From our first conversations with Great Point last year, we were impressed with their knowledge of the professional radiology space. The rapid increase in demand for outsourced radiology solutions has created challenges as we scale our business and Great Point’s strategic guidance will be of great help. They share our existing partners’ optimism moving forward and will be a valuable addition to our organization in terms of their vision, hospital relationships and understanding of our business”, said Carl Kozlowski, CEO of Aris. “Great Point’s investment will allow us to accelerate our next phase of growth.”

Rohan Saikia of Great Point Partners stated, “Aris has established itself as one of the premier companies in the outsourced professional radiology services space, and we are excited to partner with the strong management team they have already assembled.” Adam Dolder of Great Point Partners added, “Aris is a classic Great Point platform company as it is rapidly growing, well-managed and highly scalable. We look forward to working with the Aris management team to make it a leading national player in the outsourced radiology services market.”

About Aris Teleradiology, LLC

Founded in 2007 and headquartered in Hudson, OH, Aris provides professional radiology services to patients, surgeons and healthcare institutions. The Company is a Joint Commission certified radiology services company. The Company works in concert with local hospitals and radiology groups to provide a comprehensive hybrid solution to its clients by providing high quality radiologists, 24/7 sub specialty coverage, 24/7 operations support, and quality assurance data. Aris’ breadth of service and discipline allows it to deliver high quality patient care in a cost effective manner to the hospitals, and other health care payors. Visit Aris Teleradiology for additional information.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments.Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Investment in Professional Orthopedic and Sports Physical Therapy

Introduction

GREENWICH, CT and WHITESTONE, NY – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced the growth recapitalization of Professional Orthopedic and Sports Physical Therapy (“ProPT”).

Founded in 1998 and headquartered in Whitestone, NY, ProPT is a leading provider of physical therapy and rehabilitation services in the New York metropolitan area. The Company operates 11 outpatient physical therapy centers which provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.

“From our first meeting with Great Point, we were very impressed with their knowledge of the physical therapy space and the extensive sector research they conducted over the past few years. Great Point shares our growth vision for the Company and they also uniquely understand the importance of maintaining the highest level of clinical care”, said Adam Elberg, CEO of ProPT. “All the partners and the entire management team at the Company look forward to working together with Great Point to continue to improve our service delivery as well as accelerate our growth plan.”
Adam Dolder, Managing Director at Great Point Partners stated “We are excited at this singular opportunity to partner with a management team that is as clinically distinguished as Adam Elberg, Rob Panariello and George Papadopoulos. Their clinical excellence is rivaled only by their ability to rapidly scale the Company.”

Mr. David Kroin, Managing Director at Great Point Partners added, “We spent an extensive amount of time reviewing the physical therapy and rehabilitation space and ProPT’s commitment to quality care and excellence in achieving superior outcomes clearly separated them from their competition.”

As part of the investment, David Morrison, former CEO of Mercer Management Consulting will join ProPT’s Board of Directors.

MidCap Financial, LLC, a healthcare focused-commercial finance company, acted as Administrative Agent, Lead Arranger and Sole Book Runner and provided financing in support of the transaction. NXT Capital also supported the debt financing of the transaction in the role of Co-Lead Arranger.

About Professional Orthopedic and Sports Physical Therapy

Professional Orthopedic and Sports Physical Therapy (“ProPT”), headquartered in Whitestone, NY, is a leading provider of physical therapy and rehabilitation services in the New York metropolitan area. ProPT was founded in 1998 by Adam Elberg, Rob Panariello and George Papadopoulos, and its partners include Anthony D’Angelo, Timothy Stump, Charles Byrd, Donald Demay, Timothy Mauro, Melissa Tobis and Ronald Alzate. ProPT operates 11 outpatient physical therapy centers — seven of which are located within Equinox Fitness Centers and four stand alone — and one sports performance training facility. The Company’s outpatient physical therapy centers provide treatment to patients suffering from musculoskeletal impairments associated with accidents, sports injuries, surgeries, and various other medical conditions.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments.Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic adds Greg W. Sasso, former Biomet executive, as Chief Executive Officer

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic, a Great Point Partners portfolio company, today announced the addition of Greg W. Sasso, as the Company’s Chief Executive Officer and President. Mr. Sasso joins Biotronic after a 26 year career at Biomet where he most recently was Senior Vice President and President of Biomet International, Biomet Sports Medicine and Biomet Microfixation which combined represented over $500 million in sales.
Mr. Sasso’s extensive experience encompasses driving both organic and acquisitive growth, including his leadership in Biomet’s acquisitions of Interpore, 3i and Bioelectron. Mr. Sasso was also one of the key members of the M&A team that led Biomet’s going-private transaction by a private equity consortium that consisted of Blackstone, Goldman Sachs, TPG and KKR for $11.7 Billion in 2007.
Bernie Kershner, Vice Chairman of Biotronic stated, “Biotronic has been experiencing rapid business growth both organic and acquisitive. As we expand our services and geographic footprint in intraoperative neuromonitoring, the time is right to add an admired and seasoned executive with global health care knowledge and exceptional leadership, sales and marketing expertise. We are honored to have Greg as our CEO.”
Mr. Sasso added, “Biotronic is committed to providing the highest quality intraoperative neurophysiological monitoring services in the United States and is poised for continued strong growth. I am excited to join the deep management team and clinical staff at Biotronic that have all contributed to its success thus far.”
Adam Dolder Managing Director of Great Point Partners and Chairman of the Company said, “We are thrilled to add Greg Sasso to the Biotronic team. Greg’s superior leadership skills, unparalleled industry successes and executive experience will prove to be an invaluable asset to Biotronic.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 225 administrative, support and clinical staff, including over 160 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 450 hospitals and 1,200 surgeons annually. www.biotronic.com

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Pacific Child Welcomes Mark Dorenfeld as Chief Executive Officer

Introduction

GREENWICH, CT and GLENDALE, CA – Pacific Child & Family Associates, LLC a leading provider of Applied Behavior Analysis (“ABA”) therapy and ancillary services today announced the appointment of Mark Dorenfeld as Chief Executive Officer. Mark brings 14 years of behavioral healthcare experience in various roles with the Aspen Education Group out of Cerritos, California. Most recently, Mark oversaw the 14-site Western Region and provided leadership to a diverse set of high quality programs that included Residential Treatment Centers, Therapeutic Boarding Schools, and Outdoor therapeutic programs.

Adam Dolder, Chairman of Pacific Child said, “As the company has expanded its quality, multi-pronged service offering, geographical footprint, and payor base, we identified Mark as being an ideal candidate to help maintain that growth and further position Pacific Child as the preeminent ABA provider in the country. We welcome him aboard.”
Mark Dorenfeld added, “Pacific Child has a 23+ year track record of providing high quality services to children, parents, and their referral sources. I look forward to joining them in this evolving vision of providing care to children across the country.”

Currently the company is providing therapy to over 1100 children across the United States and continues to playing a leading role in the delivery of ABA. The company will continue to expand with the advent of an increasing number of children in need of therapy and the opening of funding sources with insurance mandates, state legislation, and others.

Dr. Ira Heilveil, after founding and leading the Company for 23 years into a preeminent company in the autism field, is transitioning from active day-to-day duties at the Company and has become Chairman Emeritus and Director of Research.

About Pacific Child & Family Associates

Founded in 1988, Pacific Child and Family Associates offers applied behavior analysis and other services for children and adults with autism and other developmental disabilities. Pacific Child is committed to providing the highest quality, scientifically validated services, built on a foundation of respect for those we serve. The cornerstones Pacific Child’s work include family involvement, collaboration with other professionals, recruiting and retaining qualified staff and ensuring their success by providing the highest level of ongoing education and training. The Company currently serves children in 26 states and is providing services throughout the world.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International ranked 69th fastest-growing healthcare company on the Inc. 500|5000 annual report

Introduction

GREENWICH, CT AND INDIANAPOLIS, IN – Inc. magazine has ranked locally based Health Systems International No. 69 in the health category of its annual Inc. 500|5000, an exclusive ranking of the nation’s fastest-growing private companies.

Health Systems International, a Great Point Partners I portfolio company, provides medical cost management solutions to healthcare payors in multiple markets throughout the world. Founded in Indianapolis in 2004, the company employs approximately 220 people. Revenue in 2010 was $42.1 million, a 298 percent increase over 2007 revenue of $10.6 million.

The company connects clients to the lowest possible cost of care, utilizing advanced technology, customized solutions, exclusive offerings, and personalized service to drive optimal savings and reduce administrative demands.

Inc.’s list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. “This ranking is a great recognition for our company and our employees,” said Russell W. Sherlock, Chief Executive Officer of Health Systems International, “but even more important is the central truth behind this recognition: Our clients are saving millions of dollars on healthcare. That is the greatest measure of our success.”

In a stagnant economic environment, median growth rate of 2011 Inc. 500|5000 companies remains an impressive 94 percent. The companies on this year’s list report having created 350,000 jobs in the past three years, and aggregate revenue among the honorees reached $366 billion, up 14 percent from last year.

About Health Systems International

Health Systems International provides medical cost management solutions to healthcare payors in multiple markets throughout the world. The company connects clients to the lowest possible cost of care utilizing advanced technology, customized solutions, exclusive offerings, and personalized service to drive optimal savings and reduce administrative demands.

About Great Point Partners

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public (the Biomedical Value Fund) and private equity funds (GPP I – a $156 million private equity fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. The private equity fund invests in profitable companies across all sectors of the health care industry including behavioral health, biologics manufacturing, health care services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Pacific Child & Family Associates Acquires Autism Services North

Introduction

GREENWICH, CT and Santa Paula, CA – Pacific Child & Family Associates (“PCFA”), a Great Point Partners I, L.P. (“GPP”) portfolio company and a leading provider of applied behavior analysis (“ABA”) and other services for children and adults with autism and other developmental disabilities, today announced that it has acquired Autism Services North (“ASN”), a premier ABA network provider in the United States.

Founded in 2008, ASN provides access to approximately 135 Board Certified Behavior Analysts (BCBAs) and an additional 85 behavioral tutors across 25 states and growing. The acquisition of ASN significantly extends PCFA’s already robust service offering to those along the autism spectrum. Following the acquisition, PCFA has the capability to provide value-added, high quality behavioral therapy to its families, children, and referral sources under a variety of operating models. This enables PCFA to continue to be a very flexible partner, structuring and managing program design that best addresses the unique needs of each child and payer served. ASN’s senior management team, led by President and Founder, Paul Eschbach, as well as Director of Operations, Lisa Gibbner, will continue to play an integral role in management of the combined entity going forward.

Dr. Ira Heilveil, PhD, Chief Executive of Pacific Child commented, “The ASN acquisition marks a truly significance step in creating a national presence. We look forward to working with our families to provide greater access to quality care with additional scope and reach across the country.”

This acquisition marks the second acquisition that the company has closed in 2011 and the first strategic acquisition outside of California. Combined, PCFA now provides access to over 1,000 therapists serving over 1,100 children across the United States.

About Pacific Child & Family Associates

Founded in 1988, Pacific Child and Family Associates (“Pacific Child”) offers applied behavior analysis and other services for children and adults with autism and other developmental disabilities. Pacific Child is committed to providing the highest quality, scientifically validated services, built on a foundation of respect for those we serve. The cornerstones Pacific Child’s work include family involvement, collaboration with other professionals, recruiting and retaining qualified staff and ensuring their success by providing the highest level of ongoing education and training. The Company currently has fifteen offices in California, Texas, New Mexico, Pennsylvania and Minnesota, and is providing services throughout the world.

About Great Point Partners, LLC

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including life sciences, biologics manufacturing, reagents and media, consumer health, generic drugs, health care services, behavioral health, information technology, insurance, medical devices, specialty pharmaceuticals, outsourced hospital services, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Pacific Child & Family Associates Acquires Children’s Learning Connection

Introduction

GREENWICH, CT and Santa Paula, CA – Pacific Child & Family Associates (“PCFA”), a Great Point Partners I, L.P. (“GPP”) portfolio company and a leading provider of applied behavior analysis (“ABA”) and other services for children and adults with autism and other developmental disabilities, today announced that it has acquired Children’s Learning Connection (“CLC”), a leading provider of multidisciplinary therapy to children with autism and related disorders.

Founded in 2001, CLC provides ABA, speech, occupational and physical therapy to clients through an integrated, multidisciplinary delivery model. The acquisition of CLC expands PCFA’s clinical service offering, and allows the company to serve as a one-stop solution for the variety of therapies that clients often require. PCFA will also roll out this integrated delivery model to new service locations as the company continues to expand geographically. CLC’s senior management team, led by Co-founders and Co-Executive Directors Melanie Foshee and Kimberly Eissing, will continue to play an integral role in management of the combined entity going forward.

Dr. Ira Heilveil, PhD, Chief Executive of Pacific Child commented, “Children’s Learning Connection gives Pacific Child the expertise it needs to significantly expand the variety of services it provides for those on the autism spectrum. Kim and Melanie bring state of the art knowledge in the integration of a broad range of primary and ancillary services to the table. This is a win-win.”
This acquisition marks the first acquisition that the company has closed in 2011 and the first strategic acquisition to diversify the company’s service offering. In addition to PCFA’s core competency in ABA therapy, the company will now be able to integrate speech, occupational and physical therapy into its suite of services.

About Pacific Child & Family Associates

Founded in 1988, Pacific Child and Family Associates (“Pacific Child”) offers applied behavior analysis and other services for children and adults with autism and other developmental disabilities. Pacific Child is committed to providing the highest quality, scientifically validated services, built on a foundation of respect for those we serve. The cornerstones Pacific Child’s work include family involvement, collaboration with other professionals, recruiting and retaining qualified staff and ensuring their success by providing the highest level of ongoing education and training. The Company currently has fifteen offices in California, Texas, New Mexico, Pennsylvania and Minnesota, and is providing services throughout the world.

About Great Point Partners, LLC

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including life sciences, biologics manufacturing, reagents and media, consumer health, generic drugs, health care services, behavioral health, information technology, insurance, medical devices, specialty pharmaceuticals, outsourced hospital services, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International, LLC Named One of Indiana’s Fastest Growing Companies for the 3rd Year in a Row

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a global provider of outsourced medical cost management solutions, has just received recognition in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies. Health Systems International’s solutions include advanced healthcare cost-management technology and business solutions that are customized to meet specific industry needs in the Commercial Health, Property and Casualty, Maritime and International Payor markets.

“Our continued growth affirms that we successfully execute our vision of connecting clients to the lowest possible cost of care utilizing advanced technology, customized solutions, exclusive offerings and personalized service to drive optimal healthcare claim savings and reduce administrative demands,” said Anthony Browne, President and Chief Operating Officer, “ We have grown significantly in the past few years by assembling the market’s broadest selection of medical cost management solutions available through a single source.”

Russell Sherlock, CEO of Health Systems International added, “In addition to our organic growth strategy, we continue our focus on strategic acquisitions that will enhance our comprehensive cost management solutions. In the future, we will continue to build and acquire platforms and solutions that drive the lowest possible healthcare cost.”

Jeffrey R. Jay, MD, Managing Director of Great Point Partners stated, “HSI has grown into a national powerhouse in medical cost management. Their three year revenue growth rate of 54% is outstanding.” Noah Rhodes also of Great Point Partners’ private equity team and a member of HSI’s Board of Directors added, “HSI continues to invest in better technology and services for its clients and we expect this investment will continue to drive rapid growth.

About HSI

Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm focused on medical and health care information services companies. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

American Surgical Welcomes Mark Cherney as Chairman

Introduction

GREENWICH, CT and HOUSTON, TX – American Surgical Assistants, Inc (“American Surgical”), a portfolio company of Great Point Partners I, LP and a leading provider of in operating room surgical assistants today announced the appointment of Mark Cherney as Chairman. Mr. Cherney is currently the CEO and President of Prologics, Inc, a therapeutic radiation services company which he co-founded in 2005 and has extensive health care services experience. Previously, Mr. Cherney was CEO of Dolphin Medical, CEO of Princeps and President of Endocare.

Zak Elgamal, CEO of American Surgical said, “GPP brought in, as the Company’s Chairman, an entrepreneur who as CEO grew four prior health care services companies. We will work with Mark to provide market leading quality service to our customers. We are honored to have Mr. Cherney as Chairman.”

Mr. Cherney added, “American Surgical has consistently done a great job of providing high quality surgical assistant services to the hospitals, surgeons and patients. I am excited to become the Chairman of its Board.”

Adam Dolder, Managing Director of Great Point Partners concluded, “Mark is a seasoned health care services industry expert and also serves on GPP’s CEO Advisory Board. We are excited at what the combination of Mark’s experience and leadership can add to the Company.”

About American Surgical Assistants, Inc.

Founded in 1999 and headquartered in Houston, TX, American Surgical through its subsidiaries provides professional surgical assistant services to patients, surgeons and healthcare institutions. The Company is a joint commission certified (JCAHO) surgical assistant services company. Its services result in cost savings for patients, insurance carriers, hospitals, surgeons, and healthcare institutions while maintaining high quality of service. Reach American Surgical at Asainc.us or by calling 713-779-9800.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, biotechnology and life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Cytovance Biologics Adds Bernhard Hampl, Ph.D., as Co-Chairman

Introduction

GREENWICH, CT and OKLAHOMA CITY, OK – Great Point Partners I portfolio company, Cytovance Biologics, Inc (“Cytovance”), today announced the appointment of Bernhard Hampl, Ph.D., the former CEO of Eon Labs and the Sandoz US-division of Novartis, as Co-Chairman of Cytovance Biologics. Dr. Hampl joined Eon as CEO and President in 1996 and led Eon’s transformation from a small niche player into one of the most successful US pharmaceutical companies by 2005 when it was acquired by Novartis. During the period he was CEO, Eon’s revenue grew from $20 million to $435 million.

Darren Head, CEO of Cytovance indicated, “Cytovance has been experiencing rapid business growth and the equity financing from Great Point Partners puts additional muscle on an already strong balance sheet that has no debt. As we expand our capabilities and facility in biologics contract manufacturing in both mammalian and microbial cell cultures for proteins and antibodies in the U.S. and internationally, we wanted to add an admired executive with global biologics and biosimilar manufacturing and marketing expertise. We are honored to have Dr. Hampl as Co-Chairman.”

Dr. Hampl added, “Cytovance is committed to providing the highest quality contract biologics manufacturing services and delivering real value to their customers. I am excited to become both the Co-Chairman and an investor in Cytovance.”

Jeffrey R. Jay, M.D. Managing Director of Great Point Partners said, “As a long time Board member at Eon Labs, I witnessed Dr. Hampl’s ability to build an outstanding management team, implement and execute an organic growth strategy and increase shareholder value. In fact, after the Eon IPO in 2001, the share price increased four-fold over the next three and a half years.”

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, biotechnology and life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Acquires True Course

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a global provider of outsourced medical cost management solutions and a Great Point Partners I portfolio company, today announced the acquisition of True Course, a data informatics and claims services company, based in Milwaukee. True Course provides high quality medical data analysis and supportive claim services in the Midwestern, United States. True Course is at the forefront of workers’ compensation medical fee schedule development and offers the most comprehensive set of certified databases in Wisconsin. The acquisition further expands the exclusive technology and business offerings of Health Systems International.

“Medical costs are the fastest rising component of workers’ compensation programs,” says Glen Boyle, President of True Course. “The integration of True Course with Health Systems International allows us to deliver a full suite of medical cost management solutions to our current and prospective clients.”

Jeff Brand, President, Network Solution for Health Systems International further added, “The key to maximizing savings in workers’ compensation is partnering with experts who offer a full understanding of ALL the components necessary to achieve maximum savings results such as fee schedules, medical services, and payment systems — True Course is that partner.”

This acquisition marks the fifth tuck-in acquisition HSI has closed in the last several years. HSI’s strong revenue growth rate in excess of 60% per year clearly demonstrates its ability to successfully meet the existing and future needs of its customers. Jeffrey Jay, M.D. a founder and Managing Director of Great Point Partners said, “This extends HSI’s capabilities into data informatics and medical data analysis. Moreover, it adds another proprietary solution to HSI, expanding its range of unique product offerings.”

About Health Systems International

Health Systems International provides medical cost management solutions to healthcare payors in multiple markets throughout the world. The company connects clients to the lowest possible cost of care utilizing advanced technology, customized solutions, exclusive offerings, and personalized service to drive optimal savings and reduce administrative demands.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $450 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including behavioral health, biologics manufacturing, biotechnology and life sciences, health care services, hospital outsourcing, information technology, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Completes Take Private Acquisition of American Surgical

Introduction

GREENWICH, CT and HOUSTON, TX – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, today announced the completion of its take private of American Surgical Holdings, LLC (“American Surgical” or the “Company” or “OTCBB:ASRG”) a leading provider of in operating room surgical assistants.

The Company markets its services to hospitals, surgeons and healthcare institutions and currently provides its service in Oklahoma, Virginia, Texas, Tennessee and Georgia. American Surgical currently employs over 100 surgical assistants.

Zak Elgamal, CEO of American Surgical commented, “Great Point Partners impressed us with their understanding and knowledge of the surgical assistant market and our customer base. I am confident that through our partnership with GPP we will continue to provide market leading quality service to our customers”.

“American Surgical has consistently done a great job of providing high quality services to the hospitals, surgeons and patients. We hope to continue providing its customers with the highest quality service and continue growing the business in the long term,” said Adam B. Dolder of Great Point Partners. Dr. Jeffrey Jay added, “Surgical Assistants are highly skilled, fully trained professionals credentialed through an extensive process similar to that utilized to evaluate physicians. They are an integral part of the surgical team and provide a high quality and cost effective solution to the health care system”.

About American Surgical Holdings, LLC

Founded in 1999 and headquartered in Houston, TX, American Surgical provides professional surgical assistant services to patients, surgeons and healthcare institutions. The Company is a joint commission certified surgical assistant services company. Its services result in cost savings for patients, insurance carriers, hospitals, surgeons, and healthcare institutions while maintaining the quality of service.

About Great Point Partners, LLC

Great Point Partners, LLC is a leading health care investment firm with approximately $400 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently, the Firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. You can find more about Great Point at www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Growth Equity Investment in Cytovance Biologics

Introduction

GREENWICH, CT and OKLAHOMA CITY, OK – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, announced today a growth equity investment in Cytovance Biologics, LLC (“Cytovance”). Founded in 2004 and headquartered in Oklahoma City, OK, Cytovance is a leading full service contract manufacturer (“CMO”) of mammalian and microbial biologics for biotechnology and pharmaceutical companies.

Cytovance specializes in the production of therapeutic proteins and monoclonal antibodies from mammalian and microbial cell cultures. The Company offers a comprehensive and collaborative approach to manufacturing biologics that adds significant value by partnering with biopharmaceutical companies to advance their recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in domestic and international markets. In addition to their cGMP manufacturing services, Cytovance offers process development, cGMP cell banking, in-house analytical development and testing and a full complement of client support services. In addition, Cytovance operations are supported by teams of highly experienced quality control and quality assurance professionals that are solely focused on complying with all contractual and global regulatory requirements.

The equity investment will fund a major facility, service and personnel expansion which will add significant development and production capacity to its existing state-of-the-art facility to accommodate client demand for continued clinical trial and commercial scale CGMP manufacturing.

“Great Point reached out to us last year. It was evident from our first conversation they were very knowledgeable about the biologics manufacturing space and recognized the potential growth opportunities for Cytovance with additional working capital. They share our existing partners’ optimism moving forward and will be a valuable addition to our organization in terms of their vision and understanding of our business”, said Darren Head, CEO of Cytovance. “Great Point’s investment allows us to accelerate our next phase of growth.”

As part of their investment, Great Point Managing Directors Dr. Jeffrey R. Jay and David Kroin, and Senior Vice President Noah F. Rhodes, III will join Cytovance’s Board of Directors along with Darren Head, Cytovance’s CEO and Dr. William Canfield, former Founder of Novazyme Pharmaceuticals. “We welcome Great Point Partners and Presbyterian Health Foundation as new investors in Cytovance. This transaction marks a transition of the company from angel investors to professional investors. The transition is reflective of the company’s progress in the last couple of years due to the hard work of Darren and the entire team.” said Dr. William Canfield, Chairman of Cytovance. Dr. Canfield led a recapitalization and reorganization of Cytovance in 2005. The recapitalization investor group included Canfield, Aubrey K. McClendon and Tom L. Ward and provided local ownership for the first time.

Dr. Jeffrey Jay of Great Point Partners stated, “Cytovance has established itself as one of the premier CMO’s in the biologics manufacturing space and we are excited to partner with the strong management team they have already assembled.” Furthermore, he added, “Cytovance is a classic Great Point platform company as it is: rapidly growing, well-managed and highly scalable.”

About Great Point Partners, LLC

Great Point Partners, LLC is a leading health care investment firm with approximately $400 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently, the Firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. You can find more about Great Point at www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic NeuroNetwork Acquires US Neuromonitoring

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the leading intraoperative neurophysiological monitoring (“IONM”) company, today announced that it has acquired US Neuromonitoring, Inc, a premier regional IONM provider based in Chicago, IL.

Dr. Gene Balzer, Chief Executive Officer of Biotronic commented, “The US Neuromonitoring team has done a great job of providing high quality services to the hospitals, surgeons, and patients that they served. Our goal is to improve upon the solid foundation that was built. In addition, this is a great fit for Biotronic as this partnership allows us to strengthen our market presence in the Midwest and Chicago markets.”

The acquisition marks the fourth such transaction Biotronic has closed over the past three years and second in 2010. The acquisitions, and successful integrations, clearly demonstrate the Company’s ability to execute on its strategic plan. Adam B. Dolder, Chairman of Biotronic and Managing Director at Great Point Partners said, “This transaction demonstrates Biotronic’s continued ability to consolidate the fragmented IONM industry and is an important step for the Company as it deepens their market position in the Midwest and also deepens their already strong team. We are excited at the continued organic and acquisitive growth of Biotronic NeuroNetwork.”

IONM utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) and organs in real-time during surgeries such as neurological, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 225 administrative, support and clinical staff, including over 160 technicians throughout the country. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 450 hospitals and 1,200 surgeons annually. www.biotronic.com

About Great Point Partners

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Caprion Proteomics Identifies Biomarkers that Predict Response to Anti-Viral Hepatitis C Treatment Developed by Vertex

Introduction

GREENWICH, CT and MONTREAL, QC – Caprion Proteomics announced today that it has identified protein biomarker panels that appear to predict patient responsiveness to treatment for hepatitis C.

The study employed Caprion’s proprietary CellCarta® mass spectrometry-based proteomics discovery platform to measure and compare the expression levels of thousands of proteins contained in blood samples collected from patients infected with the hepatitis C virus (HCV), in order to discover predictive biomarkers of sustained response to hepatitis C therapy.

Analysis of data from the study identified a panel of candidate protein biomarkers that correlate with sustained viral response (SVR) or viral cure to treatment with a novel drug candidate for hepatitis C, telaprevir (being developed by Vertex Pharmaceuticals), in combination with pegylated-interferon and ribavirin. Additional candidate biomarkers were identified that may predict SVR in patients treated with current standard of care hepatitis C treatment, which is a combination of pegylated-interferon and ribavirin alone. In both cases, the biomarkers were identified in plasma samples collected from hepatitis C patients prior to treatment. The identification of a panel of candidate biomarkers is a result of an ongoing collaboration between Vertex and Caprion.

The study also revealed biological insights into differences in response to hepatitis C treatment for specific segments of the population, opening the door to the potential for patient stratification and individualized treatment of the disease. A number of protein biomarkers identified in the panel are known to be correlated to the underlying severity of liver damage, and the data suggests that increased liver damage is associated with a poor therapeutic outcome.

“We are highly encouraged by the results of the study, which provide further validation of Caprion’s robust and industrialized proteomics approach to biomarker discovery and validation,” said Martin LeBlanc, President and CEO of Caprion. “We are privileged to have the opportunity to work with innovative partners such as Vertex on projects aimed at advancing the field of biomarker research and treatment of disease”.

Noah Rhodes, Senior Vice-President of Great Point Partners stated, “The results of the Vertex study are yet another example of the team at Caprion delivering on its value proposition to clients. Research analysts expect telaprevir, a novel anti-viral in Phase III trials to be a multi-billion dollar product. The ability to predict who will benefit from this treatment in advance, has tremendous pharmaco-economic value. We look forward to continuing our work with partners such as Vertex as they look to further expand the possibilities of personalized medicine.”

About Caprion Proteomics

Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical and biotech industries. Caprion has been providing proteomics biomarker and target identification services since 2002, and has performed multiple large-scale biomarker discovery and validation projects for over 20 major pharmaceutical industry clients in virtually all of the major disease areas. Caprion has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectious diseases with the NIH-NIAID. In 2008, Caprion entered into a worldwide strategic marketing and distribution alliance for biomarker services with Covance, Inc. (NYSE:CVD), which also involved the purchase by Covance of a minority equity stake in the company. Caprion Proteomics, a privately-held company, is majority owned by Great Point Partners, LP. For more information, please visit: www.caprion.com.

About the Collaboration

Caprion and Vertex entered into collaboration in March 2006, to evaluate relevant protein targets and biomarkers in diseases of interest to Vertex using Caprion’s CellCarta® platform. Through the collaboration, Vertex and Caprion are tracking protein markers that may predict, very early on in therapy, which patients will successfully respond to treatment. The collaboration was expanded in 2007 to provide a more comprehensive evaluation of these targets and biomarkers.

About Great Point Partners, LLC

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or at www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic Highlighted as one of the Top 20 Hospital Outsourcing Firms in the United States

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the leading intraoperative neurophysiological monitoring (“IONM”) company in the United States, recently received recognition in Modern Healthcare’s September 20th issue as one of the Top 20 Outsourcing Firms in the United States. Please contact Great Point Partners for a PDF copy of the article.

Dr. Gene Balzer, Chief Executive Officer of Biotronic, said, “The biggest trend for us is that the hospitals we work with are looking at outsourcing as a standardized risk-management tool to give better care to patients.” When asked further about why Biotronic in particular has found such success with hospitals, Dr. Balzer stated, “The hospitals want a sole-source vendor that can provide quality assessment reports and that can follow set protocols; Biotronic consistently matches their needs.”

Adam Dolder, MD, Managing Director of Great Point Partners and Chairman of Biotronic stated, “Biotronic’s growth is directly reflective of the trends and pressures facing hospitals today as hospitals look to ease overall management complexity, appropriately manage their cost infrastructure while also providing the best clinical care possible. Biotronic enables its customers to do that with respect to IONM services.” Jeffrey Jay M.D. co-founder of Great Point Partners and a member of Biotronic’s Board of Directors added, “We are pleased with Biotronic’s rapid growth and leading market position and congratulate all the Biotronic employees with the recognition the Company has received.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 225 administrative, support and clinical staff, including over 175 technicians throughout 17 states. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 450 hospitals and 1,200 surgeons annually. www.biotronic.com.

About Great Point Partners, LLC

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300 or at www.gppfunds.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International, LLC Named One of Indiana's Fastest Growing Companies for the 2nd Year in a Row

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a global provider of outsourced medical cost management solutions, has just received recognition in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies – coming in at number 3 (up from number 9 in the prior year). View the full list of companies who were acknowledged in the IBJ’s Top 25 list on the second page of the link, http://us-hsi.com/files/Fastest%20Growing%20HSI_July%202010.pdf.

Russell W. Sherlock, Chief Executive Officer of HSI, said, “Spiraling medical costs is one of the pressing issues of our time, and our sole purpose in life at HSI is to reduce the cost of that bill you receive from your physicians or your hospitals. The more we can save people money, the better off we are as a company.” When asked further about the Company’s recent growth and future prospects, Mr. Sherlock added, “We’re enjoying the growth, and it doesn’t show any signs of stopping.”

Jeffrey R. Jay, MD, Managing Director of Great Point Partners stated, “HSI has grown revenues four fold in the last three years due to strong customer demand for its best in class cost containment services. We congratulate HSI on the recognition they have received.” Noah Rhodes also of Great Point Partners’ private equity team and a member of HSI’s Board of Directors added, “HSI continues to invest in better technology and services for its clients in anticipation of their evolving needs and of this exceptional customer commitment we are justly proud.”

About HSI

Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm focused on medical and health care information services companies. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.us-hsi.com for more information.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic NeuroNetwork Acquires BiWater Surgical Monitoring

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the leading intraoperative neurophysiological monitoring (“IONM”) company, today announced that it has acquired BiWater Surgical Monitoring, LLC, a premier regional IONM provider based in Salt Lake City, Utah.

Dr. Gene Balzer, Chief Executive Officer of Biotronic commented, “The BiWater team has done a great job of providing high quality services to the hospitals, surgeons, and patients that they served. Our goal is to improve upon the solid foundation that was built. In addition, this is a great fit for Biotronic as this partnership allows us to expand into attractive geographic areas we have been targeting.”

The acquisition marks the third such transaction Biotronic has closed over the past three years. The acquisitions, and successful integrations, clearly demonstrate the Company’s ability to execute on its strategic plan. Adam B. Dolder, Chairman of Biotronic and Managing Director at Great Point Partners said, “This is an important strategic step for Biotronic as it provides an ideal entry into attractive markets and a strong base from which to expand in those markets. We are excited at the continued growth of Biotronic NeuroNetwork.”

IONM utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) and organs in real-time during surgeries such as neurological, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

About Biotronic

Founded in 1978, Biotronic NeuroNetwork is headquartered in Ann Arbor, Michigan and currently employs over 225 administrative, support and clinical staff, including over 175 technicians throughout 17 states. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 450 hospitals and 1,200 surgeons annually. www.biotronic.com

About Great Point Partners, LLC

GPP, based in Greenwich, Connecticut, is a leading health care investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Investment in Pacific Child & Family Associates

Introduction

GREENWICH, CT and SANTA PAULA, CA – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, announced today the growth recapitalization of Pacific Child & Family Associates, LLC (“Pacific Child”). Founded in 1988 and headquartered in Santa Paula, CA Pacific Child is a leading provider of applied behavior analysis (“ABA”) services to children with autism and other related disorders in the Western United States.

The Company administers ABA therapy and supervision, the most comprehensive and most effective approach to improving the lives of persons with autism and their families. Pacific Child’s methods are grounded in an appreciation for the most current research and are scientifically-based. The Company works from within the broad spectrum of applied behavior analytic techniques, employing empirically validated approaches as needed by the autistic child. The Company’s curriculum includes skills required for success in school, social relationships, and the acquisition of language skills.

As part of their investment, Great Point Managing Directors Adam B. Dolder, Dr. Jeffrey R. Jay, and Vice President Noah F. Rhodes, III will join Pacific Child’s Board of Directors along with Dr. Ira Heilveil, Pacific Child’s founder and CEO.

“From our initial conversation, Great Point Partners demonstrated a clear command of the autism services business”, said Dr. Heilveil, CEO of Pacific Child. “We looked at bringing on various partners but selected Great Point based on their extensive work within the industry, their pre-identified expansion opportunities, and the strength and guidance they can provide as we look to execute on an accelerated growth plan.”

“We are excited to be Dr. Heilveil’s partner and look forward to building upon the strong foundation he and his team have laid at Pacific Child,” said Adam Dolder of Great Point. Furthermore, he added, “We spent an extensive amount of time understanding the autism industry and reviewing different companies in which to invest, but each time we came back to Pacific Child given the Company’s differentiation, clinical expertise, and positive outcomes the Company helps children and families achieve.”

About Pacific Child & Family Associates

Founded in 1988, Pacific Child and Family Associates (“Pacific Child”) offers applied behavior analysis and other services for children and adults with autism and other developmental disabilities. Pacific Child is committed to providing the highest quality, scientifically validated services, built on a foundation of respect for those we serve. The cornerstones Pacific Child’s work include family involvement, collaboration with other professionals, recruiting and retaining qualified staff and ensuring their success by providing the highest level of ongoing education and training. The Company currently has nine offices in California and offices in Texas and New Mexico, and is providing services throughout the world.

About Great Point Partners, LLC

Great Point Partners, LLC is a leading health care investment firm with approximately $400 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently, the Firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. You can find more about Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Caprion Proteomics Acquires Biomarker Unit from PPD

Introduction

GREENWICH, CT and MONTREAL, CANADA – Caprion Proteomics Inc. announced today that it has acquired from PPD, Inc. (Nasdaq: PPDI) the shares and assets of PPD Biomarker Discovery Sciences, LLC, PPD’s proteomics-based biomarker services division based in Menlo Park, Calif. The acquisition further strengthens Caprion’s market leadership position in the area of proteomics biomarker services and will also broaden its client portfolio and revenue base. Financial terms of the acquisition were not disclosed.

Caprion will perform existing contractual obligations acquired as part of this acquisition from both Caprion’s facilities in Montreal and from a new facility in Menlo Park that will operate under the name Caprion Proteomics, U.S., LLC.

“We are very pleased to add the solid scientific capabilities, experience and customer relationships of PPD’s biomarker unit to Caprion’s rapidly growing biomarker services business,” said Martin LeBlanc, President and CEO of Caprion. “By acquiring this business, we will expand our capacity and be able to better meet the growing biomarker needs of our current and future clients.”

“This acquisition will be immediately accretive for Caprion both from a financial and strategic standpoint,” said Adam Dolder, Managing Director at Great Point Partners, LP, Caprion’s majority shareholder. “It further positions the Company for continued growth and solidifies its market leadership position in the biomarker space.”

About Caprion Proteomics

Caprion Proteomics is the leading provider of proteomics-based services to the pharmaceutical and biotech industries. Caprion’s proprietary proteomics technology, CellCarta®, is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. Caprion has been providing proteomics biomarker and target identification services since 2002, and has performed multiple large-scale biomarker discovery and validation projects for pharmaceutical industry clients such as Pfizer, J&J, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, GSK, Schering-Plough, Merck-Serono, Vertex, DebioPharm and Solvay. Caprion also has been awarded two consecutive 5-year US$13 million contracts for Biodefense proteomics research in the area of infectious diseases with the NIH-NIAID. In 2008, Caprion also entered into a worldwide strategic marketing and distribution alliance for biomarker services with Covance, Inc. (NYSE:CVD), which also involved the purchase by Covance of a minority equity stake in the company. Caprion Proteomics, a privately-held company, is majority owned by Great Point Partners, LP. For more information, please visit: www.caprion.com.

About PPD

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 40 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at www.ppdi.com.

About PPD Biomarker Discovery Sciences, LLC

PPD Biomarker Discovery Sciences, LLC provides biomarker solutions to pharmaceutical and biotechnology companies using proprietary, integrated proteomics technologies to identify biomarkers that may have a useful role in disease detection and in the evaluation of therapeutic response. The company, originally founded in 1997 under the name SurroMed, Inc., was acquired by PPD Inc. in 2005 and has since operated as a subsidiary of PPD based in Menlo Park, California.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Acquires @Global

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a leading provider of outsourced medical cost management solutions to payors and health care provider networks around the world, today announced that it has acquired @Global. @Global has been developing and supporting best-in-class software solutions for workers’ compensation, casualty insurance, claims administration, and medical cost management environments since 1996.

Russell W. Sherlock, Chief Executive Officer of HSI, said, “@Global makes an exceptional fit for HSI by not only enhancing the infrastructure of all of HSI’s solutions but also providing additional software applications for clients as yet another way for them to control cost.”

President of @Global, Steve Graham, commented “The combination of HSI and @Global represents a highly strategic offering of software assets, customer service capabilities, and vendor relationships. HSI’s resources will allow us to be able to offer complete, fully integrated medical cost management solutions to current @Global clients.”

Jeffrey R. Jay, MD, Managing Director of Great Point Partners commented, “One of the ways we add value for our platform companies is by sourcing add-on acquisitions such as @Global.” Noah Rhodes, an HSI Board member, added “@Global provides technology solutions that make HSI the best of breed cost containment solution in the marketplace.”

About HSI

Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions to health plan payors and provider networks around the world. HSI is backed by Great Point Partners, LLC, a private investment firm with over $500 million of equity capital under management. Since 1987, HSI has utilized proprietary technology, experienced staff and the market’s broadest selection of medical discount solutions to relieve client’s administrative burdens and achieve the lowest possible cost of medical care. Go to www.us-hsi.com for more information.

About @Global

@Global creates real and tangible value for organizations by integrating software strategies that help make the business of managing insurance claims more productive. Applications developed generate the maximum return on technology investment by improving health care loss outcomes and costs, enabling labor efficiencies, and reducing technology costs. Services include custom programming, project management, software training, system documentation and 24/7 technical support.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International Named One of Indiana’s Fastest Growing Companies

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a global provider of outsourced medical cost management solutions, has just received the spotlight in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies – coming in at number 9. View the full list of companies who were acknowledged in the IBJ’s Top 25 list on the second page of the link, http://www.us-hsi.com/files/Top%2025_Press%20Release.pdf.

Russell W. Sherlock, Chief Executive Officer of HSI, said, “We are pleased with our company’s progress and with HSI’s exceptional team. Our company is uniquely positioned to become the leading provider of medical cost management solutions. We have strong management, blue chip customers, and a solid blueprint for growth. This foundation serves as an excellent platform for future acquisitions and organic growth initiatives even in our current economic environment. I share all of HSI staff’s excitement about our IBJ ranking and look forward to continuing to work together as a team to build a market leading position.”

Jeffrey R. Jay, MD, Managing Director of Great Point Partners stated, “We congratulate the HSI team on their exceptional pay for performance model which has been embraced by the marketplace.” Noah Rhodes also of Great Point Partners and a member of HSI’s Board of Directors added, “The rapid growth of HSI stands out particularly in this time of general economic contraction.”

In the past two year period, HSI has expanded its solutions and the markets it serves. Solutions include PPO Access / Repricing, Bill Negotiation, Bill Review, Bill Auditing, Care Management, Rx, and Ancillary Cost Control. The Company’s solutions have been developed and customized to meet specific industry needs in the PPO, Maritime, Workers’ Compensation, Property and Casualty, HMO, Health Insurance Carrier, TPA, Self-funded, Reinsurer, and International Health Payor Markets.

About HSI

Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm focused on medical and health care information services companies. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.us-hsi.com for more information.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic NeuroNetwork Achieves JCAHO Accreditation

March 25, 2009

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the nation’s leading intraoperative neurophysiological monitoring (“IONM”) company, is pleased to announce that it has been awarded the Gold Seal of ApprovalTM by the Joint Commission on Accreditation of Healthcare Organizations (“JCAHO”). Biotronic believes it is the first intraoperative neurophysiological monitoring provider to receive JCAHO accreditation.

As an independent, not-for-profit organization with a 50 year history, JCAHO is the nation’s largest and oldest health care evaluation and certifying agency for nearly 15,000 health care organizations and programs in the United States including hospitals, hospice services, nursing homes, laboratories, rehabilitation centers, and behavioral health care organizations. The JCAHO certification signifies that Biotronic meets rigorous national standards and performance measurements for health care quality and safety in improving patient outcomes during surgery.

Gene K. Balzer, PhD, Chief Executive Officer of Biotronic NeuroNetwork stated, “This is an important achievement for Biotronic, which represents our continual commitment to offering the highest level of quality and service to hospitals, surgeons and patients throughout the country.” Adam B. Dolder, Chairman of Biotronic and Managing Director at Great Point Partners adds, “This achievement further demonstrates that Biotronic is the premier provider of intraoperative neuromonitoring services. Dr. Balzer and the entire organization, have taken the lead in ensuring the highest quality and clinical standards in the IONM industry.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork, is headquartered in Ann Arbor, MI and currently employs over 200 administrative, support and clinical staff, including over 150 technicians throughout 17 states. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 400 hospitals and 1,200 surgeons annually. www.biotronic.com

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $500 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point Partners at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biotronic NeuroNetwork Completes Acquisition of Neurophysiology Consultants

Introduction

GREENWICH, CT and ANN ARBOR, MI – Biotronic NeuroNetwork (“Biotronic”), a Great Point Partners I, L.P. (“GPP”) portfolio company and the leading intraoperative neurophysiological monitoring (“IONM”) company, is pleased to announce that it has acquired Neurophysiology Consultants, LLC (“NPC”), a strong regional IONM provider based in Omaha, NE. IONM utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) and organs in real-time during surgeries such as neurological, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

Adam B. Dolder, Managing Director at Great Point Partners said, “We are thrilled to support Dr. Balzer and the Biotronic team in this opportunity. The successful completion of this acquisition affirms Biotronic’s ability to target and integrate regional IONM providers and it entrenches Biotronic as the leading IONM company in the market.” The acquisition of NPC marks the second acquisition Biotronic has made in a little over a year.

Gene K. Balzer, Chief Executive Officer of Biotronic NeuroNetwork commented, “We believe that the substantial underlying synergies between Biotronic and Neurophysiology Consultants will provide NPC’s client hospitals with even higher quality services through the ability to rely on a provider with a comprehensive set of services through the addition of Biotronic’s remote monitoring capabilities which will augment the existing current on-site monitoring.”

“We simply couldn’t have found a better partner than Biotronic. They have first-in-class IONM services with a trusted name and care deeply about their employees and their customers. In addition, this transaction will provide NPC with solid financial backing, continued access to leading technology, and the organizational infrastructure to provide higher quality and more extensive services to our current and future customers,” said Robert Hankey, Founder and Managing Member of Neurophysiology Consultants.

About Biotronic

Founded in 1978, Biotronic NeuroNetwork, is headquartered in Ann Arbor, MI and currently employs over 200 administrative, support and clinical staff, including over 150 technicians throughout 17 states. Biotronic is the largest independent provider of intraoperative neurophysiological monitoring in the world, serving over 400 hospitals and 1,200 surgeons annually. www.biotronic.com

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $600 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity and growth recapitalization financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point Partners at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Covance Purchases Equity Stake in Caprion Proteomics

Introduction

MONTRÉAL, QC and GREENWICH, CT – Caprion Proteomics Inc. of Montréal, Canada announced today that it has entered into a strategic marketing and distribution alliance with Covance Inc. (NYSE:CVD), a leading provider of drug development services. As part of the alliance, Covance which is based in Princeton, New Jersey has purchased a minority equity stake in Caprion Proteomics, and will act as the exclusive contract research organization (“CRO”) distributor of Caprion’s proteomic biomarker services. In addition, Caprion will become Covance’s exclusive provider of such services. Financial terms of the alliance were not disclosed.

The combination of Caprion’s distinctive capabilities for proteomic biomarker discovery, verification, and validation, with Covance’s leading research services platform, will offer pharmaceutical and biotechnology customers a distinctive, innovative, and fully-integrated biomarker solution across the entire drug development continuum  from early proof of concept through late-stage clinical trials and post-marketing surveillance. Through the support of Covance’s extensive worldwide marketing, sales and distribution capabilities, as well as its extensive customer base, the alliance will also enable Caprion to significantly enhance its visibility and reach into this emerging high-growth service market.

“We are very pleased to be adding Caprion’s solid scientific capabilities and leading biomarker technology platform to Covance’s line up,” said Deborah Tanner, Corporate Senior Vice President and President of Covance Central Laboratory Services. “We expect that our clients will have a keen interest in this additional capability given Caprion’s impressive track record of accelerating biomarker validation for early drug safety and efficacy assessment.”

“We are excited to join forces with Covance’s market-leading central laboratory and world-class scientific talent,” said Martin LeBlanc, President and CEO of Caprion. “Caprion has established a large pharmaceutical and biotech customer base through the use of our distinctive, best-in-class technology platform, which we expect will be further adopted in the market as a result of our alliance with Covance and will ultimately yield superior biomarker solutions for our clients.”

“This alliance with Covance marks an important strategic milestone for Caprion” said Adam Dolder, Managing Director at Great Point Partners, LP, Caprion’s majority shareholder. “Covance’s ability to expand Caprion’s customer outreach will be key in the realization of the company’s full potential.”

About Caprion Proteomics

Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical and biotech industries. Caprion’s proprietary proteomics discovery technology, CellCarta®, is a gel-free, label-free mass spectrometry platform that enables a comprehensive, quantitative and robust measurement of the protein expression differences across large sets of biological samples. Caprion has been providing biomarker and target identification services since 2002, performing more than 30 large-scale biomarker projects for pharmaceutical industry clients such as Pfizer, Johnson & Johnson, Abbott Laboratories, Biogen Idec, Daiichi-Sankyo, Mitsubishi-Tanabe, Wyeth, AstraZeneca, Merck, Boehringer Ingelheim, ICOS, Bayer-Schering , EMD-Serono, Vertex, DebioPharm and Transgene. Caprion also has been awarded two major 5-year Biodefense proteomics research contracts in infectious disease with the NIH-NIAID, and was awarded the Frost & Sullivan Biomarker Technology award in 2007. Caprion Proteomics, a privately-held company, is majority owned by Great Point Partners, LP. For more information, please visit: www.caprion.com.

About Great Point Partners, LLC

Great Point Partners, LLC, based in Greenwich, CT, is a leading health care investment firm with approximately $700 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently, the firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals and workers compensation.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Investment in Biotronic NeuroNetwork

Introduction

GREENWICH, CT and ANN ARBOR, MI – Great Point Partners, LLC, a Greenwich-based private investment firm focused on the health care industry, announced today the growth recapitalization of the Biotronic NeuroNetwork (“Biotronic”). Founded in 1978 and headquartered in Ann Arbor, MI, Biotronic is the leading independent national provider of intra-operative neurophysiological monitoring services.

The Company utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) in real-time during surgeries such as neurosurgical, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk.

As part of their investment, Great Point Managing Directors Adam B. Dolder and Jeffrey R. Jay, MD, will join Biotronic’s Board of Directors along with Gene K. Balzer, Ph.D., Biotronic’s CEO, H.B. Calder, Ph.D., the Company’s original founder and Kevin Clark, Founder and CEO of Onward Healthcare.

Dr. Calder stated, “We received dozens of inquiries from private equity firms over the past couple of years but the Great Point Partners team presented a differentiated value-add proposition for the Company. They not only had a clear command of our business and marketplace but also brought a depth of health care experience that will accelerate our pace of growth and strategic development.”

“We are thrilled at the opportunity to partner with Drs. Calder and Balzer in this investment and look forward to helping the team expand its market presence through rapid organic growth and an intelligent acquisition strategy,” said Adam B. Dolder of Great Point. Dr. Jeffrey Jay added, “The investment in Biotronic enables Great Point to partner with an outstanding management team in a market leading company which operates in a high growth sector. We thoroughly believe in the value proposition that the Company provides to patients, physicians and payors.”

About Biotronic

Founded in 1978, Biotronic NeuroNetwork, and its predecessor entities, provides intraoperative neurophysiological monitoring services. The Company utilizes advanced electrophysiological modalities to monitor and record the functional integrity of critical neural structures (brain, nerves, and spinal cord) in real-time during surgeries such as neurosurgical, spinal, vascular, cardiothoracic, orthopedic and other complex procedures where these structures potentially could be at risk. Biotronic is headquartered in Ann Arbor, MI.

About Great Point Partners, LLC

Great Point Partners, LLC is a leading health care investment firm with approximately $700 million of equity capital under management. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Currently, the firm manages capital in both public equity and private equity funds. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals and workers compensation.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Health Systems International, LLC, Expands Into Workers’ Compensation Through Acquisition of Bass & Babb

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Health Systems International (“HSI”), a Great Point Partners (“GPP”) portfolio company and a rapidly growing provider of outsourced medical cost management solutions, announced that it has acquired the Bass & Babb Companies (“Bass & Babb”). Bass & Babb is a leading provider of case management, vocational counseling and bill review services to the workers’ compensation market. The combined companies provide medical cost management solutions to health care payors and provider networks throughout the world. Their solutions are designed to relieve clients’ administrative burden and achieve the lowest possible cost of care.

Dr. Jeffrey R. Jay, Managing Director at Great Point Partners, said, “The acquisition of Bass & Babb represents a valuable strategic addition to the HSI platform. This transaction expands HSI’s core service offering into the high growth workers’ compensation market. It also brings many valuable new client relationships. We look forward to working with our new partners at Bass and Babb.”

Russell W. Sherlock, Chief Executive Officer of HSI, said, “Bass & Babb’s current customers will benefit from access to HSI’s PPO network relationships, technology and repricing services, which can now be integrated with their medical bill review and negotiation services”, Sherlock added. “Overall, we were very impressed with their team. The combination of our companies will produce better results for our customers. The expanded breadth of our combined services serves to fulfill our vision of becoming the leading provider of medical cost management solutions.”

“Bass & Babb started out contracting with HSI as our network access and repricing vendor,” added Kathleen A. Bass, President and CEO of Bass & Babb. “This is a very exciting opportunity for all of us since our company, our leadership and our employees will become the platform for HSI’s growth into the workers’ compensation market. HSI’s health care expertise, complementary service solutions and the strong financial backing of Great Point Partners made them the perfect partner for our future. We will now be able to offer a complete, fully integrated medical cost management solution to our combined clients.”

As part of the transaction, Kathleen A. Bass has been named President and Kevin Babb, Vice President of HSI’s Workers Compensation Division.

About Health Systems International, LLC

Health Systems International, LLC, headquartered in Indianapolis, Indiana, is a healthcare information technology company offering outsourced medical cost management solutions to health plan payors and medical provider networks around the world. Since 1987, HSI has utilized proprietary technology, experienced staff and the markets broadest selection of medical discount solutions to relieve their client’s administrative burdens and achieve the lowest possible cost of care.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biodel Inc. Announces Closing of Secondary Offering

Introduction

DANBURY, CT – Biodel Inc. (Nasdaq: BIOD) today announced the closing of the underwritten public offering of 3,810,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being sold in the offering, 3,260,000 were sold by Biodel and 550,000 shares were sold by existing stockholders of the Company including an entity affiliated with Great Point Partners. Biodel received net proceeds from the offering of approximately $46.4 million.

Morgan Stanley & Co. Incorporated acted as the sole book-runner manager and J.P. Morgan Securities Inc. acted as co-lead manager for this offering. Leerink Swann LLC and Natixis Bleichroeder Inc. were co-managers. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 7, 2008.

A copy of the final prospectus relating to the offering may be obtained from the Morgan Stanley & Co. Incorporated, Prospectus Department, 180 Varick Street, New York, NY 10014, by telephone at 866-718-1649 or by email at prospectus@morganstanley.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel’s Viaject® is a faster acting injectable meal-time insulin that offers numerous advantages including: fewer hypoglycemic events, less hyperglycemia, and less weight gain.

Reach Great Point at 203-971-3300.
www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Makes Strategic Investment in Health Systems International, LLC

Introduction

GREENWICH, CT and INDIANAPOLIS, IN – Great Point Partners, LLC (GPP) announced today a strategic investment in Health Systems International, LLC (HSI). HSI is a health care information technology company offering cost management solutions to payors and PPO networks around the world. HSI solutions relieve clients’ administrative burden and achieve the lowest possible cost of care.

As part of their investment, GPP Managing Director Jeffrey R. Jay, MD will join the HSI Board of Directors. Russell W. Sherlock, HSI’s President and CEO, and A. John Ansay, HSI’s Executive Vice President, will continue to oversee day-to-day operations and also serve on the Board of Directors.

Russell W. Sherlock stated, “We evaluated many potential partners to help us achieve our vision. The Great Point Partners team stood out amongst the field. Their track record of successful health care investing, strong business relationships, and capital resources necessary for our desired growth were unmatched. We look forward to an experienced partner helping us grow our company and expand our service.”

Dr. Jeffrey R. Jay of GPP said, “We are pleased to be partnering with HSI’s exceptional team. They are uniquely positioned to become the leading provider of medical cost management solutions. The company has strong management, blue chip customers, and a solid blueprint for growth. This foundation serves as an excellent platform for future acquisitions and organic growth initiatives. We look forward to working together to build a market leading position.”

About Health Systems International, LLC

Headquartered in Indianapolis, Indiana, HSI is a health care information technology company offering outsourced medical cost management solutions to health plan payors and provider networks around the world. Since 1987, HSI has utilized proprietary technology, experienced staff and the broadest selection of medical discount solutions to relieve client’s administrative burdens and achieve the lowest possible cost of care.

About Great Point Partners, LLC

GPP, based in Greenwich, CT, is a leading health care investment firm with approximately $900 million of equity capital under management. The firm manages capital in public and private equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. The firm pursues a proactive and proprietary approach to sourcing investments. Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

APT Pharmaceuticals Closes New $22 Million Funding Round

Introduction

BURLINGAME, CA – APT Pharmaceuticals, a specialty drug development company focused on effective treatments for significant unmet medical needs, announced today that it has closed on $22 million in growth equity financing. New investors Great Point Partners and Versant Ventures joined existing firms Vivo Ventures and Charter Life Sciences in the round. Coinciding with the funding, David Kroin, Managing Director, Great Point Partners has joined the APT board.

The Company will use the new funding to advance its development pipeline which includes Pulminiq, a Phase III drug for prevention of lung transplant rejection, a novel cardioprotectant and several other projects.

“We are extremely pleased with the outcome of this funding round” said Dr. Stephen Dilly, CEO of APT. “We have added two more high-caliber private equity firms to our investor base and secured the resources to make major progress with our development pipeline. I am very excited to welcome David Kroin onto our Board. We now have the people, the products and the resources we need to build significant value over the next few years.”

About APT Pharmaceuticals, Inc.

APT Pharmaceuticals, Inc. is a drug development company based in Burlingame, California. APT is backed by Great Point Partners a leading health care investment firm and by several leading venture capital firms, including Vivo Ventures, Versant Ventures and Charter Life Sciences.

About Great Point Partners, LLC

Great Point Partners, LLC, based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management. Currently, the firm manages capital in both public equity and private equity funds. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation.

Notable drug development companies financed by the principals include Akorn Laboratories, AMAG Pharmaceuticals, Biodel, Centocor (now part of Johnson & Johnson) and Eon Labs (now part of Novartis). Reach Great Point at 203-971-3300. www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Leads Investment in Caprion Proteomics

Introduction

MONTRÉAL, QUEBEC and GREENWICH, CT – Great Point Partners today announced that it has acquired a majority stake in Caprion Proteomics, Inc. (“Caprion” or the “Company”), a leading proteomics based biopharmaceutical research company, from Thallion Pharmaceuticals (TSX: TLN). Caprion is a rapidly growing leader in the proteomics market.

When asked about the transaction, Martin LeBlanc, CEO of Caprion Proteomics indicated “Great Point Partners’ financial support, track record of industry success, philosophy of supporting management teams, and strategic leadership, in combination with Caprion’s customer base and experienced leadership team, position us well to capitalize on the growing demand for proteomics services in the area of drug discovery and development.” The Caprion senior management team will continue to run the Company with no change in location, personnel, or business model.

“Caprion represents an opportunity to invest in not only a company with industry leading technology, but also a talented, eager and entrepreneurial management team. We believe that the Company’s powerful proteomic discovery engine and superior bioinformatics capabilities will enable Caprion to expand its leading position in the proteomics industry,” said Mr. Dolder, Managing Director at Great Point Partners. “Caprion provides a complex, differentiated and high value-add service to a customer base that relies heavily on the ability to determine which proteins, molecules and antibodies will yield successful therapeutics – Caprion does just that.” Great Point’s Adam Dolder and David Kroin will join the Board of Caprion.

“This transaction enables both Thallion and Caprion to focus on their respective core missions while also allowing Thallion to retain substantial upside in the proteomics business that we pioneered,” said Lloyd M. Segal, Chief Executive Officer of Thallion Pharmaceuticals Inc. “Great Point Partners is a best-in-class investment partner in the life sciences and health care services sector and we look forward to working with them as co-investors in order to support Caprion and its management team.”

About Caprion Proteomics

Caprion Proteomics is the leading provider of proteomics-based discovery solutions to the pharmaceutical industry. Caprion uses its proprietary proteomics technology platform – CellCarta® – to discover novel targets for therapeutics development as well as clinical biomarkers that can significantly reduce risk and enhance productivity and decision making in pharmaceutical research. Caprion has established strategic alliances in the area of novel oncology target discovery and antibody development with Abbott, Biogen-Idec, and Centocor, as well as multiple biomarker collaborations with such leading companies as Pfizer, Johnson & Johnson, Wyeth, Daiichi-Sankyo, Boehringer-Ingelheim, Berlex (now Bayer HealthCare) and Vertex. Caprion also has a major 5-year bio-defense contract in infectious disease proteomics with the NIH-NIAID. In addition, Caprion was recently awarded the Frost & Sullivan 2007 North American Proteomics for Biomarker Discovery Excellence in Technology award. For more information, please visit: www.caprion.com.

About Great Point Partners, LLC

Great Point Partners, LLC, based in Greenwich, CT, is a leading health care investment firm with approximately $800 million of equity capital under management. Currently, the firm manages capital in both public equity and private equity funds. Great Point has provided growth equity, recapitalization and management buyout financing to more than 100 health care companies. Both the private and public funds invest across all sectors of the health care industry including biotechnology and life sciences, consumer health, generic drugs, health care services, information technology, insurance, medical devices, specialty pharmaceuticals, and workers compensation. Notable drug development companies financed by the principals include AMAG Pharmaceuticals, Akorn Inc., Biodel, Centocor, Eon Labs (Now part of Novartis) and Memory Pharmaceuticals. Reach Great Pointat 203-971-3300. www.gppfunds.com

About Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc. (TSX: TLN) is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Thallion’s clinical-stage programs include: Shigamabs®, a dual antibody product for the treatment of Shigatoxinproducing E. coli bacterial infections; ECO-4601, a novel anticancer therapy derived from a nonpathogenic microorganism; and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. Thallion Pharmaceuticals was formed on March 14, 2007 by the amalgamation of Ecopia and Caprion. Additional information about the Company can be obtained at www.thallion.com.

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Biodel Inc. Announces the Pricing of its Initial Public Offering of Common Stock

Introduction

DANBURY, CT – Biodel Inc. (Nasdaq: BIOD – News) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $15.00 per share. All of the 5,000,000 shares being sold in the offering are being sold by Biodel (the “Company”). In addition, the Company has granted to the underwriters a 30-day over-allotment option to purchase up to an additional 750,000 shares of common stock. Great Point Partners invested in Biodel in 2006.

The Company’s common stock will trade on the Nasdaq Global Market on May 11, 2007 under the symbol “BIOD”.

Morgan Stanley & Co. Incorporated is acting as the sole book-runner and lead manager, Banc of America Securities LLC is acting as co-lead manager, and Leerink Swann & Co., Inc. and Natexis Bleichroeder Inc. are acting as co-managers in the offering.

Copies of the final prospectus relating to the offering may be obtained from the Morgan Stanley & Co. Incorporated Prospectus Department, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at (866) 718-1649 or by emailing prospectus@morganstanley.com.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 10, 2007. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Biodel is a specialty pharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.

Reach Great Point at 203-971-3300.
www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Closes Debut Private Equity Fund

Introduction

GREENWICH, CT – Great Point Partners, which manages a $500 million value based health care hedge fund, has just closed its debut private equity fund, Great Point Partners I LP, with $156 million in commitments, well ahead of the vehicle’s $100 million target, Managing Director Dr. Jeffrey Jay told LBO Wire.

The firm decided to raise a separate private equity fund to pursue the health care private equity investment opportunities it was seeing. Its hedge fund, “the Great Point Biomedical Value Fund, remains focused solely on publicly traded companies, with an emphasis on structured investments often referred to as PIPEs,” said Dr. Jay.

The firm started raising the PE fund late last year and held several closings, said Dr. Jay. Investors in the fund include University of Virginia, Georgetown University, Tufts University and Goldman Sachs & Co. The fund also received $11.5 million in commitments from general partners of the firm. The firm did not use a placement agent.

The fund plans to make proprietary growth equity investments in such health care sectors as medical devices, information services, and outsourcing services, taking both non-control and control stakes, said Dr. Jay.

It will look to invest between $10 million and $25 million of equity per deal, said Dr. Jay, and is targeting lower middle market growth companies with $2 to $10 mm of EBITDA because it believes there is less competition there.

Great Point was co-founded in 2003 by Dr. Jeffrey Jay, the former head of health care investments at J.H. Whitney along with Managing Director David Kroin. The firm has a total of 20 investment professionals, including seven that are dedicated to private equity.

Reach Great Point at 203-971-3300.
www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Leads Biodel's $21 Million Growth Equity Financing

Introduction

DANBURY, CT – Biodel Inc., a developer of drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take, announced a $21 million growth equity financing led by Great Point Partners.

As a part of the financing, Biodel also announced the addition of David Kroin, Managing Director at Great Point Partners to its Board of Directors.

“I am enthusiastic to be joining the Biodel team as we are highly impressed by the superior pharmacodynamics associated with Viaject rapid acting insulin and believe that the clinical trials will demonstrate that this is a major advancement in the treatment of diabetes,” said Mr. Kroin, Managing Director at Great Point Partners. “Biodel has shown compelling proof of concept in initial clinical trials, and we look forward to the results of the ongoing Phase 2 studies and soon to be initiated Phase 3 clinical trials.”

“The strong interest in this financing by top healthcare investors validates the progress we have made since our inception in 2003,” said Solomon S. Steiner, Ph.D., Chairman and CEO of Biodel. “We are excited to continue our great progress in developing Biodel’s technology which we see as a new paradigm in the management of diabetes patients. We also welcome our newly added board members as they each bring extensive knowledge of this space and add to our highly experienced team.”

Biodel’s first potential product is a rapid acting injectable insulin called Viaject. This product is a novel formulation of recombinant human insulin designed to speed the delivery of insulin into the blood, and in a manner that closely resembles the body’s normal release of insulin into the bloodstream which will improve the efficacy and efficiency of the drug.

Mr. David Kroin is a Managing Director at Great Point Partners. Prior to co-founding Great Point in 2003, Mr. Kroin was an investment professional at J.H. Whitney & Co., a multi-billion dollar alternative asset management firm, from 1998 to 2003, and a Partner of a J.H. Whitney & Co. affiliated fund. At Great Point, he has completed structured financings for companies such as Panacos Pharmaceuticals, Inc., Genta Inc. and Keryx Biopharmaceuticals.

About Biodel, Inc.

Biodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a novel drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called Viaject™. Biodel’s current focus is gaining FDA approval for Viaject to treat patients with Type 1 and Type 2 diabetes. For more information, please visit www.biodel.com.

Reach Great Point at 203-971-3300.
www.gppfunds.com

This document is intended solely to provide information regarding Great Point Partners’ potential financing capabilities for prospective portfolio companies.

Great Point Partners Invests in JPA Health, Leading Marketing Communications Agency

INTRODUCTION

GREENWICH, CT and WASHINGTON, D.C. — Today Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, announced the growth recapitalization of JPA Health (“JPA” or the “Company”). JPA is a high growth and leading public relations, marketing, and patient advocacy firm, providing strategic and creative services across the health care industry. The Company was founded in 2007 by Carrie Jones, its Chief Executive Officer. The Company is headquartered in Washington D.C., with offices in Boston, New York, and London, and has more than 90 employees.

JPA has been recognized for its outstanding marketing campaign efforts across the life sciences and public health sectors.

“Carrie and the entire JPA team have done an extraordinary job serving their clients with best-in-class insights and responsiveness,” said Bret Tenenhaus, Principal at GPP. “We look forward to helping them expand their services by facilitating add-on acquisitions and partnerships in strategic, complementary services.”

“Our clients are increasingly relying on multi-disciplinary practices to achieve their goals. With our team of specialists, we synchronize insights, ideas and incredible execution for results that impress,” said Carrie Jones, CEO at JPA Health. “Building upon our expertise in the space and unparalleled commitment to client service, we are well positioned to expand as an integrated agency attracting the best talent in the sector.”

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Great Point manages $1.2B of capital (including GPP IV which has been closed but not been activated) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

About JPA

JPA Health is an award-winning independent, full-service agency established in 2007. With offices in the U.S. and UK, the agency provides marketing, public relations and advocacy services. JPA Health works with many of the world’s leading healthcare companies, NGOs and federal government agencies. The firm is a leader in the health sector recognized for its work designing health campaigns that drive change and deliver measurable results. The JPA Health team is passionate about helping people live healthier lives. To learn more, visit www.jpa.com.

 

Great Point Partners Closes Fourth Health Care Growth Buyout Fund at $506 Million

Introduction

GREENWICH, CT – Great Point Partners, a global health care investment firm today announced the closing of its fourth lower middle market growth buyout fund, Great Point Partners IV (GPP IV), focused on rapidly growing health care companies in the United States, Canada, and Western Europe.  GPP IV, which closed on $506 million was significantly oversubscribed in four months of fundraising and closed at its hard cap.

“Great Point’s combination of both a private and public fund health care strategy enables us to have a team of approximately 30 people dedicated to generating and sharing thematic ideas across the full spectrum of the health care field.  This concentration of health care focused talent working cooperatively differentiates our investment process.  Since our first private equity fund launched in 2005, our private equity funds have generated a 3.9x gross multiple on realized investments as of March 31, 2022,” said Jeffrey Jay, MD Founding Managing Director.

“Since GPP I, we have focused on lower middle market health care investments in pharmaceutical services and products, health care information technology enabled services, medical contract manufacturing, and health care services.  We seek to create long-term value for our investors by maintaining a best-in-class proprietary sourcing program, partnering with great entrepreneurs, and investing in sectors with sustainable tailwinds of growth,” added Noah Rhodes Managing Director.

“GPP IV will target majority and minority investments in profitable companies generally with $1 to $10 million of EBITDA.  We are pursuing the same strategy we started two decades ago,” said Rohan Saikia, Managing Director.  “We have had particular success helping companies based solely in either the US or Europe become global companies with operations in multiple countries.”

“We are grateful for our investor support, especially in a hectic and crowded fundraising environment,” added Emily St. Thomas, Head of Investor Relations and Marketing for the private equity funds and the public life sciences fund.  “We continue to diversify our investor base, particularly in Europe.  We manage capital for some of the most sophisticated investors in the world.  It is gratifying that with our investors support, our firm is dedicated to investing in companies that improve the health and well-being of people across the globe.”

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III.  Including GPP IV, Great Point manages $1.7B of capital in its private funds and public life sciences equity strategy. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device, and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

Past performance is not indicative of future results and there can be no assurance that any fund will achieve comparable results or avoid substantial losses.  The information provided is solely to educate Great Point’s current investors and potential portfolio companies and intermediary partners about Great Point’s performance and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Great Point Partners or any other third party regardless of whether such security, product or service is referenced. Great Point’s private equity funds are closed-end funds and therefore are not accepting any new investors.  The net multiple on realized and unrealized investments of the private equity funds is 2.3x which is a ratio equal to the value of distributions made by all funds plus Great Point’s valuation of the fair value of all unrealized investments divided by the total amount of capital paid into the funds as of December 31, 2021.  This is calculated after accounting for management fees, carried interest, and all fund expenses.   Recalled distributions are subtracted from the numerator and reinvested capital is subtracted from the denominator.  Gross multiple on realized investments is a ratio equal to the value of distributions made to date by all funds divided by the total amount of capital paid into the funds to make such investments.  Distributions include cash (generated by sale proceeds and dividends) as well as shares from one public company.  Gross multiple on realized investments does not take into account management fees, carried interest, and fund expenses which in the aggregate are significant.  Net multiple on realized investments is not presented as it is unable to be calculated at the individual investment level and across funds. No investor has received the returns listed here because these returns are across multiple funds.  Net returns reflect those of fee-paying investors and exclude those amounts invested by co-investors and Great Point related investors.

 

Great Point Partners Exits Investment in SteriPack

INTRODUCTION

GREENWICH, CT and MULLINGAR, IRELAND – Great Point Partners (“GPP”), a Greenwich-based private investment firm focused exclusively on the health care industry, announced today that it has exited its investment in SteriPack Group (“SteriPack” or the “Company”) to Inflexion, a market-leading private equity firm.  With facilities in Poland, the United States, and Malaysia, SteriPack is a global contract manufacturer providing integrated solutions for medical device, diagnostic, and pharmaceutical combination products. The Company provides award winning product design & development, human factors research & engineering, design for manufacturing, regulatory, quality assurance, manufacturing, sterilization, and supply chain management.

Bret Tenenhaus, Principal at GPP, commented, “In 2019 we were proactively searching globally for an investment in the medical device manufacturing sector.  We wanted a platform whose leaders saw the value of both vertical integration of capabilities and geographic expansion. During our ownership period SteriPack grew revenue approximately 40% per year by expanding its business lines through both organic investments and two add-on acquisitions. We were fortunate to work with great entrepreneurs and leaders at SteriPack and look forward to watching the Company prosper for years to come.”

“When I joined SteriPack, I was excited to partner with Great Point because of their health care expertise, track record of success in life sciences manufacturing services, and trans-Atlantic M&A experience. I am proud of what we have all accomplished together and the bright future ahead,” Andrew McLean, Chief Executive Officer at SteriPack, stated.

“GPP sourced and led the negotiations of our two U.S. based design & development acquisitions: New Jersey based HS Design and Colorado-based Halleck Willard, Inc” added David Lennon, Chairman of SteriPack. “These have exceeded our own expectations and opened doors into several new growth opportunities already.”

CMD Global Partners served as financial advisor to SteriPack, and Maples served as the Company’s legal counsel.

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Great Point manages $1.6B of capital (including GPP IV which has been closed but not been activated) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies

About SteriPack

SteriPack is a flexible and responsive global contract manufacturer providing comprehensive partner solutions for medical device, diagnostic, and pharmaceutical combination products. SteriPack offers a full suite of integrated product lifecycle solutions, including contract manufacturing, contract packaging, and injection molding services. SteriPack supports its customers from initial concept, design & development to product realization, including product lifecycle management solutions such as regulatory, quality, laboratory testing, sterilization, and supply chain management.
Learn more at steripackgroup.com

 

 

 

 

Great Point Partners Completes Investment in Ephicacy Consulting Group to Fund Accelerated Growth

INTRODUCTION

GREENWICH, CT and ISELIN, NJ – Today Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, announced a growth investment and partnership with Ephicacy Consulting Group, Inc., (“Ephicacy”), a leading biometrics Contract Research Organization (“CRO”) with operations in the United States, Canada, and India. The Company was founded in 2005 by Ganesh Gopal, its Chief Executive Officer. Ephicacy provides statistical programming, data management, and real-world evidence (“RWE”) analytics services to pharmaceutical and biotechnology companies around the world.

“Ephicacy has differentiated itself as a global leader in clinical analytics. Sophisticated data analysis is critical to clinical trial and regulatory success and pharma companies rely on specialized CROs like Ephicacy for outsourced biostatistics support,” said Rohan Saikia, Managing Director at Great Point Partners. “Ephicacy has been growing rapidly, and we are excited to partner with Ganesh and the rest of the team to accelerate growth.”

“Great Point’s expertise and investment success in the pharmaceutical services space was clearly evident when they first approached us about a partnership,” said Ganesh Gopal, CEO of Ephicacy. “s  Partnering with GPP which has a strong track record and deep health care network, will enable  us to accelerate  our growth as a high-quality clinical analytics services partner to our pharmaceutical and biotechnology clients.”

About Great Point Partners

Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new minority and majority private equity investments from GPP III. Great Point manages $1.5B of capital (including GPP IV which has been closed but not been activated) in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.

 

About Ephicacy Consulting Group, Inc.

Headquartered in Iselin, NJ, with employees and operations across North America and India, Ephicacy is a rapidly growing biometrics CRO, providing outsourced statistical programming, data management, and real-world evidence (“RWE”) analytics services to pharmaceutical and biotechnology companies, primarily under a Functional Service Provider (“FSP”) model. Since its founding in 2005, Ephicacy has established itself as a leading player in the clinical analytics space, leveraging a global talent pool of over 350 resources to help global pharmaceutical and biotechnology companies reduce their time to market in a cost-effective manner. More information on the Company and its services can be viewed online at www.ephicacy.com